



**Kenya**

**Country Operational Plan**

**FY 2015**



## Budget Summary Reports

### Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source	Applied Pipeline
	GAP	GHP-State	GHP-USAID	Total	
DOD		21,755,141		21,755,141	0
HHS/CDC	3,320,000	173,041,714		176,361,714	0
HHS/HRSA		3,396,964		3,396,964	0
PC		1,451,098		1,451,098	0
State		336,800		336,800	763,200
State/AF		100,000		100,000	0
USAID		285,835,083		285,835,083	0
<b>Total</b>	<b>3,320,000</b>	<b>485,916,800</b>	<b>0</b>	<b>489,236,800</b>	<b>763,200</b>

### Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency							On Hold Amount	Total
	State	DOD	HHS/CDC	HHS/HRSA	PC	State/AF	USAID		
CIRC		1,062,462	9,358,370				3,602,456	0	14,023,288
HBHC	0	2,236,051	23,847,445			50,000	18,528,388	0	44,661,884
HKID	0	1,100,050	624,165		91,159	50,000	29,755,669	0	31,621,043
HLAB		1,840,202	9,734,475	350,000			3,306,180	0	15,230,857
HMBL			1,693,939				868,969	0	2,562,908
HMIN			1,556,490				18,969	0	1,575,459
HTXD							89,990,186	0	89,990,186
HTXS		4,830,121	56,340,761				52,281,029	0	113,451,911
HVAB		40,220	405,711	546,964	416,592		881,416	0	2,290,903
HVCT		1,972,110	13,018,128				16,209,744	0	31,199,982
HVMS	336,800	2,531,821	9,133,724		876,276		7,123,746	0	20,002,367
HVOP		852,959	8,560,342		60,071		8,152,448	0	17,625,820



HVSI	0	2,058,179	10,633,804	2,500,000			10,596,700	0	<b>25,788,683</b>
HVTB		769,102	7,543,774				6,865,852	0	<b>15,178,728</b>
IDUP		700	1,514,261				971,357	0	<b>2,486,318</b>
MTCT		1,668,150	12,193,153		7,000		14,086,555	0	<b>27,954,858</b>
OHSS	0		3,771,448				6,221,267	0	<b>9,992,715</b>
PDCS		588,135	3,808,253				4,018,872	0	<b>8,415,260</b>
PDTX		204,879	2,623,471				12,355,280	0	<b>15,183,630</b>
	<b>336,800</b>	<b>21,755,141</b>	<b>176,361,714</b>	<b>3,396,964</b>	<b>1,451,098</b>	<b>100,000</b>	<b>285,835,083</b>	<b>0</b>	<b>489,236,800</b>



## Technical Areas

### Technical Area Summary

#### Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	43,899,997	0
HKID	31,021,067	0
HVTB	14,999,997	0
PDCS	7,800,001	0
<b>Total Technical Area Planned Funding:</b>	<b>97,721,062</b>	<b>0</b>

#### Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	14,425,000	0
HVSI	24,100,000	0
OHSS	8,000,000	0
<b>Total Technical Area Planned Funding:</b>	<b>46,525,000</b>	<b>0</b>

#### Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
CIRC	13,535,000	0
HMBL	2,500,000	0
HMIN	1,500,000	0
HVAB	2,000,001	0
HVCT	30,623,966	0
HVOP	17,265,570	0
IDUP	2,439,040	0
MTCT	27,422,907	0



<b>Total Technical Area Planned Funding:</b>	<b>97,286,484</b>	<b>0</b>
--	-------------------	----------

**Technical Area: Treatment**

<b>Budget Code</b>	<b>Budget Code Planned Amount</b>	<b>On Hold Amount</b>
HTXD	89,783,410	0
HTXS	112,584,975	0
PDTX	15,000,000	0
<b>Total Technical Area Planned Funding:</b>	<b>217,368,385</b>	<b>0</b>



## Technical Area Summary Indicators and Targets

Indicator Number	Label	2015	2016
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	100 %	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,119,400	271,055
	Number of new ANC and L&D clients	1,119,400	273,708
	By: Known positives at entry	39,019	33,213
	By: Number of new positives identified	39,954	27,965
	Sum of Positives Status disaggregates	78,973	61,178
	Required only for DREAMS Countries - By Number of new positives: <15		630
	Required only for DREAMS Countries - By Number of new positives: 15-19		650
	Required only for DREAMS Countries - By Number of new positives: 20-24		3,849
	Required only for DREAMS Countries - By Number of new positives: 25+		6,762

	Required only for DREAMS Countries - By Number of known positives: <15		98
	Required only for DREAMS Countries - By Number of known positives: 15-19		451
	Required only for DREAMS Countries - By Number of known positives: 20-24		3,163
	Required only for DREAMS Countries - By Number of known positives: 25+		6,722
	Required only for DREAMS Countries - Denominator: <15		1,214
	Required only for DREAMS Countries - Denominator: <15-19		5,523
	Required only for DREAMS Countries - Denominator: 20-24		35,655
	Required only for DREAMS Countries - Denominator: 25+		75,276
PMTCT_STAT_TA	PMTCT_STAT_TA Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (TA)	100 %	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	313,600	349

	Number of new ANC and L&D clients	313,600	1,918
	By: Known positives at entry	2,161	11
	By: Number of new positives identified	6,483	9
	Sum of Positives Status disaggregates	8,644	20
	Required only for DREAMS countries - By known positives: <15		0
	Required only for DREAMS countries - By known positives: 15-19		0
	Required only for DREAMS countries - By known positives: 20-24		3
	Required only for DREAMS countries - By known positives: 25+		7
	Required only for DREAMS countries - By new positives: <15		0
	Required only for DREAMS countries - By new positives: 15-19		0
	Required only for DREAMS countries - By new positives: 20-24		3
	Required only for DREAMS countries - By new positives: 25+		7
	Required only for DREAMS countries - Denominator: <15		19
	Required only for DREAMS countries - Denominator:		75



	15-19		
	Required only for DREAMS countries - Denominator: 20-24		576
	Required only for DREAMS countries - Denominator: 25+		1,248
PMTCT_ARV_DSD	PMTCT_ARV_DSD Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for mother-to-child-transmission (MTCT) during pregnancy and delivery (DSD)	97 %	
	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	76,434	8,082
	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	78,973	8,515
	Life-long ART (including Option B+)	50,294	
	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	19,720	4,385
	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	30,574	2,622

	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	
	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	26,140	664
	Single-dose nevirapine (with or without tail)	0	114
	Sum of Regimen Type disaggregates	76,434	778
	Sum of New and Current disaggregates	50,294	7,007
PMTCT_ARV_TA	PMTCT_ARV_TA Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for mother-to-child-transmission (MTCT) during pregnancy and delivery (TA)	99 %	
	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	8,554	17
	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	8,644	17

	Life-long ART (including Option B+)	5,628	
	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	2,207	6
	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	3,421	6
	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	2,926	4
	Single-dose nevirapine (with or without tail)	0	1
	Sum of Regimen Type disaggregates	8,554	5
	Sum of New and Current disaggregates	5,628	12
PMTCT_FO_DSD	PMTCT_FO_DSD Final outcomes among HIV exposed infants registered in the birth cohort	n/a	
	Number of HIV-exposed infants with a documented outcome by 18 months of age disaggregated by outcome type.		6,828
	Number of HIV-exposed infants registered in the birth		6,976

	cohort at any time between 0 and 18 months of age (including transfer-ins)		
	HIV-infected: Linked to ART		3,073
	HIV-infected: Not linked to ART		947
	HIV-infected: Unknown link		
	HIV-uninfected: Not breastfeeding		0
	HIV-uninfected: Still breastfeeding		0
	HIV-uninfected: Breastfeeding status unknown		0
	Other: In care but no test done		24
	Other: Lost to follow-up		97
	Other: Died		2
	Other: Transferred out		884
KP_MAT_DSD	KP_MAT_DSD Percentage of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	n/a	
	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	2,169	424
	Sex: Male	1,735	390
	Sex: Female	434	34
	Sum of Sex disaggregates	2,169	424
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that	163	234

	experienced at least one moderate or severe adverse event(s) (AEs)		
	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	475	
	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	366	
	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	45	
	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	474	
	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	420	
	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category:	49	

	Number of clients with one or more severe surgical intra-operative AE(s)		
	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	302	
	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)	46	
	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	0	
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	215,842	118,618
	By Age: <1	0	1
	By Age: 1-9	0	17
	By Age: 10-14	78,950	3,137
	By Age: 15-19	85,183	55,320
	By Age: 20-24	26,667	34,695
	By Age: 25-29		18,300
	By Age: 30-49		7,059
	By Age: 50+	364	89

	Sum of age disaggregates	215,842	93,259
	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	11,129	1,281
	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	183,097	100,099
	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	10,421	17,238
	By circumcision technique: Surgical VMMC	199,521	118,618
	By circumcision technique: Device-based VMMC	13,458	0
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	161,615	52,931
	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	44,649	61,234
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	22 %	

	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	1,242,312	205,042
	Total number of people in the target population	5,573,537	688,667
	Age/sex: 10-14 Male	252,197	1,531
	Age/sex: 15-19 Male	77,536	5,497
	Age/sex: 20-24 Male	84,735	8,148
	Age/sex: 25-49 Male	131,363	25,030
	Age/sex: 50+ Male	14,672	11,465
	Age/sex: 10-14 Female	281,509	17,266
	Age/sex: 15-19 Female	138,007	47,022
	Age/sex: 20-24 Female	138,433	57,051
	Age/sex: 25-49 Female	108,302	29,286
	Age/sex: 50+ Female	15,558	6,414
	Sum of Age/Sex disaggregates	1,242,312	208,710
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a	
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	195,394	61,526



	Total estimated number of key population in the catchment area		41,351
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	173,334	52,932
	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	8,948	2,744
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,260	569
	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key	11,852	5,281

	populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)		
	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,732	
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)		33,665
	By key population type: Males who inject drugs ( Male PWID) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Men		

	who have sex with men/Transgender (MSM/TG) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Denominator: Total estimated number of key population in the catchment area)		387
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	4,484,673	981,253
	By Test Result: Negative	4,306,353	252,115
	By Test Result: Positive	178,320	10,546
	Sum of Test Result disaggregates	4,484,673	262,661
	Test Result by Age and Sex: Positive: <1 Male		31
	Test Result by Age and Sex: Positive: 1-4 Male		2,953
	Test Result by Age and Sex: Positive: 5-9 Male		897
	Test Result by Age and Sex: Positive: 10-14 Male		1,526
	Test Result by Age and Sex: Positive: 15-19 Male		3,800
	Test Result by Age and Sex: Positive: 20-24 Male		7,045
	Test Result by Age and Sex:		11,389

	Positive: 25-49 Male		
	Test Result by Age and Sex: Positive: 50+ Male		2,775
	Test Result by Age and Sex: Positive: <1 Female		310
	Test Result by Age and Sex: Positive: 1-4 Female		1,967
	Test Result by Age and Sex: Positive: 5-9 Female		886
	Test Result by Age and Sex: Positive: 10-14 Female		1,497
	Test Result by Age and Sex: Positive: 15-19 Female		3,942
	Test Result by Age and Sex: Positive: 20-24 Female		8,457
	Test Result by Age and Sex: Positive: 25-49 Female		12,064
	Test Result by Age and Sex: Positive: 50+ Female		2,865
	Test Result by Age and Sex: Negative: <1 Male		875
	Test Result by Age and Sex: Negative: 1-4 Male		22,487
	Test Result by Age and Sex: Negative: 5-9 Male		12,116
	Test Result by Age and Sex: Negative: 10-14 Male		24,101
	Test Result by Age and Sex: Negative: 15-19 Male		56,228
	Test Result by Age and Sex: Negative: 20-24 Male		96,510
	Test Result by Age and Sex: Negative: 25-49 Male		151,816
	Test Result by Age and Sex:		36,741

	Negative: 50+ Male		
	Test Result by Age and Sex: Negative: <1 Female		780
	Test Result by Age and Sex: Negative: 1-4 Female		24,917
	Test Result by Age and Sex: Negative: 5-9 Female		11,587
	Test Result by Age and Sex: Negative: 10-14 Female		22,072
	Test Result by Age and Sex: Negative: 15-19 Female		45,355
	Test Result by Age and Sex: Negative: 20-24 Female		101,790
	Test Result by Age and Sex: Negative: 25-49 Female		153,693
	Test Result by Age and Sex: Negative: 50+ Female		36,918
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	348,629	57,909
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,840,603	340,349
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	306,140	58,505
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,989,301	357,998
	Sum of Aggregated Age/Sex <15	654,769	116,414
	Sum of Aggregated Age/Sex 15+	3,829,904	698,347
	Sum of Aggregated Age/Sex	4,484,673	814,761

	disaggregates		
	Service Delivery Point by Result: Antenatal Clinic - All results		
	Service Delivery Point by Result: Antenatal Clinic - Positive		1,408
	Service Delivery Point by Result: Antenatal Clinic - Negative		39,242
	Service Delivery Point by Result: Labor & delivery - All results		271
	Service Delivery Point by Result: Labor & delivery - Positive		28
	Service Delivery Point by Result: Labor & delivery - Negative		250
	Service Delivery Point by Result: Under 5 Clinic – All results		4,728
	Service Delivery Point by Result: Under 5 Clinic - Positive		307
	Service Delivery Point by Result: Under 5 Clinic - Negative		4,415
	Service Delivery Point by Result: Maternal and Child Health Clinic – All Results		60
	Service Delivery Point by Result: Maternal and Child Health Clinic - Positive		22
	Service Delivery Point by		37

	Result: Maternal and Child Health Clinic - Negative		
	Service Delivery Point by Result: Tuberculosis – All results		129
	Service Delivery Point by Result: Tuberculosis - Positive		11
	Service Delivery Point by Result: Tuberculosis - Negative		118
	Service Delivery Point by Result: Sexually Transmitted Infections – All Results		1,261
	Service Delivery Point by Result: Sexually Transmitted Infections - Positive		113
	Service Delivery Point by Result: Sexually Transmitted Infections - Negative		1,148
	Service Delivery Point by Result: Outpatient Department – All Results		13,693
	Service Delivery Point by Result: Outpatient Department - Positive		267
	Service Delivery Point by Result: Outpatient Department - Negative		13,421
	Service Delivery Point by Result: Inpatient – All Results		4,366
	Service Delivery Point by Result: Inpatient - Positive		110
	Service Delivery Point by		4,254

	Result: Inpatient - Negative		
	Service Delivery Point by Result: HIV care and treatment clinic – All Results		474
	Service Delivery Point by Result: HIV care and treatment clinic - Positive		84
	Service Delivery Point by Result: HIV care and treatment clinic - Negative		390
	Service Delivery Point by Result: Voluntary Medical Male Circumcision – All Results		676
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Positive		87
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Negative		589
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) – All Results		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Positive		1,466
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Negative		28,720
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – All		



	Results		
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – Positive		2,406
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – Negative		75,101
	Service Delivery Point by Result: Mobile – All Results		101,783
	Service Delivery Point by Result: Mobile - Positive		4,400
	Service Delivery Point by Result: Mobile - Negative		97,383
	Service Delivery Point by Result: Home-based – All Results		17
	Service Delivery Point by Result: Home-based - Positive		5
	Service Delivery Point by Result: Home-based - Negative		12
	Service Delivery Point by Result: Other – All Results		1
	Service Delivery Point by Result: Other - Positive		0
	Service Delivery Point by Result: Other - Negative		1
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,664,677	0



	By Test Result: Negative	1,534,445	
	By Test Result: Positive	130,232	
	Sum of Test Result disaggregates	1,664,677	
	Test Result by Age and Sex: Positive: <1 Male		0
	Test Result by Age and Sex: Positive: 1-4 Male		0
	Test Result by Age and Sex: Positive: 5-9 Male		0
	Test Result by Age and Sex: Positive: 10-14 Male		0
	Test Result by Age and Sex: Positive: 15-19 Male		0
	Test Result by Age and Sex: Positive: 20-24 Male		0
	Test Result by Age and Sex: Positive: 25-49 Male		
	Test Result by Age and Sex: Positive: 50+ Male		0
	Test Result by Age and Sex: Positive: <1 Female		0
	Test Result by Age and Sex: Positive: 1-4 Female		0
	Test Result by Age and Sex: Positive: 5-9 Female		0
	Test Result by Age and Sex: Positive: 10-14 Female		0
	Test Result by Age and Sex: Positive: 15-19 Female		0
	Test Result by Age and Sex: Positive: 20-24 Female		0
	Test Result by Age and Sex: Positive: 25-49 Female		0



	Test Result by Age and Sex: Positive: 50+ Female		0
	Test Result by Age and Sex: Negative: <1 Male		0
	Test Result by Age and Sex: Negative: 1-4 Male		0
	Test Result by Age and Sex: Negative: 5-9 Male		0
	Test Result by Age and Sex: Negative: 10-14 Male		0
	Test Result by Age and Sex: Negative: 15-19 Male		0
	Test Result by Age and Sex: Negative: 20-24 Male		0
	Test Result by Age and Sex: Negative: 25-49 Male		0
	Test Result by Age and Sex: Negative: 50+ Male		0
	Test Result by Age and Sex: Negative: <1 Female		0
	Test Result by Age and Sex: Negative: 1-4 Female		0
	Test Result by Age and Sex: Negative: 5-9 Female		0
	Test Result by Age and Sex: Negative: 10-14 Female		0
	Test Result by Age and Sex: Negative: 15-19 Female		0
	Test Result by Age and Sex: Negative: 20-24 Female		0
	Test Result by Age and Sex: Negative: 25-49 Female		0
	Test Result by Age and Sex: Negative: 50+ Female		0

	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	124,850	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	707,489	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	124,851	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	707,487	
	Sum of Aggregated Age/Sex <15	249,701	
	Sum of Aggregated Age/Sex 15+	1,414,976	
	Sum of Aggregated Age/Sex disaggregates	1,664,677	
	Service Delivery Point by Result: Antenatal Clinic - All results		
	Service Delivery Point by Result: Antenatal Clinic - Positive		
	Service Delivery Point by Result: Antenatal Clinic - Negative		
	Service Delivery Point by Result: Labor & delivery - All results		
	Service Delivery Point by Result: Labor & delivery - Positive		
	Service Delivery Point by Result: Labor & delivery -		

	Negative		
	Service Delivery Point by Result: Under 5 Clinic – All results		
	Service Delivery Point by Result: Under 5 Clinic - Positive		
	Service Delivery Point by Result: Under 5 Clinic - Negative		
	Service Delivery Point by Result: Maternal and Child Health Clinic – All Results		
	Service Delivery Point by Result: Maternal and Child Health Clinic - Positive		
	Service Delivery Point by Result: Maternal and Child Health Clinic - Negative		
	Service Delivery Point by Result: Tuberculosis – All results		
	Service Delivery Point by Result: Tuberculosis - Positive		
	Service Delivery Point by Result: Tuberculosis - Negative		
	Service Delivery Point by Result: Sexually Transmitted Infections – All Results		
	Service Delivery Point by Result: Sexually Transmitted Infections - Positive		
	Service Delivery Point by		

	Result: Sexually Transmitted Infections - Negative		
	Service Delivery Point by Result: Outpatient Department – All Results		
	Service Delivery Point by Result: Outpatient Department - Positive		
	Service Delivery Point by Result: Outpatient Department - Negative		
	Service Delivery Point by Result: Inpatient – All Results		
	Service Delivery Point by Result: Inpatient - Positive		
	Service Delivery Point by Result: Inpatient - Negative		
	Service Delivery Point by Result: HIV care and treatment clinic – All Results		
	Service Delivery Point by Result: HIV care and treatment clinic - Positive		
	Service Delivery Point by Result: HIV care and treatment clinic - Negative		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision – All Results		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Positive		
	Service Delivery Point by		

	Result: Voluntary Medical Male Circumcision - Negative		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) – All Results		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Positive		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Negative		
	Service Delivery Point by Result: Voluntary Counseling & Testing (standalone) - All		
	Service Delivery Point by Result: Voluntary Counseling & Testing (standalone) - Positive		
	Service Delivery Point by Result: Voluntary Counseling & Testing (standalone) - Negative		
	Service Delivery Point by Result: Mobile – All Results		
	Service Delivery Point by Result: Mobile - Positive		
	Service Delivery Point by Result: Mobile - Negative		
	Service Delivery Point by Result: Home-based – All Results		
	Service Delivery Point by		

	Result: Home-based - Positive		
	Service Delivery Point by Result: Home-based - Negative		
	Service Delivery Point by Result: Other – All Results		
	Service Delivery Point by Result: Other - Positive		
	Service Delivery Point by Result: Other - Negative		
	Test Result by Aggregated Age and Sex: Negative <15 Male		
	Test Result by Aggregated Age and Sex: Negative 15+ Male		
	Test Result by Aggregated Age and Sex: Negative <15 Female		
	Test Result by Aggregated Age and Sex: Negative 15+ Female		
	Test Result by Aggregated Age and Sex: Positive <15 Male		
	Test Result by Aggregated Age and Sex: Positive 15+ Male		
	Test Result by Aggregated Age and Sex: Positive <15 Female		
	Test Result by Aggregated Age and Sex: Positive 15+ Female		



TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	n/a	
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.		7,927
	Total number of registered new and relapsed TB cases, during the reporting period.		8,558
	Sex: Male		3,938
	Sex: Female		3,681
	Age: <1		31
	Age: 1-4		183
	Age: 5-9		136
	Age: 10-14		181
	Age 15-19		
	Age: 20+		6,050
	Status: Positive		2,331
	Status: Negative		5,212
TB_STAT_TA	TB_STAT_TA Percentage of registered new and relapsed TB cases with documented HIV status.	n/a	
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.		-82
	Total number of registered new and relapsed TB cases, during the reporting period.		

	Age 15-19		
	Age: <1		
	Age: 1-4		
	Age: 10-14		
	Age: 20+		
	Age: 5-9		
	Sex: Female		
	Sex: Male		
	Status: Negative		
	Status: Positive		
GEND_GBV_DSD	Number of people receiving post-GBV care	19,009	28,398
	Age/Sex: <10 Male		4
	Age/Sex: 10-14 Male		1,043
	Age/Sex: 15-17 Male		642
	Age/Sex: 18-24 Male		624
	Age/Sex: 25+ Male		27
	Age/Sex: <10 Female		383
	Age/Sex: 10-14 Female		6,155
	Age/Sex: 15-17 Female		10,258
	Age/Sex: 18-24 Female		9,792
	Age/Sex: 25+ Female		265
	Sum of Age/Sex Disaggregates		29,193
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	7,516	11,627
	By type of service: Sexual Violence (Post-Rape Care)	9,538	6,109
By PEP service provision (related to sexual violence services provided)	3,901		
GEND_NORM_DSD	Number of people	74,525	83,152

	completing an intervention pertaining to gender norms, that meets minimum criteria		
	Age/Sex: <10 Male		4
	Age/Sex: 10-14 Male		9,126
	Age/Sex: 15-19 Male		12,739
	Age/Sex: 20-24 Male		12,423
	Age/Sex: 25+ Male		948
	Age/Sex: <10 Female		0
	Age/Sex: 10-14 Female		9,975
	Age/Sex: 15-19 Female		17,586
	Age/Sex: 20-24 Female		18,147
	Age/Sex: 25+ Female		2,425
	By Age: 0-9	3,100	0
	By Age: 10-14	5,000	3
	By Age: 15-19	9,000	31
	By Age: 20-24	19,212	40
	By Age: 25+	38,213	63
	Sum of Age disaggregates	74,525	137
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	73,630	162,776
	Age/Sex: <1 Male		5,958
	Age/Sex: 1-4 Male		9,509
	Age/Sex: 5-9 Male		12,951
	Age/Sex: 10-14 Male		13,280
	Age/Sex: 15-17 Male		9,879
	Age/Sex: 18-24 Male		942
	Age/Sex: 25+ Male		238
	Age/Sex: <1 Female		5,343
	Age/Sex: 1-4 Female		8,821

	Age/Sex: 5-9 Female		12,577
	Age/Sex: 10-14 Female		28,138
	Age/Sex: 15-17 Female		36,614
	Age/Sex: 18+ Female		
	Age/Sex: 18-24 Female		17,048
	Age/Sex: 25+ Female		366
	Sum of Age/Sex disaggregates		161,664
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	675,561	283,067
	Age/Sex: <1 Male		7,217
	Age/Sex: 1-4 Male		17,681
	Age/Sex: 5-9 Male		25,261
	Age/Sex: 10-14 Male		27,321
	Age/Sex: 15-17 Male		21,270
	By: Age/sex: Male 18-24		3,010
	By: Age/sex: Male 25+		248
	Age/Sex: <1 Female		5,561
	Age/Sex: 1-4 Female		12,733
	Age/Sex: 5-9 Female		24,284
	Age/Sex: 10-14 Female		44,873
	Age/Sex: 15-17 Female		69,881
	By: Age/sex: 18-24 Female		18,770
	By: Age/sex: 25+ Female		553
	Sum of Age/Sex disaggregates		256,082
	Required only for DREAMS countries - By service, age and sex: Education Support Female <1		



	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+		
	Required only for DREAMS countries - By service, age and sex: Education Support Male <1		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Education Support		



	Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14		
	Required only for DREAMS countries - By service, age		



	and sex: Parenting/Caregiver Programs Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24		
	Required only for DREAMS		



	countries - By service, age and sex: Parenting/Caregiver Programs Male 25+		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1		



	Required only for DREAMS countries - By service, age and sex: Social Protection Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1		0
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-4		0
	Required only for DREAMS countries - By service, age and sex: Economic		0

	Strengthening Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Economic		1,705
	Strengthening Female 10-14		
	Required only for DREAMS countries - By service, age and sex: Economic		4,014
	Strengthening Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Economic		4,171
	Strengthening Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Economic		6,536
	Strengthening Female 25+		
	Required only for DREAMS countries - By service, age and sex: Economic		0
	Strengthening Male <1		
	Required only for DREAMS countries - By service, age and sex: Economic		0
	Strengthening Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Economic		0
	Strengthening Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Economic		0
	Strengthening Male 10-14		
	Required only for DREAMS countries - By service, age		47

	and sex: Economic Strengthening Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24		271
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+		1,531
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	989,172	82,371
	Age/sex: <1 Male	2,400	93
	Age/sex: 1-4 Male	9,000	704
	Age/sex: 5-9 Male	13,718	1,306
	Age/sex: 10-14 Male	11,344	1,264
	Age/sex: 15-19 Male	9,424	622
	Age/sex: 20-24 Male	30,183	858
	Age/sex: 25-49 Male	157,598	14,960
	Age/sex: 50+ Male	48,284	5,340
	Age/sex: <1 Female	3,273	100
	Age/sex: 1-4 Female	9,508	676
	Age/sex: 5-9 Female	14,725	1,321
	Age/sex: 10-14 Female	12,380	1,262
	Age/sex: 15-19 Female	16,605	969
	Age/sex: 20-24 Female	68,523	3,083
	Age/sex: 25-49 Female	317,872	30,854
	Age/sex: 50+ Female	57,478	6,363
	Sun of Age/Sex	782,315	69,775

	disaggregates		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	41,500	652
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	284,261	4,021
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	44,844	651
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	527,729	6,023
	Sum of Aggregated Age/Sex disaggregates	898,334	11,347
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	193,388	17,056
	Age/sex: <1 Male	536	25
	Age/sex: 1-4 Male	1,616	221
	Age/sex: 5-9 Male	2,559	299
	Age/sex: 10-14 Male	2,217	226
	Age/sex: 15-19 Male	1,948	124
	Age/sex: 20-24 Male	7,739	205
	Age/sex: 25-49 Male	32,714	3,078
	Age/sex: 50+ Male	6,781	1,280
	Age/sex: <1 Female	733	84
	Age/sex: 1-4 Female	1,756	170

	Age/sex: 5-9 Female	2,852	342
	Age/sex: 10-14 Female	2,618	243
	Age/sex: 15-19 Female	3,990	212
	Age/sex: 20-24 Female	11,864	884
	Age/sex: 25-49 Female	56,482	6,614
	Age/sex: 50+ Female	17	1,287
	Sum of Age/sex disaggregates	136,422	15,294
	Aggregated Age/sex: <15 Male	8,014	92
	Aggregated Age/sex: 15+ Male	56,156	530
	Aggregated Age/sex: <15 Female	8,792	92
	Aggregated Age/sex: 15+ Female	102,106	895
	Sum of Aggregated Age/sex disaggregates	175,068	1,609
FN_THER_DSD	FN_THER_DSD Proportion of clinically undernourished PLHIV who received therapeutic or supplementary food	74 %	
	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	326,741	105,825
	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	438,678	105,733
	Age: <1	32,370	13,986
	Age: 1-4	54,745	18,685

	Age: 5-14	26,802	10,655
	Age: 15-17	5,108	1,842
	Age: 18+	207,717	60,163
	Sum of Age disaggregates	326,742	105,331
	Aggregated Age: <18	119,082	44,983
	Aggregated Age: 18+	207,659	58,918
	Sum of Aggregated Age disaggregates	326,741	103,901
	By Pregnancy/Postpartum Status: Pregnant		4,293
	By Pregnancy/Postpartum Status: Postpartum		6,191
TB_IPT_DSD	TB_IPT_DSD Proportion of PLHIV newly enrolled in HIV clinical care who start isoniazid preventive therapy (IPT)	n/a	
	The number of PLHIV newly enrolled in HIV care who start IPT during the reporting period		19,525
	Number of HIV-positive adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load		
	Age: <1		22
	Age: 1-4		318
	Age: 5-9		532
	Age: 10-14		500

	Age: 15-19		508
	Age: 20+		12,119
	Sum of Age disaggregates		13,999
	Age (Aggregated)- USE WITH HQ PERMISSION ONLY: <15		75
	Age (Aggregated)- USE WITH HQ PERMISSION ONLY: 15+		442
	Sex: Male		6,123
	Sex: Female		8,599
FN_ASSESS_DSD	FN_ASSESS_DSD Proportion of PLHIV who were nutritionally assessed via anthropometric measurement	n/a	
	The number of PLHIV who were nutritionally assessed via anthropometric measurement		181,236
	Number of HIV positive adults and children who received care and treatment services		206,273
	Age: <1		19,739
	Age: 1-4		27,046
	Age: 5-14		17,228
	Age: 15-17		3,717
	Age: 18+ years		113,294
	Sum of Age disaggregates		181,024
	Age (Aggregated) - USE WITH HQ PERMISSION ONLY <18		65,391
	Age (Aggregated) - USE		101,454

	WITH HQ PERMISSION ONLY 18+		
	By Pregnancy/Postpartum Status: Pregnant		6,021
	By Pregnancy/Postpartum Status: Postpartum		8,606
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	89 %	
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	38,611	2,644
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	43,403	3,177
	Age: <1		1
	Age: 1-4		36
	Age: 5-9		38
	Age: 10-14		49
	Age: 15-19		53
	Age: 20+		2,165
	Sum of Age disaggregates		2,342
	Male	20,400	1,158
	Female	19,874	1,267
	Sum of Sex disaggregates	40,274	2,425
	Newly tested	21,036	
	Known HIV-positive	21,913	545



	Sum of Test Status disaggregates	42,949	545
	Aggregated Age: <15	3,577	131
	Aggregated Age: 15+	35,898	140
	Sum of Aggregated Age disaggregates	39,475	271
	Timeliness: Art initiation <8 weeks of start of TB treatment		810
	Timeliness: Art initiation >8 weeks of start of TB treatment		210
	TB_OUTCOME_DSD TB treatment outcomes among registered new and relapsed TB cases who are HIV-positive	n/a	
	Aggregated outcomes of TB treatment among registered new and relapsed TB cases who are HIV-positive in the treatment cohort		1,161
TB_OUTCOME_DSD	The total number of registered new and relapsed TB cases who are HIV-positive registered in the treatment cohort		1,168
	Outcome by Age: Cured <1		6
	Outcome by Age: Cured 1-4		25
	Outcome by Age: Cured 5-9		17
	Outcome by Age: Cured 10-14		28
	Outcome by Age: Cured: 15-19		84



	Outcome by Age: Cured 20+		891
	Outcome by Age: Treatment Complete <1		1
	Outcome by Age: Treatment Complete 1-4		0
	Outcome by Age: Treatment Complete 5-9		0
	Outcome by Age: Treatment Complete 10-14		0
	Outcome by Age: Treatment Complete 15-19		0
	Outcome by Age: Treatment Complete 20+		6
	Outcome by Age: Treatment Failed <1		0
	Outcome by Age: Treatment Failed 1-4		0
	Outcome by Age: Treatment Failed 5-9		0
	Outcome by Age: Treatment Failed 10-14		0
	Outcome by Age: Treatment Failed 15-19		0
	Outcome by Age: Treatment Failed 20+		3
	Outcome by Age: Died <1		0
	Outcome by Age: Died 1-4		0
	Outcome by Age: Died 5-9		0
	Outcome by Age: Died 10-14		0
	Outcome by Age: Died 15-19		1
	Outcome by Age: Died 20+		11
	Outcome by Age: Lost to Follow-up <1		0
	Outcome by Age: Lost to		0



	Follow-up 1-4		
	Outcome by Age: Lost to Follow-up 5-9		0
	Outcome by Age: Lost to Follow-up 10-14		0
	Outcome by Age: Lost to Follow-up 15-19		0
	Outcome by Age: Lost to Follow-up 20+		8
	Outcome by Age: Not Evaluated <1		0
	Outcome by Age: Not Evaluated 1-4		0
	Outcome by Age: Not Evaluated 5-9		0
	Outcome by Age: Not Evaluated 10-14		0
	Outcome by Age: Not Evaluated 15-19		0
	Outcome by Age: Not Evaluated 20+		7
	Outcome by Sex: Treatment Complete Female		
	Outcome by Sex: Treatment Complete Male		5
	Outcome by Sex: Cured Female		
	Outcome by Sex: Cured Male		
	Outcome by Sex: Treatment failed Female		
	Outcome by Sex: Treatment failed Female		
	Outcome by Sex: Died		

	Female		
	Outcome by Sex: Died Male		
	Outcome by Sex: Lost to Follow-up Female		
	Outcome by Sex: Lost to Follow-up Male		
	Outcome by Sex: Not Evaluated Female		
	Outcome by Sex: Not Evaluated Male		
TB_SCREEN_DSD	TB_SCREEN_DSD Percentage of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period.	n/a	
	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period		49,572
	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	989,172	82,371
	Age: <1	3,817	134
	Age: 1-4	16,649	957
	Age: 5-9	27,891	1,643
	Age: 10-14	24,430	1,519
	Age: 15-19	30,873	1,236
	Age: 20+		38,152

	Sum of Age disaggregates	103,660	43,641
	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	78,548	402
	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	718,603	2,806
	Sum of Aggregated Age disaggregates	797,151	3,208
	Sex: Male	274,049	16,438
	Sex: Female	523,101	27,203
	Sum of Sex disaggregates	797,150	43,641
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	100 %	
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	87,617	7,279
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	87,617	
	By infants who received a virologic test within 2 months of birth	17,524	3,264
	By infants who received their first virologic HIV test between 2 and 12 months of age	70,093	2,540
	Sum of Infant Age	87,617	5,804

	disaggregates		
	By infants with a positive virologic test result within 12 months of birth		
	Number of infants with a positive virological test result within 2 months of birth		147
	Number of infants with a positive virological test result within 12 months of birth		101
PMTCT_EID_TA	PMTCT_EID_TA Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (TA)	n/a	
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period		17
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)		
	By infants who received a virologic test within 2 months of birth		8
	By infants who received their first virologic HIV test between 2 and 12 months of age		9
	Sum of Infant Age disaggregates		17
	By infants with a positive virologic test result within 12		

	months of birth		
	Number of infants with a positive virological test result within 2 months of birth		
	Number of infants with a positive virological test result within 12 months of birth		
PMTCT_CTX_DSD	PMTCT_CTX_DSD Percentage of infants born to HIV-positive pregnant women who were started on cotrimoxazole (CTX) prophylaxis within two months of birth	n/a	
	Number of infants born to HIV-infected women who were started on cotrimoxazole (CTX) prophylaxis within two months of birth within the reporting period		3,875
	Number of HIV-positive pregnant women identified in the reporting period (include known HIV- positive at entry)		
PMTCT_CTX_TA	PMTCT_CTX_TA Percentage of infants born to HIV-positive pregnant women who were started on cotrimoxazole (CTX) prophylaxis within two months of birth	n/a	
	Number of infants born to HIV-infected women who were started on cotrimoxazole (CTX) prophylaxis within two months of birth within the		20

	reporting period		
	Number of HIV-positive pregnant women identified in the reporting period (include known HIV- positive at entry)		
CARE_COMM_DSD	Number of HIV-infected adults and children receiving care and support services outside of the health facility		4,891
	Age/Sex: <1 Male		4
	Age/Sex: 1-4 Male		38
	Age/Sex: 5-9 Male		91
	Age/Sex: 10-14 Male		104
	Age/Sex: 15-19 Male		51
	Age/Sex: 20-24 Male		53
	Age/Sex: 25-49 Male		898
	Age/Sex: 50+ Male		398
	Age/Sex: <1 Female		4
	Age/Sex: 1-4 Female		37
	Age/Sex: 5-9 Female		85
	Age/Sex: 10-14 Female		101
	Age/Sex: 15-19 Female		75
	Age/Sex: 20-24 Female		186
	Age/Sex: 25-49 Female		2,231
	Age/Sex: 50+ Female		531
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	819,637	90,007
	Age/Sex: <1 Male	892	88
	Age/Sex: 1-4 Male	8,552	806
	Age/Sex: 5-14 Male	29,492	3,357
	Age/Sex: 15-19 Male		1,291
	Age/Sex: 20+ Male		26,873



	Age/Sex: <1 Female	972	99
	Age/Sex: 1-4 Female	8,273	1,241
	Age/Sex: 5-14 Female	30,449	3,137
	Age/Sex: 15-19 Female		1,683
	Age/Sex: 20+ Female		52,143
	Aggregated Age/Sex: <1 Male	892	53
	Aggregated Age/Sex: <1 Female	972	1,292
	Aggregated Age/Sex: 15+ Male	244,663	6,007
	Aggregated Age/Sex: 1-14 Female		889
	Aggregated Age/Sex: 15+ Female	496,343	10,373
	Sum of Aggregated Age/Sex <15	78,630	
	Sum of Aggregated Age/Sex 15+	741,006	16,380
	Sum of Aggregated Age/Sex disaggregates	819,636	16,380
	Aggregated Age/Sex: 1-14 Male		899
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	1,864	3,133
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	141,485	21,170
	By Age/Sex: <1 Male	2,215	109
	By Age/Sex: 1-4 Male	1,611	230
	By Age/Sex: 5-9 Male	2,355	440
	By Age/Sex: 10-14 Male	1,875	281
	By Age/Sex: 15-19 Male	1,614	144

	By Age/Sex: 20-24 Male	3,842	321
	By Age/Sex: 25-49 Male	24,231	3,720
	By Age/Sex: 50+ Male	7,104	1,304
	By Age/Sex: <1 Female	2,364	273
	By Age/Sex: 1-4 Female	1,701	287
	By Age/Sex: 5-9 Female	2,539	1,552
	By Age/Sex: 10-14 Female	2,124	1,241
	By Age/Sex: 15-19 Female	3,088	244
	By Age/Sex: 20-24 Female	10,080	1,161
	By Age/Sex: 25-49 Female	44,939	8,218
	By Age/Sex: 50+ Female	8,446	1,661
	Sum of Age/Sex disaggregates	120,128	21,186
	Aggregated Grouping by Age: <1 Male	2,381	59
	Aggregated Grouping by Age/Sex: 1-14 Male		310
	Aggregated Grouping by Age/Sex: 15+ Male	38,283	1,805
	Aggregated Grouping by Age/Sex: <1 Female	2,626	165
	Aggregated Grouping by Age/Sex: 15+ Female	71,533	2,743
	Sum of Aggregated Age/Sex disaggregates	127,356	4,548
	Pregnancy status	17,026	464
	Breastfeeding status	1,817	39
	Aggregated Grouping by Age/Sex: 1-14 Female		286
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of	85 %	

	antiretroviral therapy		
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	119,479	18,483
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	139,990	27,884
	Age/Sex: <5 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		1,512
	Age/Sex: 5-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		839
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		137
	Age/Sex: 20+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating		4,357

	ART)		
	Age/Sex: <5 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		265
	Age/Sex: 5-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		715
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		512
	Age/Sex: 20+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		9,931
	Age/Sex: <5 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		299
	Age/Sex: 5-14 Male		725

	(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		231
	Age/Sex: 20+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		5,205
	Age/Sex: <5 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have		565

	died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 5-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		1,087
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		462
	Age/Sex: 20+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		12,119
	Numerator by Status: Pregnant		906
	Numerator by Status:		27

	Breastfeeding		
	Denominator by Status: Pregnant		2,923
	Denominator by Status: Breastfeeding		189
TX_VIRAL_DSD	TX_VIRAL_DSD Percentage of ART patients with an undetectable viral load at 12 months after initiation of ART	n/a	
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record within the past 12 months		94,979
	Number of adults and children on ART at least 6 months whose medical records were reviewed		91,504
	Age/Sex: <1 Male		93
	Age/Sex: 1-4 Male		808
	Age/Sex: 5-14 Male		3,583
	Age/Sex: 15-19 Male		1,055
	Age/Sex: 20+ Male		29,136
	Age/Sex: <1 Female		117
	Age/Sex: 1-4 Female		831
	Age/Sex: 5-14 Female		3,377
	Age/Sex: 15-19 Female		2,408
	Age/Sex: 20+ Female		49,551
	Results Category: Undetectable		32,391
	Results Category: Detectable		2,429
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that	281	127

	are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation		
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	4,261	225
	By clinical laboratories	46	225
	By Point-of-care testing sites	416	0
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	75	
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	7,030	225
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	7,030	225
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	5,280	211



	CD4: Number of laboratories that perform this testing	803	8
	CD4: Number of laboratories that participate in this PT program	311	8
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	234	6
	Early infant diagnostics: Number of laboratories that perform this testing	15	1
	Early infant diagnostics: Number of laboratories that participate in this PT program	7	1
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	7	1
	HIV viral load: Number of laboratories that perform this testing	8	1
	HIV viral load: Number of laboratories that participate in this PT program	10	1
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	10	1
	TB diagnostics (AFB microscopy): Number of laboratories that perform this		8

	testing		
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program		8
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program		6
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing		2
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program		2
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program		2
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing		0
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program		0
	TB diagnostics (Culture/DST): Number of		0

	laboratories that achieve acceptable successful passing criteria in this PT program		
TX_UNDETECT_DSD	TX_UNDETECT_DSD Proportion of viral load tests with an undetectable viral load (<1000 copies/ml)	n/a	
	Number of viral load tests from adult and pediatric ART patients conducted in the past 12 months with a viral load <1,000 copies/ml		78,696
	Number of viral load tests performed from adults and children on ART within the current reporting period		84,326
	Age/Sex: <1 Male		74
	Age/Sex: 1-4 Male		650
	Age/Sex: 5-14 Male		3,157
	Age/Sex: 15-19 Male		942
	Age/Sex: 20+ Male		22,966
	Age/Sex: <1 Female		78
	Age/Sex: 1-4 Female		640
	Age/Sex: 5-14 Female		2,984
	Age/Sex: 15-19 Female		1,560
	Age/Sex: 20+ Female		45,393
	Pregnant		850
	Breastfeeding		365
	Test indication: Routine monitoring		10,219
Test indication: Targeted monitoring			

HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	1,265	730
	By Graduates: Doctors	275	0
	By Graduates: Nurses	248	395
	By Graduates: Midwives	0	0
	By Graduates: Social service workers	16	0
	By Graduates: Laboratory professionals	311	82
	By Graduates: Other	415	253
	Sum of Graduates disaggreagtes	1,265	730
FPINT_SITE_DSD	FPINT_SITE_DSD Family Planning and HIV Integration: Percentage of HIV service delivery points supported by PEPFAR that are directly providing integrated voluntary family planning services	80 %	
	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	1,882	19
	Total number of PEPFAR-supported HIV service delivery points:	2,367	19



	PMTCT, Care and Treatment		
	Service delivery type: Care and Support		5
	Service delivery type: Treatment		
	Service delivery type: PMTCT		0
	Sum of Service delivery type (Care, Tx and PMTCT) disaggregates		

## Partners and Implementing Mechanisms

### Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
2866	CENTERS FOR HEALTH SOLUTIONS	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	5,960,011
7139	TBD	TBD	Redacted	Redacted	Redacted
7305	University Research Corporation, LLC	Private Contractor	U.S. Agency for International Development	GHP-State	520,000
9039	American Society for Microbiology	Private Contractor	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
9076	ICF Macro	Private Contractor	U.S. Agency for International Development	GHP-State	579,445
9108	American International Health Alliance Twinning Center	NGO	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	896,964

9110	Association of Public Health Laboratories	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	925,000
9136	International Medical Corps	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,874,654
9143	Henry Jackson Foundation	Private Contractor	U.S. Department of Defense	GHP-State	2,038,786
9171	Henry Jackson Foundation	Private Contractor	U.S. Department of Defense	GHP-State	12,841,756
11406	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	100,000
12054	CHF International	NGO	U.S. Agency for International Development	GHP-State	1,065,916
12056	Ananda Marga Universal Relief Teams	NGO	U.S. Agency for International Development	GHP-State	289,913
12082	United Nations High Commissioner for Refugees	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12083	Liverpool VCT	NGO	U.S. Department	GHP-State	761,501

	and Care		of Health and Human Services/Centers for Disease Control and Prevention		
12530	Nyanza Reproductive Health Society	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12540	University of North Carolina	University	U.S. Agency for International Development	GHP-State	2,800,000
12551	University of California at San Francisco	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	14,926,223
12555	University of Nairobi	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,895,614
12585	Columbia University Mailman School of Public Health	University	U.S. Department of Health and Human Services/Centers for Disease Control and	GHP-State	26,005,928



			Prevention		
12598	International Rescue Committee	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12605	Care International	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	5,446,715
12637	Futures Group	Private Contractor	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,100,000
12656	Eastern Deanery AIDS Relief Program	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	6,774,111
12658	Mkomani Society Clinic	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,736,584

12664	African Medical and Research Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,191,863
13025	Impact Research and Development Organization	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	6,707,884
13028	Community Housing Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13050	Coptic Hospital	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,941,356
13061	MINISTRY OF PUBLIC HEALTH AND SANITATION	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	7,951,009
13121	University of	University	U.S. Department	GHP-State	0

	Maryland		of Health and Human Services/Centers for Disease Control and Prevention		
13164	Management Sciences for Health	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13179	Association of Schools of Public Health	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	595,000
13210	Global Healthcare Public Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13287	Program for Appropriate Technology in Health	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13302	Hope Worldwide	FBO	U.S. Department of Health and	GHP-State	454,093



			Human Services/Centers for Disease Control and Prevention		
13307	Impact Research and Development Organization	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,070,435
13309	Kenya Medical Research Institute	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13312	Abt Associates	Private Contractor	U.S. Agency for International Development	GHP-State	2,675,000
13340	FHI 360	NGO	U.S. Agency for International Development	GHP-State	12,675,778
13346	World Health Organization	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	281,000
13354	Kenya Episcopal Conference	FBO	U.S. Department of Health and Human Services/Centers	GHP-State	11,216,756



			for Disease Control and Prevention		
13366	Christian Health Association of Kenya	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	7,203,953
13385	University of Manitoba	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,170,311
13399	University of Maryland	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	5,282,816
13474	Hope Worldwide	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	266,309
13481	University of Nairobi	University	U.S. Department of Health and Human Services/Centers for Disease	GHP-State	1,477,331

			Control and Prevention		
13543	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	13,541,789
13545	U.S. Peace Corps	Other USG Agency	U.S. Peace Corps	GHP-State	484,386
13546	Henry Jackson Foundation	Private Contractor	U.S. Department of Defense	GHP-State	2,875,556
13548	Management Sciences for Health	NGO	U.S. Agency for International Development	GHP-State	1,189,818
13588	Program for Appropriate Technology in Health	NGO	U.S. Agency for International Development	GHP-State	31,814,620
13636	JHPIEGO	University	U.S. Agency for International Development	GHP-State	12,297,301
13701	Kenya Medical Supplies Agency	Host Country Government Agency	U.S. Agency for International Development	GHP-State	134,769,375
13802	University of Nairobi	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,402,505
13805	University of Washington	University	U.S. Department of Health and	GHP-State	2,500,000



			Human Services/Health Resources and Services Administration		
13868	Population Services International	NGO	U.S. Agency for International Development	GHP-State	3,293,027
13882	Children of God Relief Institute	FBO	U.S. Agency for International Development	GHP-State	1,675,975
13919	Clinical and Laboratory Standards Institute	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	630,000
13922	African Field Epidemiology Network	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
14009	FHI 360	NGO	U.S. Agency for International Development	GHP-State	3,587,100
14012	Moi Teaching and Referral Hospital	Parastatal	U.S. Agency for International Development	GHP-State	16,776,539
14015	IntraHealth International, Inc	NGO	U.S. Agency for International Development	GHP-State	3,670,000
14022	African Medical	NGO	U.S. Agency for	GHP-State	4,179,464

	and Research Foundation		International Development		
14034	Equity Group Foundation	NGO	U.S. Agency for International Development	GHP-State	1,667,390
16450	Kenya Community Development Foundation	NGO	U.S. Agency for International Development	GHP-State	268,421
16670	University of Nairobi	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,000,000
16679	International Business & Technical Consultants Inc.	Private Contractor	U.S. Agency for International Development	GHP-State	1,250,000
16682	Kenya National Bureau of Statistics	Host Country Government Agency	U.S. Agency for International Development	GHP-State	150,000
16684	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,058,282
16687	Health Strat Kenya	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,610,046



16698	Catholic Relief Services	FBO	U.S. Agency for International Development	GHP-State	0
16705	United Nations Office on Drug and Crime (UNODC)	Multi-lateral Agency	U.S. Agency for International Development	GHP-State	942,904
16709	Center for Health Solutions (CHS)	NGO	U.S. Agency for International Development	GHP-State	1,800,000
16710	Equity Group Foundation	NGO	U.S. Agency for International Development	GHP-State	0
17190	Life Skills Promoters	NGO	U.S. Agency for International Development	GHP-State	902,458
17191	Reformed Church of East Africa	FBO	U.S. Agency for International Development	GHP-State	155,680
17707	TBD	TBD	Redacted	Redacted	Redacted
17709	IntraHealth International, Inc	NGO	U.S. Agency for International Development	GHP-State	2,950,000
17711	National Blood Transfusion Service, Kenya	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,250,000
17712	University of California at San Francisco	University	U.S. Department of Health and Human Services/Centers for Disease	GHP-State	3,050,000



			Control and Prevention		
17718	TBD	TBD	Redacted	Redacted	Redacted
17719	TBD	TBD	Redacted	Redacted	Redacted
17944	FHI 360	NGO	U.S. Agency for International Development	GHP-State	2,597,240
17945	mHealth Kenya	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	950,000
17947	African Medical and Research Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	895,000
17948	African Society for Laboratory Medicine	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	200,000
17950	University of Maryland	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,609,437

17951	FHI 360	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	895,000
17954	Global Implementation Solutions	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,585,000
17956	JHPIEGO	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	270,014
17957	TBD	TBD	Redacted	Redacted	Redacted
17958	TBD	TBD	Redacted	Redacted	Redacted
17959	University of Nairobi	University	U.S. Agency for International Development	GHP-State	700,000
17960	Population Council	NGO	U.S. Agency for International Development	GHP-State	50,000
17963	TBD	TBD	Redacted	Redacted	Redacted
17964	University of North Carolina	University	U.S. Agency for International Development	GHP-State	150,000



## Implementing Mechanism(s)

### Implementing Mechanism Details

<b>Mechanism ID: 2866</b>	<b>Mechanism Name: DUMISHA/TEGEMEZA</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: CENTERS FOR HEALTH SOLUTIONS	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 5,960,011</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	5,960,011

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	1,923,423
Gender: GBV	149,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Gender: Gender Equality	149,000
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Implementation
Sub Area:	Capacity building



## Key Issues

(No data provided.)

## Budget Code Information

<b>Mechanism ID:</b> 2866			
<b>Mechanism Name:</b> DUMISHA/TEGEMEZA			
<b>Prime Partner Name:</b> CENTERS FOR HEALTH SOLUTIONS			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1,249,683	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	405,923	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	169,969	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	868,437	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	508,123	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,599,737	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	158,139	0

## Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	2,734		Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	2,734		Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	2,050		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	957		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	1,093		Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	684		Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	2,734		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	2,050		Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their	41,144		Redacted

	results)		
PMTCT_STAT_DS D	Number of new ANC and L&D clients	41,144	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	1,285	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	1,449	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	2,734	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	233,197	Redacted
HTC_TST_DSD	By Test Result: Negative	223,869	Redacted
HTC_TST_DSD	By Test Result: Positive	9,328	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	233,197	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	8,161	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	3,498	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	5,830	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	11,660	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	29,149	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	46,639	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	11,661	Redacted
HTC_TST_DSD	Age/sex: <1 Female	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	8,161	Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	3,498	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	5,830	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	11,660	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	29,151	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	46,638	Redacted
HTC_TST_DSD	Age/sex: 50+ Female	11,661	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	233,197	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ	17,489	Redacted

	PERMISSION ONLY: <15 Male			
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	99,109		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	17,489		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	99,110		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	34,978		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	198,219		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	233,197		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	29,302		Redacted
CARE_CURR_DS D	Age/sex: <1 Male	46		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	318		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	537		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	421		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	225		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	416		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	6,260		Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	2,163		Redacted
CARE_CURR_DS D	Age/sex: <1 Female	46		Redacted



CARE_CURR_DS D	Age/sex: 1-4 Female	302		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	555		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	419		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	371		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	1,540		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	13,155		Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	2,528		Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	29,302		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,322		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	9,064		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,322		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	17,594		Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	29,302		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	5,328		Redacted
CARE_NEW_DSD	Age/sex: <1 Male	8		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	58		Redacted

CARE_NEW_DSD	Age/sex: 5-9 Male	98		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	77		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	35		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	144		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	1,233		Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	237		Redacted
CARE_NEW_DSD	Age/sex: <1 Female	8		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	55		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	101		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	76		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	79		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	147		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	2,209		Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	763		Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	5,328		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	240		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	1,648		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	241		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	3,199		Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	5,328		Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	4,627		Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	6,169		Redacted
FN_THER_DSD	Age: <1	15		Redacted
FN_THER_DSD	Age: 1-4	100		Redacted
FN_THER_DSD	Age: 5-14	312		Redacted
FN_THER_DSD	Age: 15-17	93		Redacted
FN_THER_DSD	Age: 18+	4,107		Redacted

FN_THER_DSD	Sum of Age disaggregates	4,627		Redacted
FN_THER_DSD	Aggregated Age: <18	520		Redacted
FN_THER_DSD	Aggregated Age: 18+	4,107		Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	4,627		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,319		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,465		Redacted
TB_ART_DSD	Age: 0-4	33		Redacted
TB_ART_DSD	Age: 5-14	89		Redacted
TB_ART_DSD	Age: 15+	1,197		Redacted
TB_ART_DSD	Male	712		Redacted
TB_ART_DSD	Female	607		Redacted
TB_ART_DSD	Sum of Sex disaggregates	1,319		Redacted
TB_ART_DSD	Newly tested	791		Redacted
TB_ART_DSD	Known HIV-positive	528		Redacted
TB_ART_DSD	Sum of Test Status disaggregates	1,319		Redacted
TB_ART_DSD	Aggregated Age: <15	122		Redacted
TB_ART_DSD	Aggregated Age: 15+	1,197		Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	1,319		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,187		Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	2,734		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,640		Redacted

PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	547		Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	2,187		Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	109		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	26,325		Redacted
TX_CURR_DSD	Age/Sex: <1 Male	41		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	278		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	868		Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	8,383		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	41		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	278		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	868		Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	15,568		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	2,374		Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	1		Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	1		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	41		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	41		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,187		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	8,383		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,187		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	15,568		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	2,374		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	23,951		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex	26,325		Redacted

	disaggregates			
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	82		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,540		Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	75		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	42		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	75		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	58		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	26		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	49		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	735		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	254		Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	75		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	42		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	75		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	58		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	42		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	173		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	1,478		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	283		Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	3,540		Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	75		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	250		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,064		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	75		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	250		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,976		Redacted

TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	3,540		Redacted
TX_NEW_DSD	Pregnancy status	861		Redacted
TX_NEW_DSD	Breastfeeding status	96		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,050		Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	3,588		Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	76		Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	206		Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,769		Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	89		Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning	242		Redacted

	of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,257		Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	281		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,769		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	331		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,257		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on	1,708		Redacted

	treatment at 12 months after initiating ART)			
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,010		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	67		Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	67		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	67		Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	143		Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	190		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	143		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0		Redacted



FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	143		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	190		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	0		Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	190		Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	143		Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	143		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	27,837		Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	29,302		Redacted
TB_SCREEN_DSD	Age: <1	89		Redacted
TB_SCREEN_DSD	Age: 1-4	601		Redacted
TB_SCREEN_DSD	Age: 5-9	1,060		Redacted
TB_SCREEN_DSD	Age: 10-14	816		Redacted
TB_SCREEN_DSD	Age: 15-19	563		Redacted
TB_SCREEN_DSD	Age: 20-24	1,877		Redacted
TB_SCREEN_DSD	Age: 25-49	18,434		Redacted
TB_SCREEN_DSD	Age: 50+	4,397		Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	3,129		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ	2,566		Redacted



	PERMISSION ONLY: <15			
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	25,271		Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	27,837		Redacted
TB_SCREEN_DSD	Sex: Male	9,875		Redacted
TB_SCREEN_DSD	Sex: Female	17,962		Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	27,837		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 7139</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

### Implementing Mechanism Details

<b>Mechanism ID: 7305</b>	<b>Mechanism Name: Applying Science to Strengthen and Improve Systems-ASSIST</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University Research Corporation, LLC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 520,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	520,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)



(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 7305			
<b>Mechanism Name:</b> Applying Science to Strengthen and Improve Systems-ASSIST			
<b>Prime Partner Name:</b> University Research Corporation, LLC			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	320,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 9039	<b>Mechanism Name:</b> Capacity Building for LAB
---------------------------	--



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: American Society for Microbiology	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 9039			
<b>Mechanism Name:</b> Capacity Building for LAB			
<b>Prime Partner Name:</b> American Society for Microbiology			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	0	0



## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

<b>Mechanism ID: 9076</b>	<b>Mechanism Name: Demographic and Health Surveys - 7</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: ICF Macro	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 579,445</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	579,445

## Sub Partner Name(s)

(No data provided.)

## Cross-Cutting Budget Attribution(s)

(No data provided.)

## Key Issues

(No data provided.)

## Budget Code Information

<b>Mechanism ID:</b>	<b>9076</b>
----------------------	-------------



<b>Mechanism Name:</b> Demographic and Health Surveys - 7			
<b>Prime Partner Name:</b> ICF Macro			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	179,445	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	
PMTCT_STAT_DSD	Number of new ANC and L&D clients	0	

KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	0	
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	0	
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0	
PP_PREV_DSD	Total number of people in the target population	0	
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	0	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	
GEND_GBV_DSD	Number of people receiving post-GBV care	0	
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	0	
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	0	
OVC_SERV_DSD	Number of active beneficiaries served by	0	

	PEPFAR OVC programs for children and families affected by HIV/AIDS		
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	0	
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	0	
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	0	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	0	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	0	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	0	
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	0	
TX_CURR_DSD	Number of adults and children receiving	0	



	antiretroviral therapy (ART)		
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	0	
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	0	
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	0	
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	0	
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	0	
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	0	
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	0	
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV	0	



	service delivery points: PMTCT, Care and Treatment		
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	0	
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	

### Implementing Mechanism Details

<b>Mechanism ID: 9108</b>	<b>Mechanism Name: AIHA</b>
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: American International Health Alliance Twinning Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 896,964</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	896,964

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Education	112,464
Gender: GBV	33,973
Focus Area:	GBV Prevention



Sub Area:	Capacity building
Gender: Gender Equality	18,978
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Implementation

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID: 9108</b>			
<b>Mechanism Name: AIHA</b>			
<b>Prime Partner Name: American International Health Alliance Twinning Center</b>			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	350,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	546,964	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 9110</b>	<b>Mechanism Name: APHL</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Association of Public Health Laboratories	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No



Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 925,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	925,000

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 9110			
<b>Mechanism Name:</b> APHL			
<b>Prime Partner Name:</b> Association of Public Health Laboratories			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	825,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HMBL	100,000	0

**Implementing Mechanism Indicator Information**

Indicator Number	Label	2015	2016	Planning Budget Targets
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	75		Redacted
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	80		Redacted
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	60		Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	2		Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	2		Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that participate in this PT program	1		Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	1		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 9136</b>	<b>Mechanism Name: IMC MARPS</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: International Medical Corps	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 1,874,654</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,874,654

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Key Populations: MSM and TG	200,000
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Key Populations: FSW	800,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners,



	and clients
Focus Area:	Monitoring and evaluation of SW programs
Condom programming	20,000
Gender: GBV	50,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	9136		
<b>Mechanism Name:</b>	IMC MARPS		
<b>Prime Partner Name:</b>	International Medical Corps		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	265,266	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	1,595,488	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	13,900	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	18,121	46,945	Redacted
PP_PREV_DSD	Total number of people in the target population	70,303	78,545	Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	2,400	4,215	Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	7,203	7,495	Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	892	2,183	Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	3,915	6,429	Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	3,711	12,392	Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	18,121	50,101	Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	8,620	9,875	Redacted
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum	8,331	9,214	Redacted



	standards required)			
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	289	522	Redacted
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	115		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	31,971	68,609	Redacted
HTC_TST_DSD	By Test Result: Negative	30,692	42,431	Redacted
HTC_TST_DSD	By Test Result: Positive	1,279	1,780	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	31,971	44,211	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	3,000		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	9,000		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	2,191		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	8,896		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	8,503		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	381		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	31,971		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	12,000	13,994	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	19,971	21,544	Redacted



HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	31,971	35,538	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	31,971	44,211	Redacted
GEND_NORM_DS D	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	14,550	14,458	Redacted
GEND_NORM_DS D	By Age: 20-24	3,637		Redacted
GEND_NORM_DS D	By Age: 25+	10,913		Redacted
GEND_NORM_DS D	Sum of Age disaggregates	14,550		Redacted
GEND_NORM_DS D	By Sex: Male	9,603		Redacted
GEND_NORM_DS D	By Sex: Female	4,947		Redacted
GEND_NORM_DS D	Sum of Sex disaggregates	14,550		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 9143</b>	<b>Mechanism Name: Kenya Department of Defense</b>
Funding Agency: DOD	Procurement Type: Cooperative Agreement
Prime Partner Name: Henry Jackson Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,038,786</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,038,786



**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Food and Nutrition: Commodities	30,000
Gender: GBV	2,000
Focus Area:	Post GBV Care
Sub Area:	Capacity building
Education	8,000

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 9143			
<b>Mechanism Name:</b> Kenya Department of Defense			
<b>Prime Partner Name:</b> Henry Jackson Foundation			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	310,199	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	11,322	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	101,834	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	46,258	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Governance and Systems	HVSI	335,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	32,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	59,553	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	273,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	62,528	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	720,361	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	86,731	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	143	130
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	143	130
PMTCT_ARV_DSD	Life-long ART (including Option B+)	107	

PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	50	74
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	57	56
PMTCT_ARV_DSD	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	
PMTCT_ARV_DSD	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	36	
PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	143	
PMTCT_ARV_DSD	Sum of New and Current disaggregates	107	130
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	3,050	3,355
PMTCT_STAT_DSD	Number of new ANC and L&D clients	3,050	3,420
PMTCT_STAT_DSD	By: Known positives at entry	57	65
PMTCT_STAT_DSD	By: Number of new positives identified	86	65
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	143	130
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	0	1
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	0	
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	0	
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical	0	

	intra-operative AE(s)		
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	0	
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	0	
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	0	
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	0	
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)	0	
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	0	
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	75	500
VMMC_CIRC_DSD	By Age: <1	0	1
VMMC_CIRC_DSD	By Age: 1-9	0	17
VMMC_CIRC_DSD	By Age: 10-14	42	16
VMMC_CIRC_DSD	By Age: 15-19	14	46
VMMC_CIRC_DSD	By Age: 20-24	11	236
VMMC_CIRC_DSD	By Age: 25-49	5	

VMMC_CIRC_DSD	By Age: 50+	3	15
VMMC_CIRC_DSD	Sum of age disaggregates	75	331
VMMC_CIRC_DSD	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	1	5
VMMC_CIRC_DSD	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	73	495
VMMC_CIRC_DSD	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0	0
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	74	500
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	74	450
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	50
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	39,000	39,000
PP_PREV_DSD	Total number of people in the target population	135,000	135,000
PP_PREV_DSD	Age/sex: 10-14 Male	1,083	1,115
PP_PREV_DSD	Age/sex: 15-19 Male	2,167	402
PP_PREV_DSD	Age/sex: 20-24 Male	5,417	1,239
PP_PREV_DSD	Age/sex: 25-49 Male	8,667	12,051
PP_PREV_DSD	Age/sex: 50+ Male	2,167	5,314
PP_PREV_DSD	Age/sex: 10-14 Female	1,083	931
PP_PREV_DSD	Age/sex: 15-19 Female	2,167	478
PP_PREV_DSD	Age/sex: 20-24 Female	5,417	1,690
PP_PREV_DSD	Age/sex: 25-49 Female	8,665	14,030
PP_PREV_DSD	Age/sex: 50+ Female	2,167	1,750



PP_PREV_DSD	Sum of Age/Sex disaggregates	39,000	39,000
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	39,000	18,611
HTC_TST_DSD	By Test Result: Negative	38,300	18,421
HTC_TST_DSD	By Test Result: Positive	700	190
HTC_TST_DSD	Sum of Test Result disaggregates	39,000	18,611
HTC_TST_DSD	Age/sex: <1 Male	0	
HTC_TST_DSD	Age/sex: 1-4 Male	1,720	
HTC_TST_DSD	Age/sex: 5-9 Male	737	
HTC_TST_DSD	Age/sex: 10-14 Male	1,229	
HTC_TST_DSD	Age/sex: 15-19 Male	2,457	
HTC_TST_DSD	Age/sex: 20-24 Male	6,143	
HTC_TST_DSD	Age/sex: 25-49 Male	9,826	
HTC_TST_DSD	Age/sex: 50+ Male	2,457	
HTC_TST_DSD	Age/sex: <1 Female	0	
HTC_TST_DSD	Age/sex: 1-4 Female	1,010	
HTC_TST_DSD	Age/sex: 5-9 Female	433	
HTC_TST_DSD	Age/sex: 10-14 Female	722	
HTC_TST_DSD	Age/sex: 15-19 Female	1,443	
HTC_TST_DSD	Age/sex: 20-24 Female	3,608	
HTC_TST_DSD	Age/sex: 25-49 Female	5,772	
HTC_TST_DSD	Age/sex: 50+ Female	1,443	
HTC_TST_DSD	Sum of Age/Sex disaggregates	39,000	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,685	794
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	20,885	8,540
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,164	763
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	12,266	8,514
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	5,849	1,557



HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	33,151	17,054
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	39,000	18,611
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	220	276
OVC_ACC_DSD	Sex: Male	114	
OVC_ACC_DSD	Sex: Female	106	
OVC_ACC_DSD	Sum of Sex disaggregates	220	
OVC_ACC_DSD	Age: <1	7	
OVC_ACC_DSD	Age: 1-4	54	
OVC_ACC_DSD	Age: 5-9	65	
OVC_ACC_DSD	Age: 10-14	94	
OVC_ACC_DSD	Age: 15-17	0	
OVC_ACC_DSD	Age: 18+	0	
OVC_ACC_DSD	Sum of Age disaggregates	220	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	250	276
OVC_SERV_DSD	Sex: Male	157	
OVC_SERV_DSD	Sex: Female	93	
OVC_SERV_DSD	Sum of Sex disaggregates	250	
OVC_SERV_DSD	Age: <1	10	
OVC_SERV_DSD	Age: 1-4	42	
OVC_SERV_DSD	Age: 5-9	52	
OVC_SERV_DSD	Age: 10-14	52	
OVC_SERV_DSD	Age: 15-17	52	
OVC_SERV_DSD	Age: 18+	42	
OVC_SERV_DSD	Sum of Age disaggregates	250	
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	3,200	3,487

CARE_CURR_DSD	Age/sex: <1 Male	3	4
CARE_CURR_DSD	Age/sex: 1-4 Male	20	23
CARE_CURR_DSD	Age/sex: 5-9 Male	37	42
CARE_CURR_DSD	Age/sex: 10-14 Male	54	33
CARE_CURR_DSD	Age/sex: 15-19 Male	20	28
CARE_CURR_DSD	Age/sex: 20-24 Male	23	46
CARE_CURR_DSD	Age/sex: 25-49 Male	1,095	1,119
CARE_CURR_DSD	Age/sex: 50+ Male	370	463
CARE_CURR_DSD	Age/sex: <1 Female	4	4
CARE_CURR_DSD	Age/sex: 1-4 Female	34	22
CARE_CURR_DSD	Age/sex: 5-9 Female	28	41
CARE_CURR_DSD	Age/sex: 10-14 Female	40	32
CARE_CURR_DSD	Age/sex: 15-19 Female	47	44
CARE_CURR_DSD	Age/sex: 20-24 Female	124	143
CARE_CURR_DSD	Age/sex: 25-49 Female	1,227	1,338
CARE_CURR_DSD	Age/sex: 50+ Female	74	105
CARE_CURR_DSD	Sun of Age/Sex disaggregates	3,200	3,487
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	114	102
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,508	1,656
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	106	99
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,472	1,630
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	3,200	3,487
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	250	231
CARE_NEW_DSD	Age/sex: <1 Male	3	1

CARE_NEW_DSD	Age/sex: 1-4 Male	5	3
CARE_NEW_DSD	Age/sex: 5-9 Male	2	5
CARE_NEW_DSD	Age/sex: 10-14 Male	4	3
CARE_NEW_DSD	Age/sex: 15-19 Male	2	2
CARE_NEW_DSD	Age/sex: 20-24 Male	3	1
CARE_NEW_DSD	Age/sex: 25-49 Male	71	72
CARE_NEW_DSD	Age/sex: 50+ Male	19	30
CARE_NEW_DSD	Age/sex: <1 Female	2	0
CARE_NEW_DSD	Age/sex: 1-4 Female	6	2
CARE_NEW_DSD	Age/sex: 5-9 Female	4	4
CARE_NEW_DSD	Age/sex: 10-14 Female	3	3
CARE_NEW_DSD	Age/sex: 15-19 Female	4	3
CARE_NEW_DSD	Age/sex: 20-24 Female	20	9
CARE_NEW_DSD	Age/sex: 25-49 Female	96	87
CARE_NEW_DSD	Age/sex: 50+ Female	6	6
CARE_NEW_DSD	Sum of Age/sex disaggregates	250	231
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	14	12
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	95	105
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	15	9
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	126	105
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	250	231
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	2,436	
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	3,200	
FN_THER_DSD	Age: <1	2	
FN_THER_DSD	Age: 1-4	35	
FN_THER_DSD	Age: 5-14	120	
FN_THER_DSD	Age: 15-17	71	
FN_THER_DSD	Age: 18+	2,208	

FN_THER_DSD	Sum of Age disaggregates	2,436	
FN_THER_DSD	Aggregated Age: <18	228	
FN_THER_DSD	Aggregated Age: 18+	2,208	
FN_THER_DSD	Sum of Aggregated Age disaggregates	2,436	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	112	17
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	112	57
TB_ART_DSD	Age: 5-14	2	
TB_ART_DSD	Age: 15+	110	
TB_ART_DSD	Male	71	9
TB_ART_DSD	Female	41	8
TB_ART_DSD	Sum of Sex disaggregates	112	17
TB_ART_DSD	Newly tested	67	
TB_ART_DSD	Known HIV-positive	45	10
TB_ART_DSD	Sum of Test Status disaggregates	112	10
TB_ART_DSD	Aggregated Age: <15	2	3
TB_ART_DSD	Aggregated Age: 15+	110	14
TB_ART_DSD	Sum of Aggregated Age disaggregates	112	17
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	143	117
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	143	
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	136	111
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	7	6

PMTCT_EID_DSD	Sum of Infant Age disaggregates	143	117
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	2	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	2,739	3,342
TX_CURR_DSD	Age/Sex: <1 Male	4	4
TX_CURR_DSD	Age/Sex: 1-4 Male	23	22
TX_CURR_DSD	Age/Sex: 5-14 Male	88	42
TX_CURR_DSD	Age/Sex: 15+ Male	1,374	
TX_CURR_DSD	Age/Sex: <1 Female	3	4
TX_CURR_DSD	Age/Sex: 1-4 Female	28	22
TX_CURR_DSD	Age/Sex: 5-14 Female	54	41
TX_CURR_DSD	Age/Sex: 15+ Female	1,165	
TX_CURR_DSD	Sum of age/sex disaggregates	200	3,342
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	8	
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	42	
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	4	4
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	3	4
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	115	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	1,374	1,561
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	85	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	1,165	1,554
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	200	
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	2,539	3,115
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	2,739	3,115
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	7	125
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	341	715

TX_NEW_DSD	By Age/Sex: <1 Male	4	0
TX_NEW_DSD	By Age/Sex: 1-4 Male	2	2
TX_NEW_DSD	By Age/Sex: 5-9 Male	2	6
TX_NEW_DSD	By Age/Sex: 10-14 Male	3	3
TX_NEW_DSD	By Age/Sex: 15-19 Male	3	6
TX_NEW_DSD	By Age/Sex: 20-24 Male	4	6
TX_NEW_DSD	By Age/Sex: 25-49 Male	109	230
TX_NEW_DSD	By Age/Sex: 50+ Male	31	104
TX_NEW_DSD	By Age/Sex: <1 Female	3	0
TX_NEW_DSD	By Age/Sex: 1-4 Female	2	2
TX_NEW_DSD	By Age/Sex: 5-9 Female	2	6
TX_NEW_DSD	By Age/Sex: 10-14 Female	2	3
TX_NEW_DSD	By Age/Sex: 15-19 Female	3	8
TX_NEW_DSD	By Age/Sex: 20-24 Female	20	29
TX_NEW_DSD	By Age/Sex: 25-49 Female	137	285
TX_NEW_DSD	By Age/Sex: 50+ Female	14	25
TX_NEW_DSD	Sum of Age/Sex disaggregates	341	715
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	4	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	11	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	147	333
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	3	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	9	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	174	319
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	341	652
TX_NEW_DSD	Pregnancy status	34	70
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	273	406
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including	341	670

	those who have died, those who have stopped ART, and those lost to follow-up		
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	9	
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7	
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	257	
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	11	
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9	
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	321	
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	16	
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	20	

TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	257	
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	321	
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	27	
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	34	
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	2	
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	2	
LAB_ACC_DSD	Sum of Support Type disaggregates	2	
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	15	



LAB_CAP_DSD	By clinical laboratories	15	
LAB_CAP_DSD	By Point-of-care testing sites	5	
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	15	
LAB_CAP_DSD	Sum of Site Support Type disaggregates	15	
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	100	
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	8	
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	8	
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	8	
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	4	
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	4	
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	4	
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	8	
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	0	
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0	
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	1	
LAB_PT_DSD	HIV viral load: Number of laboratories that	1	

	participate in this PT program		
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1	
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that perform this testing	8	
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that participate in this PT program	8	
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	8	
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	17	14
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	17	14
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	17	
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	17	
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	17	
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	17	
FPINT_SITE_DSD	Service delivery type: Clinical	17	
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	17	



TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	3,200	3,138
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	3,200	3,487
TB_SCREEN_DSD	Age: <1	7	14
TB_SCREEN_DSD	Age: 1-4	54	87
TB_SCREEN_DSD	Age: 5-9	64	111
TB_SCREEN_DSD	Age: 10-14	94	165
TB_SCREEN_DSD	Age: 15-19	67	63
TB_SCREEN_DSD	Age: 20-24	148	
TB_SCREEN_DSD	Age: 25-49	2,322	
TB_SCREEN_DSD	Age: 50+	444	
TB_SCREEN_DSD	Sum of Age disaggregates	286	3,138
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	219	377
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	2,981	2,761
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	3,200	3,138
TB_SCREEN_DSD	Sex: Male	1,578	1,573
TB_SCREEN_DSD	Sex: Female	1,622	1,565
TB_SCREEN_DSD	Sum of Sex disaggregates	3,200	3,138

### Implementing Mechanism Details

<b>Mechanism ID: 9171</b>	<b>Mechanism Name: South Rift Valley</b>
Funding Agency: DOD	Procurement Type: Cooperative Agreement
Prime Partner Name: Henry Jackson Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	



G2G: No	Managing Agency:
---------	------------------

<b>Total All Funding Sources: 12,841,756</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	12,841,756

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	25,000
Food and Nutrition: Policy, Tools, and Service Delivery	10,000
Food and Nutrition: Commodities	25,000
Education	18,000
Key Populations: FSW	150,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Monitoring and evaluation of SW programs
Gender: Gender Equality	5,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Condom programming	50,000

**Key Issues**

(No data provided.)



### Budget Code Information

<b>Mechanism ID:</b> 9171			
<b>Mechanism Name:</b> South Rift Valley			
<b>Prime Partner Name:</b> Henry Jackson Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1,317,462	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	830,154	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	422,894	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	460,088	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	1,538,063	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	540,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	1,018,048	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	40,220	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,697,762	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVOP	507,530	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	IDUP	700	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	1,349,716	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	3,059,477	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	59,642	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	5,282	2,896
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	5,282	2,896
PMTCT_ARV_DSD	Life-long ART (including Option B+)	3,962	
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	1,849	877
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	2,113	1,201
PMTCT_ARV_DSD	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the	0	

	breastfeeding period)		
PMTCT_ARV_DSD	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	1,320	661
PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	5,282	757
PMTCT_ARV_DSD	Sum of New and Current disaggregates	3,962	2,078
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	105,872	120,342
PMTCT_STAT_DSD	Number of new ANC and L&D clients	105,872	121,755
PMTCT_STAT_DSD	By: Known positives at entry	2,113	10,500
PMTCT_STAT_DSD	By: Number of new positives identified	3,169	10,697
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	5,282	21,197
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	19,722	15,906
VMMC_CIRC_DSD	By Age: <1	0	0
VMMC_CIRC_DSD	By Age: 1-9	0	0
VMMC_CIRC_DSD	By Age: 10-14	7,889	3,121
VMMC_CIRC_DSD	By Age: 15-19	7,889	4,160
VMMC_CIRC_DSD	By Age: 20-24	2,071	3,789
VMMC_CIRC_DSD	By Age: 25-49	1,873	
VMMC_CIRC_DSD	By Age: 50+	0	74
VMMC_CIRC_DSD	Sum of age disaggregates	19,722	11,144
VMMC_CIRC_DSD	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	3,944	50
VMMC_CIRC_DSD	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	14,792	15,789
VMMC_CIRC_DSD	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	986	67
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	19,722	15,906

VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	19,722	11,453
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	31,429	
PP_PREV_DSD	Total number of people in the target population	2,249,206	
PP_PREV_DSD	Age/sex: 10-14 Male	5,657	
PP_PREV_DSD	Age/sex: 15-19 Male	3,143	
PP_PREV_DSD	Age/sex: 20-24 Male	1,886	
PP_PREV_DSD	Age/sex: 25-49 Male	1,886	
PP_PREV_DSD	Age/sex: 50+ Male	629	
PP_PREV_DSD	Age/sex: 10-14 Female	6,914	
PP_PREV_DSD	Age/sex: 15-19 Female	3,457	
PP_PREV_DSD	Age/sex: 20-24 Female	5,029	
PP_PREV_DSD	Age/sex: 25-49 Female	1,886	
PP_PREV_DSD	Age/sex: 50+ Female	942	
PP_PREV_DSD	Sum of Age/Sex disaggregates	31,429	
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	4,278	9,260
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	4,278	9,002
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results	317,450	567,274



	during the past 12 months		
HTC_TST_DSD	By Test Result: Negative	304,752	79
HTC_TST_DSD	By Test Result: Positive	12,698	2
HTC_TST_DSD	Sum of Test Result disaggregates	317,450	81
HTC_TST_DSD	Age/sex: <1 Male	0	
HTC_TST_DSD	Age/sex: 1-4 Male	11,110	
HTC_TST_DSD	Age/sex: 5-9 Male	4,762	
HTC_TST_DSD	Age/sex: 10-14 Male	7,937	
HTC_TST_DSD	Age/sex: 15-19 Male	15,873	
HTC_TST_DSD	Age/sex: 20-24 Male	39,682	
HTC_TST_DSD	Age/sex: 25-49 Male	63,491	
HTC_TST_DSD	Age/sex: 50+ Male	15,870	
HTC_TST_DSD	Age/sex: <1 Female	0	
HTC_TST_DSD	Age/sex: 1-4 Female	11,110	
HTC_TST_DSD	Age/sex: 5-9 Female	4,762	
HTC_TST_DSD	Age/sex: 10-14 Female	7,937	
HTC_TST_DSD	Age/sex: 15-19 Female	15,873	
HTC_TST_DSD	Age/sex: 20-24 Female	39,682	
HTC_TST_DSD	Age/sex: 25-49 Female	63,491	
HTC_TST_DSD	Age/sex: 50+ Female	15,870	
HTC_TST_DSD	Sum of Age/Sex disaggregates	317,450	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	23,809	40,194
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	134,916	227,656
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	23,809	40,012
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	134,916	227,934
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	47,618	80,206
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	269,832	455,590
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	317,450	535,796

OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	18,700	13,553
OVC_SERV_DSD	Sex: Male	9,350	
OVC_SERV_DSD	Sex: Female	9,350	
OVC_SERV_DSD	Sum of Sex disaggregates	18,700	
OVC_SERV_DSD	Age: <1	374	
OVC_SERV_DSD	Age: 1-4	2,992	
OVC_SERV_DSD	Age: 5-9	4,114	
OVC_SERV_DSD	Age: 10-14	4,862	
OVC_SERV_DSD	Age: 15-17	5,610	
OVC_SERV_DSD	Age: 18+	748	
OVC_SERV_DSD	Sum of Age disaggregates	18,700	
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	39,834	40,484
CARE_CURR_DSD	Age/sex: <1 Male	40	61
CARE_CURR_DSD	Age/sex: 1-4 Male	916	446
CARE_CURR_DSD	Age/sex: 5-9 Male	916	745
CARE_CURR_DSD	Age/sex: 10-14 Male	518	589
CARE_CURR_DSD	Age/sex: 15-19 Male	279	309
CARE_CURR_DSD	Age/sex: 20-24 Male	518	573
CARE_CURR_DSD	Age/sex: 25-49 Male	8,564	8,061
CARE_CURR_DSD	Age/sex: 50+ Male	1,354	2,826
CARE_CURR_DSD	Age/sex: <1 Female	159	70
CARE_CURR_DSD	Age/sex: 1-4 Female	956	441
CARE_CURR_DSD	Age/sex: 5-9 Female	797	800
CARE_CURR_DSD	Age/sex: 10-14 Female	558	619
CARE_CURR_DSD	Age/sex: 15-19 Female	1,434	552
CARE_CURR_DSD	Age/sex: 20-24 Female	3,983	2,219
CARE_CURR_DSD	Age/sex: 25-49 Female	16,970	18,411

CARE_CURR_DSD	Age/sex: 50+ Female	1,872	3,609
CARE_CURR_DSD	Sun of Age/Sex disaggregates	39,834	40,331
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,390	0
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	10,715	0
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,470	0
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	24,259	0
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	39,834	0
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	7,076	11,563
CARE_NEW_DSD	Age/sex: <1 Male	21	14
CARE_NEW_DSD	Age/sex: 1-4 Male	149	153
CARE_NEW_DSD	Age/sex: 5-9 Male	156	218
CARE_NEW_DSD	Age/sex: 10-14 Male	78	162
CARE_NEW_DSD	Age/sex: 15-19 Male	57	102
CARE_NEW_DSD	Age/sex: 20-24 Male	85	150
CARE_NEW_DSD	Age/sex: 25-49 Male	1,486	2,185
CARE_NEW_DSD	Age/sex: 50+ Male	212	834
CARE_NEW_DSD	Age/sex: <1 Female	57	31
CARE_NEW_DSD	Age/sex: 1-4 Female	170	119
CARE_NEW_DSD	Age/sex: 5-9 Female	127	256
CARE_NEW_DSD	Age/sex: 10-14 Female	120	182
CARE_NEW_DSD	Age/sex: 15-19 Female	255	172
CARE_NEW_DSD	Age/sex: 20-24 Female	778	622
CARE_NEW_DSD	Age/sex: 25-49 Female	3,042	4,954
CARE_NEW_DSD	Age/sex: 50+ Female	283	1,006

CARE_NEW_DSD	Sum of Age/sex disaggregates	7,076	11,160
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	404	0
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	1,840	0
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	474	0
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	4,358	0
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	7,076	0
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	5,975	5,940
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	11,950	5,884
FN_THER_DSD	Age: <1	956	14
FN_THER_DSD	Age: 1-4	1,315	113
FN_THER_DSD	Age: 5-14	1,912	383
FN_THER_DSD	Age: 15-17	1,075	142
FN_THER_DSD	Age: 18+	717	4,821
FN_THER_DSD	Sum of Age disaggregates	5,975	5,473
FN_THER_DSD	Aggregated Age: <18	5,258	454
FN_THER_DSD	Aggregated Age: 18+	717	3,594
FN_THER_DSD	Sum of Aggregated Age disaggregates	5,975	4,048
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,793	997
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,992	997
TB_ART_DSD	Age: 0-4	34	
TB_ART_DSD	Age: 5-14	181	
TB_ART_DSD	Age: 15+	1,578	
TB_ART_DSD	Male	968	517

TB_ART_DSD	Female	825	476
TB_ART_DSD	Sum of Sex disaggregates	1,793	993
TB_ART_DSD	Newly tested	1,076	
TB_ART_DSD	Known HIV-positive	717	388
TB_ART_DSD	Sum of Test Status disaggregates	1,793	388
TB_ART_DSD	Aggregated Age: <15	215	6
TB_ART_DSD	Aggregated Age: 15+	1,578	11
TB_ART_DSD	Sum of Aggregated Age disaggregates	1,793	17
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	4,226	2,195
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	5,282	
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	2,641	1,119
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	1,585	1,076
PMTCT_EID_DSD	Sum of Infant Age disaggregates	4,226	2,195
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	42	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	29,712	37,364
TX_CURR_DSD	Age/Sex: <1 Male	147	46
TX_CURR_DSD	Age/Sex: 1-4 Male	1,149	418
TX_CURR_DSD	Age/Sex: 5-14 Male	1,237	903
TX_CURR_DSD	Age/Sex: 15+ Male	16,800	
TX_CURR_DSD	Age/Sex: <1 Female	235	50
TX_CURR_DSD	Age/Sex: 1-4 Female	1,090	406
TX_CURR_DSD	Age/Sex: 5-14 Female	1,119	982
TX_CURR_DSD	Age/Sex: 15+ Female	7,935	
TX_CURR_DSD	Sum of age/sex disaggregates	4,977	37,084

TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	9	
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	64	
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	139	11
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	139	11
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,387	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	9,467	2,214
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,387	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	17,471	4,706
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	2,774	
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	26,938	6,920
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	29,712	6,920
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	278	697
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	4,394	10,180
TX_NEW_DSD	By Age/Sex: <1 Male	44	9
TX_NEW_DSD	By Age/Sex: 1-4 Male	154	105
TX_NEW_DSD	By Age/Sex: 5-9 Male	88	178
TX_NEW_DSD	By Age/Sex: 10-14 Male	62	144
TX_NEW_DSD	By Age/Sex: 15-19 Male	9	85
TX_NEW_DSD	By Age/Sex: 20-24 Male	40	191
TX_NEW_DSD	By Age/Sex: 25-49 Male	1,845	2,025
TX_NEW_DSD	By Age/Sex: 50+ Male	149	713
TX_NEW_DSD	By Age/Sex: <1 Female	44	10
TX_NEW_DSD	By Age/Sex: 1-4 Female	154	105
TX_NEW_DSD	By Age/Sex: 5-9 Female	57	193
TX_NEW_DSD	By Age/Sex: 10-14 Female	101	147
TX_NEW_DSD	By Age/Sex: 15-19 Female	158	137
TX_NEW_DSD	By Age/Sex: 20-24 Female	417	619

TX_NEW_DSD	By Age/Sex: 25-49 Female	923	4,612
TX_NEW_DSD	By Age/Sex: 50+ Female	149	886
TX_NEW_DSD	Sum of Age/Sex disaggregates	4,394	10,159
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	99	4
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	332	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,306	706
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	99	4
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	332	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	2,425	1,500
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	4,395	2,206
TX_NEW_DSD	Pregnancy status	1,230	0
TX_NEW_DSD	Breastfeeding status	439	0
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,515	5,336
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	4,394	5,595
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	281	
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	562	
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,671	
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the	352	

	reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	703	
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,339	
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	844	
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,671	
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,055	
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,339	
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12	2,812	



	months after initiating ART)		
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,515	
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	7	
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	7	
LAB_ACC_DSD	Sum of Support Type disaggregates	7	
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	19	
LAB_CAP_DSD	By clinical laboratories	12	
LAB_CAP_DSD	By Point-of-care testing sites	7	
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	19	
LAB_CAP_DSD	Sum of Site Support Type disaggregates	19	
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	71	
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	12	
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	8	
LAB_PT_DSD	Early infant diagnostics: Number of	1	

	laboratories that perform this testing		
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	1	
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1	
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	1	
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	1	
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1	
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	31,867	40,207
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	39,834	40,484
TB_SCREEN_DSD	Age: <1	605	120
TB_SCREEN_DSD	Age: 1-4	1,115	870
TB_SCREEN_DSD	Age: 5-9	1,147	1,532
TB_SCREEN_DSD	Age: 10-14	956	1,354
TB_SCREEN_DSD	Age: 15-19	2,295	1,172
TB_SCREEN_DSD	Age: 20-24	5,896	
TB_SCREEN_DSD	Age: 25-49	17,941	
TB_SCREEN_DSD	Age: 50+	1,912	
TB_SCREEN_DSD	Sum of Age disaggregates	6,118	40,203
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	3,823	25
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	28,044	45



TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	31,867	70
TB_SCREEN_DSD	Sex: Male	11,153	14,780
TB_SCREEN_DSD	Sex: Female	20,714	25,423
TB_SCREEN_DSD	Sum of Sex disaggregates	31,867	40,203

### Implementing Mechanism Details

<b>Mechanism ID: 11406</b>	<b>Mechanism Name: Community Grants Program</b>
Funding Agency: State/AF	Procurement Type: Grant
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 100,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	100,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Economic Strengthening	50,000
Education	50,000

### Key Issues

(No data provided.)



### Budget Code Information

<b>Mechanism ID:</b> 11406			
<b>Mechanism Name:</b> Community Grants Program			
<b>Prime Partner Name:</b> U.S. Department of State			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	50,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID:</b> 12054	<b>Mechanism Name:</b> Healthy Outcomes through Prevention Education (HOPE)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: CHF International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 1,065,916	
<b>Applied Pipeline Amount:</b> 0	
Funding Source	Funding Amount
GHP-State	1,065,916

### Sub Partner Name(s)

(No data provided.)



### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 12054			
<b>Mechanism Name:</b> Healthy Outcomes through Prevention Education (HOPE)			
<b>Prime Partner Name:</b> CHF International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	1,065,916	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID:</b> 12056	<b>Mechanism Name:</b> Inuka Community Based OVC Project (ICOP)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Ananda Marga Universal Relief Teams	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



<b>Total All Funding Sources: 289,913</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	289,913

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID: 12056</b>			
<b>Mechanism Name: Inuka Community Based OVC Project (ICOP)</b>			
<b>Prime Partner Name: Ananda Marga Universal Relief Teams</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	289,913	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	

PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	
PMTCT_STAT_DSD	Number of new ANC and L&D clients	0	
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	0	
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	0	
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0	
PP_PREV_DSD	Total number of people in the target population	0	
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	0	

HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	
GEND_GBV_DSD	Number of people receiving post-GBV care	0	
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	0	
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	549	4,121
OVC_ACC_DSD	Sex: Male	274	
OVC_ACC_DSD	Sex: Female	275	
OVC_ACC_DSD	Sum of Sex disaggregates	549	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	6,000	7,077
OVC_SERV_DSD	Sex: Male	3,000	
OVC_SERV_DSD	Sex: Female	3,000	
OVC_SERV_DSD	Sum of Sex disaggregates	6,000	
OVC_SERV_DSD	Age: 1-4	500	
OVC_SERV_DSD	Age: 5-9	1,000	
OVC_SERV_DSD	Age: 10-14	2,500	
OVC_SERV_DSD	Age: 15-17	2,000	
OVC_SERV_DSD	Sum of Age disaggregates	6,000	
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the	0	



	reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load		
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	0	
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	0	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	0	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	0	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	0	
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	0	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	0	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	0	
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	0	
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including	0	

	those who have died, those who have stopped ART, and those lost to follow-up		
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	0	
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	0	
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	0	
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	0	
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	0	
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	0	
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count	0	



	OR viral load		
--	---------------	--	--

### Implementing Mechanism Details

<b>Mechanism ID: 12082</b>	<b>Mechanism Name: Refugee Health</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: United Nations High Commissioner for Refugees	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	12082		
<b>Mechanism Name:</b>	Refugee Health		
<b>Prime Partner Name:</b>	United Nations High Commissioner for Refugees		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to	81		Redacted

	reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery			
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	81		Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	61		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	29		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	32		Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	20		Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	81		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	61		Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	20,767		Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	20,767		Redacted
PMTCT_STAT_DS D	By: Known positives at entry	38		Redacted
PMTCT_STAT_DS	By: Number of new positives identified	43		Redacted

D				
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	81		Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	7,143		Redacted
PP_PREV_DSD	Total number of people in the target population	27,712		Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	0		Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	0		Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	3,572		Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	3,571		Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	7,143		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	33,903		Redacted
HTC_TST_DSD	By Test Result: Negative	32,547		Redacted
HTC_TST_DSD	By Test Result: Positive	1,356		Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	33,903		Redacted
HTC_TST_DSD	Age/sex: <1 Male	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	1,186		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	509		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	848		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	1,694		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	4,238		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	6,781		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	1,695		Redacted
HTC_TST_DSD	Age/sex: <1 Female	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	1,186		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	509		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	848		Redacted

HTC_TST_DSD	Age/sex: 15-19 Female	1,695		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	4,238		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	6,781		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	1,695		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	33,903		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,543		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	14,408		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,543		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	14,409		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	5,086		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	28,817		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	33,903		Redacted
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	26		Redacted
OVC_ACC_DSD	Sex: Male	13		Redacted
OVC_ACC_DSD	Sex: Female	13		Redacted
OVC_ACC_DSD	Sum of Sex disaggregates	26		Redacted
OVC_ACC_DSD	Age: <1	1		Redacted
OVC_ACC_DSD	Age: 1-4	3		Redacted
OVC_ACC_DSD	Age: 5-9	7		Redacted
OVC_ACC_DSD	Age: 10-14	9		Redacted
OVC_ACC_DSD	Age: 15-17	5		Redacted
OVC_ACC_DSD	Age: 18+	1		Redacted
OVC_ACC_DSD	Sum of Age disaggregates	26		Redacted
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	2,900		Redacted

OVC_SERV_DSD	Sex: Male	1,450		Redacted
OVC_SERV_DSD	Sex: Female	1,450		Redacted
OVC_SERV_DSD	Sum of Sex disaggregates	2,900		Redacted
OVC_SERV_DSD	Age: <1	58		Redacted
OVC_SERV_DSD	Age: 1-4	348		Redacted
OVC_SERV_DSD	Age: 5-9	725		Redacted
OVC_SERV_DSD	Age: 10-14	1,044		Redacted
OVC_SERV_DSD	Age: 15-17	580		Redacted
OVC_SERV_DSD	Age: 18+	145		Redacted
OVC_SERV_DSD	Sum of Age disaggregates	2,900		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	809		Redacted
CARE_CURR_DS D	Age/sex: <1 Male	1		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	9		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	15		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	12		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	6		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	12		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	172		Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	60		Redacted
CARE_CURR_DS D	Age/sex: <1 Female	1		Redacted
CARE_CURR_DS	Age/sex: 1-4 Female	8		Redacted



D				
CARE_CURR_DS D	Age/sex: 5-9 Female	16		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	12		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	10		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	43		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	362		Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	70		Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	809		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	37		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	250		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	37		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	485		Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	809		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	147		Redacted
CARE_NEW_DSD	Age/sex: <1 Male	0		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	2		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	3		Redacted

CARE_NEW_DSD	Age/sex: 10-14 Male	2		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	1		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	4		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	33		Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	7		Redacted
CARE_NEW_DSD	Age/sex: <1 Female	0		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	2		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	3		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	2		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	2		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	4		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	61		Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	21		Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	147		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	7		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	45		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	7		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	88		Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	147		Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	128		Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	170		Redacted
FN_THER_DSD	Age: <1	0		Redacted
FN_THER_DSD	Age: 1-4	3		Redacted
FN_THER_DSD	Age: 5-14	9		Redacted
FN_THER_DSD	Age: 15-17	3		Redacted
FN_THER_DSD	Age: 18+	113		Redacted
FN_THER_DSD	Sum of Age disaggregates	128		Redacted

FN_THER_DSD	Aggregated Age: <18	15		Redacted
FN_THER_DSD	Aggregated Age: 18+	113		Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	128		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	36		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	40		Redacted
TB_ART_DSD	Age: 0-4	1		Redacted
TB_ART_DSD	Age: 5-14	2		Redacted
TB_ART_DSD	Age: 15+	33		Redacted
TB_ART_DSD	Male	19		Redacted
TB_ART_DSD	Female	17		Redacted
TB_ART_DSD	Sum of Sex disaggregates	36		Redacted
TB_ART_DSD	Newly tested	21		Redacted
TB_ART_DSD	Known HIV-positive	15		Redacted
TB_ART_DSD	Sum of Test Status disaggregates	36		Redacted
TB_ART_DSD	Aggregated Age: <15	3		Redacted
TB_ART_DSD	Aggregated Age: 15+	33		Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	36		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	65		Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	81		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	49		Redacted
PMTCT_EID_DSD	By infants who received their first	16		Redacted

	virologic HIV test between 2 and 12 months of age			
PMTCT_EID_DSD	Sum of Infant Age disaggregates	65		Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	3		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	680		Redacted
TX_CURR_DSD	Age/Sex: <1 Male	1		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	7		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	23		Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	216		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	1		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	7		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	23		Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	402		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	62		Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	80		Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	79		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	1		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	1		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	31		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	216		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	31		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	402		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	62		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	618		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	680		Redacted

TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	2		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	157		Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	3		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	2		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	3		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	3		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	1		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	2		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	33		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	11		Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	3		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	2		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	3		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	3		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	2		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	8		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	65		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	13		Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	157		Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	3		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	11		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	47		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	3		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	11		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	88		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex	157		Redacted

	disaggregates			
TX_NEW_DSD	Pregnancy status	26		Redacted
TX_NEW_DSD	Breastfeeding status	3		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	135		Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	159		Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3		Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	9		Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	123		Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4		Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those	11		Redacted

	who have died, those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	144		Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	12		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	123		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	15		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	144		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating	51		Redacted

	ART)			
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	60		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	2		Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	2		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	2		Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	2		Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	2		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	2		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0		Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type	2		Redacted



	disaggregates			
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	2		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	0		Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	2		Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	2		Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	2		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	769		Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	809		Redacted
TB_SCREEN_DSD	Age: <1	2		Redacted
TB_SCREEN_DSD	Age: 1-4	17		Redacted
TB_SCREEN_DSD	Age: 5-9	29		Redacted
TB_SCREEN_DSD	Age: 10-14	23		Redacted
TB_SCREEN_DSD	Age: 15-19	16		Redacted
TB_SCREEN_DSD	Age: 20-24	52		Redacted
TB_SCREEN_DSD	Age: 25-49	509		Redacted
TB_SCREEN_DSD	Age: 50+	121		Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	87		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	71		Redacted



TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	698		Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	769		Redacted
TB_SCREEN_DSD	Sex: Male	273		Redacted
TB_SCREEN_DSD	Sex: Female	496		Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	769		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 12083</b>	<b>Mechanism Name: Community HTC</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Liverpool VCT and Care	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 761,501</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	761,501

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	90,000
Key Populations: MSM and TG	900
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Key Populations: FSW	605



Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Economic Strengthening	67,500
Education	22,500
Gender: GBV	22,500
Focus Area:	GBV Prevention
Sub Area:	Implementation
Focus Area:	Post GBV Care
Condom programming	22,500

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 12083			
<b>Mechanism Name:</b> Community HTC			
<b>Prime Partner Name:</b> Liverpool VCT and Care			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	164,471	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	213,420	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	383,610	0

## Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	30,583	17,250	Redacted
PP_PREV_DSD	Total number of people in the target population	118,651	47,829	Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	859	0	Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	7,738	0	Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	464	2,525	Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	6,595	6,937	Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	13,765	7,788	Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	1,162	0	Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	30,583	17,250	Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	7,000	98	Redacted
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	7,000	12	Redacted
HTC_TST_DSD	Number of individuals who received	96,022	43,616	Redacted

	T&C services for HIV and received their test results during the past 12 months			
HTC_TST_DSD	By Test Result: Negative	92,181	42,412	Redacted
HTC_TST_DSD	By Test Result: Positive	3,841	1,204	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	96,022	43,616	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	0		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	0		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	0		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	0		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	500		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	12,973		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	1,821		Redacted
HTC_TST_DSD	Age/sex: <1 Female	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	0		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	0		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	500		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	14,599		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	57,345		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	6,463		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	1,821		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	96,022		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	15,294	15,384	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	500	2,519	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	80,228	24,571	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	500	3,161	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	95,522	39,955	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	96,022	43,116	Redacted



GEND_GBVDSD	Number of people receiving post-GBV care	2,386	3,224	Redacted
GEND_GBVDSD	Age: 10-14	464		Redacted
GEND_GBVDSD	Age: 15-17	1,857		Redacted
GEND_GBVDSD	Age: 18-24	20		Redacted
GEND_GBVDSD	Age: 25+	45		Redacted
GEND_GBVDSD	Sum of Age disaggregates	2,386		Redacted
GEND_GBVDSD	Sex: Female	2,386		Redacted
GEND_GBVDSD	Sum of Sex disaggregates	2,386		Redacted
GEND_GBVDSD	By type of service: Sexual Violence (Post-Rape Care)	2,321	1,084	Redacted
GEND_GBVDSD	By PEP service provision (related to sexual violence services provided)	65		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 12530</b>	<b>Mechanism Name: Provision of VMMC</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Nyanza Reproductive Health Society	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)



(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 12530			
<b>Mechanism Name:</b> Provision of VMMC			
<b>Prime Partner Name:</b> Nyanza Reproductive Health Society			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0

**Implementing Mechanism Indicator Information**

Indicator Number	Label	2015	2016	Planning Budget Targets
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	61		Redacted
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	20		Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	15		Redacted

VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	5		Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	46		Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	36		Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	5		Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	43		Redacted
VMMC_CIRC_DS D	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	8,615		Redacted
VMMC_CIRC_DS D	By Age: 1-9	0		Redacted
VMMC_CIRC_DS D	By Age: 10-14	3,489		Redacted
VMMC_CIRC_DS D	By Age: 15-19	3,446		Redacted
VMMC_CIRC_DS D	By Age: 20-24	862		Redacted
VMMC_CIRC_DS D	By Age: 25-49	818		Redacted



VMMC_CIRC_DS D	By Age: 50+	0		Redacted
VMMC_CIRC_DS D	Sum of age disaggregates	8,615		Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	86		Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	5,686		Redacted
VMMC_CIRC_DS D	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	258		Redacted
VMMC_CIRC_DS D	By circumcision technique: Surgical VMMC	8,615		Redacted
VMMC_CIRC_DS D	By circumcision technique: Device-based VMMC	862		Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	5,514		Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	1,378		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	8,615		Redacted
HTC_TST_DSD	By Test Result: Negative	8,270		Redacted
HTC_TST_DSD	By Test Result: Positive	345		Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	8,615		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	0		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	0		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	3,489		Redacted



HTC_TST_DSD	Age/sex: 15-19 Male	3,446		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	862		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	818		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	0		Redacted
HTC_TST_DSD	Age/sex: <1 Female	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	0		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	0		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	0		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	0		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	0		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	0		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	0		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	8,615		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,489		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	5,126		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	3,489		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	5,126		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	8,615		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 12540</b>	<b>Mechanism Name: MEASURE Evaluation</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University of North Carolina	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	



G2G: No	Managing Agency:
---------	------------------

<b>Total All Funding Sources: 2,800,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,800,000

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	12540		
<b>Mechanism Name:</b>	MEASURE Evaluation		
<b>Prime Partner Name:</b>	University of North Carolina		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	350,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVS1	2,450,000	0

**Implementing Mechanism Indicator Information**

Indicator Number	Label	2015	2016
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	
PMTCT_STAT_DSD	Number of new ANC and L&D clients	0	
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	0	
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	0	
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0	
PP_PREV_DSD	Total number of people in the target	0	

	population		
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	0	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	
GEND_GBV_DSD	Number of people receiving post-GBV care	0	
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	0	
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	0	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	0	
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	0	
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary	0	

	food during the reporting period.		
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	0	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	0	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	0	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	0	
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	0	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	0	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	0	
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	0	
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	0	
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal	0	



	acceptable level towards attainment of such accreditation		
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	0	
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	0	
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	0	
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	0	
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	0	
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	

### Implementing Mechanism Details

<b>Mechanism ID: 12551</b>	<b>Mechanism Name: Clinical Services</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of California at San Francisco	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 14,926,223</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	14,926,223

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Gender: GBV	373,941
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	373,941
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Human Resources for Health	2,991,535
Motor Vehicles: Leased	178,351





## Key Issues

(No data provided.)

## Budget Code Information

<b>Mechanism ID:</b> 12551			
<b>Mechanism Name:</b> Clinical Services			
<b>Prime Partner Name:</b> University of California at San Francisco			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	3,461,390	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	336,804	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	600,359	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	974,950	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,603,812	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	1,166,833	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	6,197,677	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	584,398	0

## Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	8,904		Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	8,904		Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	6,678		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	3,116		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	3,562		Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	2,226		Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	8,904		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	6,678		Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were	54,403		Redacted

	tested for HIV and received their results)			
PMTCT_STAT_DS D	Number of new ANC and L&D clients	54,403		Redacted
PMTCT_STAT_DS D	By: Known positives at entry	4,185		Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	4,719		Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	8,904		Redacted
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	6		Redacted
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	6		Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	3		Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	1		Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	3		Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative	3		Redacted

	AE(s)			
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	0		Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	111		Redacted
VMMC_CIRC_DS D	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	22,179		Redacted
VMMC_CIRC_DS D	By Age: 1-9	0		Redacted
VMMC_CIRC_DS D	By Age: 10-14	8,983		Redacted
VMMC_CIRC_DS D	By Age: 15-19	8,872		Redacted
VMMC_CIRC_DS D	By Age: 20-24	2,217		Redacted
VMMC_CIRC_DS D	By Age: 25-49	2,107		Redacted
VMMC_CIRC_DS D	By Age: 50+	0		Redacted
VMMC_CIRC_DS D	Sum of age disaggregates	22,179		Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	435		Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	20,214		Redacted
VMMC_CIRC_DS D	By HIV status: Number of clients with undocumented/indeterminate HIV	1,086		Redacted

	status or not tested for HIV at site			
VMMC_CIRC_DS D	By circumcision technique: Surgical VMMC	22,179		Redacted
VMMC_CIRC_DS D	By circumcision technique: Device-based VMMC	2,218		Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	7,763		Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	14,416		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	282,750		Redacted
HTC_TST_DSD	By Test Result: Negative	271,440		Redacted
HTC_TST_DSD	By Test Result: Positive	11,310		Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	282,750		Redacted
HTC_TST_DSD	Age/sex: <1 Male	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	9,897		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	4,242		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	7,068		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	14,137		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	35,344		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	56,550		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	14,137		Redacted
HTC_TST_DSD	Age/sex: <1 Female	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	9,897		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	4,242		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	7,068		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	14,137		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	35,344		Redacted

HTC_TST_DSD	Age/sex: 25-49 Female	56,550		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	14,137		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	282,750		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	21,207		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	120,168		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	21,207		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	120,168		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	42,414		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	240,336		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	282,750		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	94,953		Redacted
CARE_CURR_DS D	Age/sex: <1 Male	148		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	1,029		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	1,739		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	1,367		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	728		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	1,349		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	20,285		Redacted

CARE_CURR_DS D	Age/sex: 50+ Male	7,010		Redacted
CARE_CURR_DS D	Age/sex: <1 Female	148		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	978		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	1,799		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	1,358		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	1,203		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	4,991		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	42,628		Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	8,193		Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	94,953		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	4,283		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	29,372		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	4,283		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	57,015		Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	94,953		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at	17,265		Redacted

	enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load			
CARE_NEW_DSD	Age/sex: <1 Male	27		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	187		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	316		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	249		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	113		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	468		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	3,993		Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	766		Redacted
CARE_NEW_DSD	Age/sex: <1 Female	27		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	178		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	327		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	247		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	257		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	476		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	7,160		Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	2,474		Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	17,265		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	779		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	5,340		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	779		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	10,367		Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	17,265		Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	14,993		Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	19,990		Redacted
FN_THER_DSD	Age: <1	48		Redacted



FN_THER_DSD	Age: 1-4	323		Redacted
FN_THER_DSD	Age: 5-14	1,011		Redacted
FN_THER_DSD	Age: 15-17	303		Redacted
FN_THER_DSD	Age: 18+	13,308		Redacted
FN_THER_DSD	Sum of Age disaggregates	14,993		Redacted
FN_THER_DSD	Aggregated Age: <18	1,685		Redacted
FN_THER_DSD	Aggregated Age: 18+	13,308		Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	14,993		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	4,273		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	4,748		Redacted
TB_ART_DSD	Age: 0-4	106		Redacted
TB_ART_DSD	Age: 5-14	288		Redacted
TB_ART_DSD	Age: 15+	3,879		Redacted
TB_ART_DSD	Male	2,307		Redacted
TB_ART_DSD	Female	1,966		Redacted
TB_ART_DSD	Sum of Sex disaggregates	4,273		Redacted
TB_ART_DSD	Newly tested	2,564		Redacted
TB_ART_DSD	Known HIV-positive	1,709		Redacted
TB_ART_DSD	Sum of Test Status disaggregates	4,273		Redacted
TB_ART_DSD	Aggregated Age: <15	394		Redacted
TB_ART_DSD	Aggregated Age: 15+	3,879		Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	4,273		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	7,123		Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant	8,904		Redacted

	women identified during the reporting period (include known HIV-positive women at entry into PMTCT)			
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	5,342		Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	1,781		Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	7,123		Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	356		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	67,905		Redacted
TX_CURR_DSD	Age/Sex: <1 Male	105		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	716		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	2,240		Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	21,624		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	106		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	716		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	2,239		Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	40,159		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	6,122		Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	1		Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	1		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	105		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	105		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	3,061		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	21,624		Redacted

TX_CURR_DSD	Aggregated Age/Sex: <15 Female	3,061		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	40,159		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	6,122		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	61,783		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	67,905		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	210		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	10,802		Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	229		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	129		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	228		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	176		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	81		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	149		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	2,243		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	775		Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	229		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	129		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	228		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	176		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	126		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	527		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	4,509		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	868		Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	10,802		Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	228		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	762		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	3,248		Redacted

TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	228		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	762		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	6,030		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	10,802		Redacted
TX_NEW_DSD	Pregnancy status	2,805		Redacted
TX_NEW_DSD	Breastfeeding status	312		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	9,306		Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	10,948		Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	230		Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	627		Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8,448		Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those	271		Redacted

	who have died, those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	738		Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9,939		Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	858		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8,448		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,009		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting	9,939		Redacted

	period, including those who have died, those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,565		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,547		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	140		Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	140		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	140		Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	105		Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	140		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	105		Redacted

FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0		Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	105		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	140		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	0		Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	140		Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	105		Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	105		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	90,206		Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	94,953		Redacted
TB_SCREEN_DSD	Age: <1	288		Redacted
TB_SCREEN_DSD	Age: 1-4	1,946		Redacted
TB_SCREEN_DSD	Age: 5-9	3,435		Redacted
TB_SCREEN_DSD	Age: 10-14	2,645		Redacted
TB_SCREEN_DSD	Age: 15-19	1,824		Redacted



TB_SCREEN_DSD	Age: 20-24	6,082		Redacted
TB_SCREEN_DSD	Age: 25-49	59,736		Redacted
TB_SCREEN_DSD	Age: 50+	14,250		Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	10,138		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	8,314		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	81,892		Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	90,206		Redacted
TB_SCREEN_DSD	Sex: Male	32,000		Redacted
TB_SCREEN_DSD	Sex: Female	58,206		Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	90,206		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 12555</b>	<b>Mechanism Name: Clinical Services/Centers of Excellence</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Nairobi	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 2,895,614</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,895,614

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)





Human Resources for Health	579,123
Gender: GBV	72,390
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	72,390
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 12555			
<b>Mechanism Name:</b> Clinical Services/Centers of Excellence			
<b>Prime Partner Name:</b> University of Nairobi			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	404,748	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	130,858	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	52,732	0

Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	350,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	64,453	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	194,475	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,693,498	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	4,850	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,178		Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	1,178		Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	884		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current	413		Redacted

	pregnancy			
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	471		Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	294		Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	1,178		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	884		Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	14,103		Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	14,103		Redacted
PMTCT_STAT_DS D	By: Known positives at entry	554		Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	624		Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	1,178		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	67,292		Redacted
HTC_TST_DSD	By Test Result: Negative	64,600		Redacted
HTC_TST_DSD	By Test Result: Positive	2,692		Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	67,292		Redacted

HTC_TST_DSD	Age/sex: <1 Male	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	2,355		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	1,009		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	1,683		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	3,365		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	8,412		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	13,458		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	3,364		Redacted
HTC_TST_DSD	Age/sex: <1 Female	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	2,355		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	1,009		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	1,683		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	3,365		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	8,412		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	13,458		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	3,364		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	67,292		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	5,047		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	28,599		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	5,047		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	28,599		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	10,094		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	57,198		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	67,292		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO	8,429		Redacted



	staging) OR CD4 count OR viral load			
CARE_CURR_DS D	Age/sex: <1 Male	13		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	91		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	154		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	122		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	65		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	121		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	1,801		Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	621		Redacted
CARE_CURR_DS D	Age/sex: <1 Female	13		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	87		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	160		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	120		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	107		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	443		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	3,784		Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	727		Redacted
CARE_CURR_DS	Sun of Age/Sex disaggregates	8,429		Redacted

D				
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	380		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,608		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	380		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	5,061		Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	8,429		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	1,533		Redacted
CARE_NEW_DSD	Age/sex: <1 Male	2		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	17		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	28		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	22		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	10		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	42		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	354		Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	68		Redacted
CARE_NEW_DSD	Age/sex: <1 Female	2		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	16		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	29		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	22		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	23		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	42		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	636		Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	220		Redacted

CARE_NEW_DSD	Sum of Age/sex disaggregates	1,533		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	69		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	474		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	69		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	921		Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	1,533		Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	1,331		Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	1,775		Redacted
FN_THER_DSD	Age: <1	4		Redacted
FN_THER_DSD	Age: 1-4	29		Redacted
FN_THER_DSD	Age: 5-14	90		Redacted
FN_THER_DSD	Age: 15-17	27		Redacted
FN_THER_DSD	Age: 18+	1,181		Redacted
FN_THER_DSD	Sum of Age disaggregates	1,331		Redacted
FN_THER_DSD	Aggregated Age: <18	150		Redacted
FN_THER_DSD	Aggregated Age: 18+	1,181		Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	1,331		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	379		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	421		Redacted
TB_ART_DSD	Age: 0-4	9		Redacted
TB_ART_DSD	Age: 5-14	26		Redacted

TB_ART_DSD	Age: 15+	344		Redacted
TB_ART_DSD	Male	205		Redacted
TB_ART_DSD	Female	174		Redacted
TB_ART_DSD	Sum of Sex disaggregates	379		Redacted
TB_ART_DSD	Newly tested	228		Redacted
TB_ART_DSD	Known HIV-positive	151		Redacted
TB_ART_DSD	Sum of Test Status disaggregates	379		Redacted
TB_ART_DSD	Aggregated Age: <15	35		Redacted
TB_ART_DSD	Aggregated Age: 15+	344		Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	379		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	943		Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	1,178		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	707		Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	236		Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	943		Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	47		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	9,013		Redacted
TX_CURR_DSD	Age/Sex: <1 Male	14		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	95		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	297		Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	2,870		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	14		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	95		Redacted



TX_CURR_DSD	Age/Sex: 5-14 Female	298		Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	5,330		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	813		Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	98		Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	98		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	14		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	14		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	406		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	2,870		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	407		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	5,330		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	813		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	8,200		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	9,013		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	28		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	980		Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	21		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	12		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	21		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	15		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	7		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	14		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	203		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	71		Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	21		Redacted

TX_NEW_DSD	By Age/Sex: 1-4 Female	12		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	21		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	15		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	12		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	48		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	409		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	78		Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	980		Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	21		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	69		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	295		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	21		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	69		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	547		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	980		Redacted
TX_NEW_DSD	Pregnancy status	371		Redacted
TX_NEW_DSD	Breastfeeding status	41		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	844		Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	993		Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on	21		Redacted

	treatment at 12 months after initiating ART)			
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	57		Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	766		Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	25		Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	67		Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	901		Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	78		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator:	766		Redacted

	Number of adults and children who are still alive and on treatment at 12 months after initiating ART)			
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	92		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	901		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	736		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	866		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	2		Redacted
LAB_CAP_DSD	By clinical laboratories	0		Redacted
LAB_CAP_DSD	By Point-of-care testing sites	0		Redacted
LAB_CAP_DSD	By site support type: Direct Service	2		Redacted

	Delivery (DSD)			
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	0		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	2		Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	2		Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	2		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	2		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0		Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	2		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	2		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	0		Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type	2		Redacted



	disaggregates			
FPINT_SITE_DSD	Service delivery type: Clinical	2		Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	2		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	8,008		Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	8,429		Redacted
TB_SCREEN_DSD	Age: <1	26		Redacted
TB_SCREEN_DSD	Age: 1-4	173		Redacted
TB_SCREEN_DSD	Age: 5-9	305		Redacted
TB_SCREEN_DSD	Age: 10-14	234		Redacted
TB_SCREEN_DSD	Age: 15-19	162		Redacted
TB_SCREEN_DSD	Age: 20-24	540		Redacted
TB_SCREEN_DSD	Age: 25-49	5,303		Redacted
TB_SCREEN_DSD	Age: 50+	1,265		Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	900		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	738		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	7,270		Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	8,008		Redacted
TB_SCREEN_DSD	Sex: Male	2,841		Redacted
TB_SCREEN_DSD	Sex: Female	5,167		Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	8,008		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 12585</b>	<b>Mechanism Name: Eastern and Western Kenya</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement



Prime Partner Name: Columbia University Mailman School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 26,005,928</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	26,005,928

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	5,205,903
Renovation	500,000
Motor Vehicles: Leased	178,351
Gender: GBV	650,738
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	650,738
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation



## Key Issues

(No data provided.)

## Budget Code Information

<b>Mechanism ID:</b> 12585			
<b>Mechanism Name:</b> Eastern and Western Kenya			
<b>Prime Partner Name:</b> Columbia University Mailman School of Public Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	6,151,247	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	1,438,789	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	1,007,256	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	731,228	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	2,924,969	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	2,669,195	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	10,753,887	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	329,357	0



## Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	12,816		Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	12,816		Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	9,612		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	4,486		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	5,126		Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	3,204		Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	12,816		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	9,612		Redacted

PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,114		Redacted
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	1,114		Redacted
PMTCT_ARV_TA	Life-long ART (including Option B+)	836		Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	390		Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	446		Redacted
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	278		Redacted
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	1,114		Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	836		Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	107,914		Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	107,914		Redacted
PMTCT_STAT_DS D	By: Known positives at entry	6,024		Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	6,792		Redacted

PMTCT_STAT_DS D	Sum of Positives Status disaggregates	12,816		Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	15,058		Redacted
PMTCT_STAT_TA	Number of new ANC and L&D clients	15,058		Redacted
PMTCT_STAT_TA	By: Known positives at entry	524		Redacted
PMTCT_STAT_TA	By: Number of new positives identified	590		Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	1,114		Redacted
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	39		Redacted
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	39		Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	11		Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	1		Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	28		Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative	22		Redacted

	AE(s)			
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	6		Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	72		Redacted
VMMC_CIRC_DS D	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	14,314		Redacted
VMMC_CIRC_DS D	By Age: 1-9	0		Redacted
VMMC_CIRC_DS D	By Age: 10-14	5,798		Redacted
VMMC_CIRC_DS D	By Age: 15-19	5,726		Redacted
VMMC_CIRC_DS D	By Age: 20-24	1,431		Redacted
VMMC_CIRC_DS D	By Age: 25-49	1,359		Redacted
VMMC_CIRC_DS D	By Age: 50+	0		Redacted
VMMC_CIRC_DS D	Sum of age disaggregates	14,314		Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	132		Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	11,984		Redacted
VMMC_CIRC_DS D	By HIV status: Number of clients with undocumented/indeterminate HIV	1,053		Redacted

	status or not tested for HIV at site			
VMMC_CIRC_DS D	By circumcision technique: Surgical VMMC	14,314		Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	5,582		Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	8,732		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	622,949		Redacted
HTC_TST_DSD	By Test Result: Negative	598,031		Redacted
HTC_TST_DSD	By Test Result: Positive	24,918		Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	622,949		Redacted
HTC_TST_DSD	Age/sex: <1 Male	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	21,803		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	9,344		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	15,574		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	31,148		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	77,869		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	124,590		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	31,146		Redacted
HTC_TST_DSD	Age/sex: <1 Female	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	21,803		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	9,344		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	15,574		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	31,148		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	77,869		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	124,590		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	31,147		Redacted

HTC_TST_DSD	Sum of Age/Sex disaggregates	622,949		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	46,721		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	264,753		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	46,721		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	264,754		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	93,442		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	529,507		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	622,949		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	149,027		Redacted
CARE_CURR_DS D	Age/sex: <1 Male	233		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	1,615		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	2,729		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	2,145		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	1,143		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	2,118		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	31,837		Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	11,000		Redacted

CARE_CURR_DS D	Age/sex: <1 Female	232		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	1,534		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	2,823		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	2,133		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	1,888		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	7,834		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	66,903		Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	12,860		Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	149,027		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	6,722		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	46,098		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	6,722		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	89,485		Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	149,027		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	27,097		Redacted

CARE_NEW_DSD	Age/sex: <1 Male	42		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	294		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	496		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	390		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	177		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	734		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	6,266		Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	1,205		Redacted
CARE_NEW_DSD	Age/sex: <1 Female	42		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	279		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	513		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	388		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	403		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	748		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	11,237		Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	3,883		Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	27,097		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	1,222		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	8,382		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	1,222		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	16,271		Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	27,097		Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	23,531		Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	31,374		Redacted
FN_THER_DSD	Age: <1	75		Redacted
FN_THER_DSD	Age: 1-4	508		Redacted
FN_THER_DSD	Age: 5-14	1,586		Redacted



FN_THER_DSD	Age: 15-17	476		Redacted
FN_THER_DSD	Age: 18+	20,886		Redacted
FN_THER_DSD	Sum of Age disaggregates	23,531		Redacted
FN_THER_DSD	Aggregated Age: <18	2,645		Redacted
FN_THER_DSD	Aggregated Age: 18+	20,886		Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	23,531		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	6,706		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	7,451		Redacted
TB_ART_DSD	Age: 0-4	166		Redacted
TB_ART_DSD	Age: 5-14	452		Redacted
TB_ART_DSD	Age: 15+	6,088		Redacted
TB_ART_DSD	Male	3,621		Redacted
TB_ART_DSD	Female	3,085		Redacted
TB_ART_DSD	Sum of Sex disaggregates	6,706		Redacted
TB_ART_DSD	Newly tested	4,024		Redacted
TB_ART_DSD	Known HIV-positive	2,682		Redacted
TB_ART_DSD	Sum of Test Status disaggregates	6,706		Redacted
TB_ART_DSD	Aggregated Age: <15	618		Redacted
TB_ART_DSD	Aggregated Age: 15+	6,088		Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	6,706		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	11,144		Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive	13,930		Redacted

	women at entry into PMTCT)			
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	8,358		Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	2,786		Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	11,144		Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	557		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	122,044		Redacted
TX_CURR_DSD	Age/Sex: <1 Male	190		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	1,288		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	4,024		Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	38,864		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	190		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	1,288		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	4,024		Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	72,176		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	11,004		Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	1		Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	1		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	190		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	190		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	5,502		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	38,864		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	5,502		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	72,176		Redacted

TX_CURR_DSD	Sum of Aggregated Age/Sex <15	11,004		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	111,040		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	122,044		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	380		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	24,088		Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	509		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	288		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	509		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	392		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	180		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	333		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	5,002		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	1,727		Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	509		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	288		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	509		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	392		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	284		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,177		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	10,055		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	1,934		Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	24,088		Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	509		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	1,698		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	7,242		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	509		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15	1,698		Redacted

	Female			
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	13,450		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	24,088		Redacted
TX_NEW_DSD	Pregnancy status	4,388		Redacted
TX_NEW_DSD	Breastfeeding status	488		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	20,751		Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	24,413		Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	514		Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,399		Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	18,838		Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	605		Redacted

TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,645		Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	22,163		Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,913		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	18,838		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,250		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	22,163		Redacted

TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8,706		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	10,242		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	212		Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	212		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	212		Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	570		Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	760		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	451		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by	119		Redacted

	PEPFAR for HIV services that are directly providing integrated voluntary family planning services			
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	570		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	601		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	159		Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	760		Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	570		Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	570		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	141,576		Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	149,027		Redacted
TB_SCREEN_DSD	Age: <1	451		Redacted
TB_SCREEN_DSD	Age: 1-4	3,055		Redacted
TB_SCREEN_DSD	Age: 5-9	5,391		Redacted
TB_SCREEN_DSD	Age: 10-14	4,152		Redacted
TB_SCREEN_DSD	Age: 15-19	2,864		Redacted
TB_SCREEN_DSD	Age: 20-24	9,545		Redacted
TB_SCREEN_DSD	Age: 25-49	93,754		Redacted



TB_SCREEN_DSD	Age: 50+	22,364		Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	15,913		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	13,049		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	128,527		Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	141,576		Redacted
TB_SCREEN_DSD	Sex: Male	50,224		Redacted
TB_SCREEN_DSD	Sex: Female	91,352		Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	141,576		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 12598</b>	<b>Mechanism Name: HIV Prevention in the General Population and Youth</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: International Rescue Committee	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)





## Key Issues

(No data provided.)

## Budget Code Information

<b>Mechanism ID:</b>	12598		
<b>Mechanism Name:</b>	HIV Prevention in the General Population and Youth		
<b>Prime Partner Name:</b>	International Rescue Committee		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVAB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	0	0

## Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	87,912		Redacted
PP_PREV_DSD	Total number of people in the target population	341,065		Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	20,099		Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	20,098		Redacted



PP_PREV_DSD	Age/sex: 15-19 Female	23,858		Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	23,857		Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	87,912		Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	271		Redacted
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	271		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	71,044		Redacted
HTC_TST_DSD	By Test Result: Negative	68,203		Redacted
HTC_TST_DSD	By Test Result: Positive	2,841		Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	71,044		Redacted
HTC_TST_DSD	Age/sex: <1 Male	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	2,477		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	1,061		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	1,769		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	3,538		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	8,986		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	14,152		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	3,538		Redacted
HTC_TST_DSD	Age/sex: <1 Female	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	2,477		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	1,061		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	1,769		Redacted



HTC_TST_DSD	Age/sex: 15-19 Female	3,538		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	8,986		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	14,153		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	3,539		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	71,044		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	5,307		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	30,214		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	5,307		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	30,216		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	10,614		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	60,430		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	71,044		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 12605</b>	<b>Mechanism Name: Clinical Services</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Care International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 5,446,715</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	5,446,715

### Sub Partner Name(s)

Custom



(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	1,089,143
Gender: GBV	136,138
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	136,138
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	12605		
<b>Mechanism Name:</b>	Clinical Services		
<b>Prime Partner Name:</b>	Care International		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	957,785	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>

Care	HVTB	323,236	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	176,175	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	1,566,549	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	515,196	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	1,904,220	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	3,554	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	2,419		Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	2,419		Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	1,814		Redacted
PMTCT_ARV_DS	Sub-Disag of Life-long ART: Newly	846		Redacted

D	initiated on treatment during the current pregnancy			
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	968		Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	605		Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	2,419		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	1,814		Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	50,641		Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	50,641		Redacted
PMTCT_STAT_DS D	By: Known positives at entry	1,137		Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	1,282		Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	2,419		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	190,122		Redacted
HTC_TST_DSD	By Test Result: Negative	182,517		Redacted
HTC_TST_DSD	By Test Result: Positive	7,605		Redacted



HTC_TST_DSD	Sum of Test Result disaggregates	190,122		Redacted
HTC_TST_DSD	Age/sex: <1 Male	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	6,654		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	2,852		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	4,753		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	9,507		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	23,765		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	38,024		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	9,506		Redacted
HTC_TST_DSD	Age/sex: <1 Female	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	6,654		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	2,852		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	4,753		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	9,507		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	23,765		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	38,024		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	9,506		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	190,122		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	14,259		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	80,802		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	14,259		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	80,802		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	28,518		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	161,604		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	190,122		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting	14,635		Redacted



	period: clinical assessment (WHO staging) OR CD4 count OR viral load			
CARE_CURR_DS D	Age/sex: <1 Male	23		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	159		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	268		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	210		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	112		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	208		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	3,127		Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	1,080		Redacted
CARE_CURR_DS D	Age/sex: <1 Female	23		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	151		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	277		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	209		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	185		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	769		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	6,570		Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	1,264		Redacted



CARE_CURR_DS D	Sun of Age/Sex disaggregates	14,635		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	660		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	4,527		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	660		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	8,788		Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	14,635		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	2,661		Redacted
CARE_NEW_DSD	Age/sex: <1 Male	4		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	29		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	49		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	38		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	18		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	72		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	615		Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	118		Redacted
CARE_NEW_DSD	Age/sex: <1 Female	4		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	29		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	49		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	38		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	40		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	73		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	1,104		Redacted

CARE_NEW_DSD	Age/sex: 50+ Female	381		Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	2,661		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	120		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	823		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	120		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	1,598		Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	2,661		Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	2,311		Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	3,081		Redacted
FN_THER_DSD	Age: <1	7		Redacted
FN_THER_DSD	Age: 1-4	50		Redacted
FN_THER_DSD	Age: 5-14	156		Redacted
FN_THER_DSD	Age: 15-17	47		Redacted
FN_THER_DSD	Age: 18+	2,051		Redacted
FN_THER_DSD	Sum of Age disaggregates	2,311		Redacted
FN_THER_DSD	Aggregated Age: <18	260		Redacted
FN_THER_DSD	Aggregated Age: 18+	2,051		Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	2,311		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	659		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	732		Redacted
TB_ART_DSD	Age: 0-4	16		Redacted

TB_ART_DSD	Age: 5-14	45		Redacted
TB_ART_DSD	Age: 15+	598		Redacted
TB_ART_DSD	Male	356		Redacted
TB_ART_DSD	Female	303		Redacted
TB_ART_DSD	Sum of Sex disaggregates	659		Redacted
TB_ART_DSD	Newly tested	395		Redacted
TB_ART_DSD	Known HIV-positive	264		Redacted
TB_ART_DSD	Sum of Test Status disaggregates	659		Redacted
TB_ART_DSD	Aggregated Age: <15	61		Redacted
TB_ART_DSD	Aggregated Age: 15+	598		Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	659		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,935		Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	2,419		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,451		Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	484		Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,935		Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	97		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	14,995		Redacted
TX_CURR_DSD	Age/Sex: <1 Male	23		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	158		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	495		Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	4,775		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	23		Redacted

TX_CURR_DSD	Age/Sex: 1-4 Female	158		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	495		Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	8,868		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	1,352		Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	1		Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	1		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	23		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	23		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	676		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	4,775		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	676		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	8,868		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,352		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	13,643		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	14,995		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	46		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,129		Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	66		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	37		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	66		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	52		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	23		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	42		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	650		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	225		Redacted

TX_NEW_DSD	By Age/Sex: <1 Female	66		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	37		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	66		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	52		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	37		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	153		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	1,306		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	251		Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	3,129		Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	66		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	221		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	940		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	66		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	221		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,747		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	3,129		Redacted
TX_NEW_DSD	Pregnancy status	762		Redacted
TX_NEW_DSD	Breastfeeding status	85		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,696		Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	3,172		Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults	67		Redacted

	and children who are still alive and on treatment at 12 months after initiating ART)			
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	182		Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,447		Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	79		Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	214		Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,879		Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	248		Redacted

TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,447		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	292		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,879		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,512		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,779		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	124		Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	124		Redacted
LAB_CAP_DSD	Sum of Site Support Type	124		Redacted

	disaggregates			
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	93		Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	124		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	93		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0		Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	93		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	124		Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	124		Redacted
FPINT_SITE_DSD	Service delivery type: Community	0		Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	93		Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	93		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility	13,904		Redacted





	during the reporting period			
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	14,635		Redacted
TB_SCREEN_DSD	Age: <1	44		Redacted
TB_SCREEN_DSD	Age: 1-4	300		Redacted
TB_SCREEN_DSD	Age: 5-9	529		Redacted
TB_SCREEN_DSD	Age: 10-14	408		Redacted
TB_SCREEN_DSD	Age: 15-19	281		Redacted
TB_SCREEN_DSD	Age: 20-24	939		Redacted
TB_SCREEN_DSD	Age: 25-49	9,207		Redacted
TB_SCREEN_DSD	Age: 50+	2,196		Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	1,562		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	1,281		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	12,623		Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	13,904		Redacted
TB_SCREEN_DSD	Sex: Male	4,933		Redacted
TB_SCREEN_DSD	Sex: Female	8,971		Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	13,904		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 12637</b>	<b>Mechanism Name: Strengthening Strategic Information in Kenya</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Futures Group	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



<b>Total All Funding Sources: 2,100,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,100,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID: 12637</b>			
<b>Mechanism Name: Strengthening Strategic Information in Kenya</b>			
<b>Prime Partner Name: Futures Group</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	2,100,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 12656</b>	<b>Mechanism Name: Clinical Services</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement



Prime Partner Name: Eastern Deanery AIDS Relief Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 6,774,111</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	6,774,111

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	3,392,332
Renovation	15,600
Gender: GBV	169,617
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	169,617
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation



## Key Issues

(No data provided.)

## Budget Code Information

<b>Mechanism ID:</b>	12656		
<b>Mechanism Name:</b>	Clinical Services		
<b>Prime Partner Name:</b>	Eastern Deanery AIDS Relief Program		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	1,184,305	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	364,380	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	84,206	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	327,112	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	83,481	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	337,084	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	4,383,458	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	10,085	0

## Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,214		Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	1,214		Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	910		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	425		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	485		Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	304		Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	1,214		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	910		Redacted
PMTCT_STAT_DS	Number of pregnant women with known	5,002		Redacted

D	HIV status (includes women who were tested for HIV and received their results)			
PMTCT_STAT_DS D	Number of new ANC and L&D clients	5,002		Redacted
PMTCT_STAT_DS D	By: Known positives at entry	571		Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	643		Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	1,214		Redacted
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	35		Redacted
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	35		Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	30		Redacted
VMMC_CIRC_DS D	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	5,957		Redacted
VMMC_CIRC_DS D	By Age: 10-14	2,413		Redacted
VMMC_CIRC_DS D	By Age: 15-19	2,383		Redacted
VMMC_CIRC_DS D	By Age: 20-24	595		Redacted
VMMC_CIRC_DS D	By Age: 25-49	566		Redacted
VMMC_CIRC_DS	By Age: 50+	0		Redacted

D				
VMMC_CIRC_DS D	Sum of age disaggregates	5,957		Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	295		Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	4,836		Redacted
VMMC_CIRC_DS D	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	766		Redacted
VMMC_CIRC_DS D	By circumcision technique: Surgical VMMC	5,957		Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	1,772		Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	3,291		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	231,235		Redacted
HTC_TST_DSD	By Test Result: Negative	221,986		Redacted
HTC_TST_DSD	By Test Result: Positive	9,249		Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	231,235		Redacted
HTC_TST_DSD	Age/sex: <1 Male	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	8,093		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	3,469		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	5,781		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	11,562		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	28,904		Redacted

HTC_TST_DSD	Age/sex: 25-49 Male	46,247		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	11,561		Redacted
HTC_TST_DSD	Age/sex: <1 Female	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	8,093		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	3,469		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	5,781		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	11,562		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	28,904		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	46,247		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	11,562		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	231,235		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	17,343		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	98,274		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	17,343		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	98,275		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	34,686		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	196,549		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	231,235		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	34,838		Redacted
CARE_CURR_DS D	Age/sex: <1 Male	54		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	378		Redacted
CARE_CURR_DS	Age/sex: 5-9 Male	638		Redacted



D				
CARE_CURR_DS D	Age/sex: 10-14 Male	502		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	267		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	495		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	7,443		Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	2,571		Redacted
CARE_CURR_DS D	Age/sex: <1 Female	54		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	359		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	660		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	498		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	441		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	1,831		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	15,640		Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	3,007		Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	34,838		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,572		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	10,776		Redacted
CARE_CURR_DS	Aggregated Age/sex - USE WITH HQ	1,571		Redacted

D	PERMISSION ONLY: <15 Female			
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	20,919		Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	34,838		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	6,335		Redacted
CARE_NEW_DSD	Age/sex: <1 Male	10		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	69		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	116		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	91		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	41		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	172		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	1,465		Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	281		Redacted
CARE_NEW_DSD	Age/sex: <1 Female	10		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	65		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	120		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	91		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	94		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	175		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	2,627		Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	908		Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	6,335		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	286		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	1,959		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	286		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	3,804		Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex	6,335		Redacted

	disaggregates			
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	5,501		Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	7,334		Redacted
FN_THER_DSD	Age: <1	18		Redacted
FN_THER_DSD	Age: 1-4	119		Redacted
FN_THER_DSD	Age: 5-14	371		Redacted
FN_THER_DSD	Age: 15-17	110		Redacted
FN_THER_DSD	Age: 18+	4,883		Redacted
FN_THER_DSD	Sum of Age disaggregates	5,501		Redacted
FN_THER_DSD	Aggregated Age: <18	618		Redacted
FN_THER_DSD	Aggregated Age: 18+	4,883		Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	5,501		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,568		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,742		Redacted
TB_ART_DSD	Age: 0-4	39		Redacted
TB_ART_DSD	Age: 5-14	106		Redacted
TB_ART_DSD	Age: 15+	1,423		Redacted
TB_ART_DSD	Male	847		Redacted
TB_ART_DSD	Female	721		Redacted
TB_ART_DSD	Sum of Sex disaggregates	1,568		Redacted
TB_ART_DSD	Newly tested	941		Redacted

TB_ART_DSD	Known HIV-positive	627		Redacted
TB_ART_DSD	Sum of Test Status disaggregates	1,568		Redacted
TB_ART_DSD	Aggregated Age: <15	145		Redacted
TB_ART_DSD	Aggregated Age: 15+	1,423		Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	1,568		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	971		Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	1,214		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	728		Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	243		Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	971		Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	49		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	27,976		Redacted
TX_CURR_DSD	Age/Sex: <1 Male	44		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	295		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	922		Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	8,909		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	44		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	295		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	922		Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	16,545		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	2,522		Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy	76		Redacted

	(ART) [CURRENT]			
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	75		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	44		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	44		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,261		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	8,909		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,261		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	16,545		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	2,522		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	25,454		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	27,976		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	88		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	4,540		Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	96		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	54		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	96		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	74		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	34		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	63		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	943		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	326		Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	96		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	54		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	96		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	74		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	53		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	222		Redacted

TX_NEW_DSD	By Age/Sex: 25-49 Female	1,895		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	364		Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	4,540		Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	96		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	320		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,365		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	96		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	320		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	2,535		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	4,540		Redacted
TX_NEW_DSD	Pregnancy status	382		Redacted
TX_NEW_DSD	Breastfeeding status	42		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,911		Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	4,601		Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	97		Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after	264		Redacted

	initiating ART)			
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,550		Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	114		Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	310		Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,177		Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	360		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,550		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children	424		Redacted

	who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,177		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	758		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	892		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	7		Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	7		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	7		Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	11		Redacted



FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	14		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	11		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0		Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	11		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	14		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	0		Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	14		Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	11		Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	11		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	33,096		Redacted
TB_SCREEN_DSD	Number of HIV positive adults and	34,838		Redacted



	children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load			
TB_SCREEN_DSD	Age: <1	105		Redacted
TB_SCREEN_DSD	Age: 1-4	714		Redacted
TB_SCREEN_DSD	Age: 5-9	1,260		Redacted
TB_SCREEN_DSD	Age: 10-14	971		Redacted
TB_SCREEN_DSD	Age: 15-19	669		Redacted
TB_SCREEN_DSD	Age: 20-24	2,231		Redacted
TB_SCREEN_DSD	Age: 25-49	21,917		Redacted
TB_SCREEN_DSD	Age: 50+	5,229		Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	3,719		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	3,050		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	30,046		Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	33,096		Redacted
TB_SCREEN_DSD	Sex: Male	11,741		Redacted
TB_SCREEN_DSD	Sex: Female	21,355		Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	33,096		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 12658</b>	<b>Mechanism Name: Clinical Services</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Mkomani Society Clinic	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 3,736,584</b>	
<b>Applied Pipeline Amount: 0</b>	



Funding Source	Funding Amount
GHP-State	3,736,584

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	1,008,878
Economic Strengthening	42,000
Education	42,000
Gender: GBV	93,415
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	93,415
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation

### Key Issues

(No data provided.)

### Budget Code Information

Mechanism ID:	12658
---------------	-------



<b>Mechanism Name:</b> Clinical Services			
<b>Prime Partner Name:</b> Mkomani Society Clinic			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	858,267	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	140,505	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	280,395	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	122,834	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	42,019	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	IDUP	127,395	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	169,674	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	1,993,114	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	2,381	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning
------------------	-------	------	------	----------

				<b>Budget Targets</b>
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	923		Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	923		Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	692		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	323		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	369		Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	231		Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	923		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	692		Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	4,959		Redacted
PMTCT_STAT_DS	Number of new ANC and L&D clients	4,959		Redacted

D				
PMTCT_STAT_DS D	By: Known positives at entry	434		Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	489		Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	923		Redacted
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	300		Redacted
KP_MAT_DSD	Sex: Male	240		Redacted
KP_MAT_DSD	Sex: Female	60		Redacted
KP_MAT_DSD	Sum of Sex disaggregates	300		Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	300		Redacted
PP_PREV_DSD	Total number of people in the target population	1,680		Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	100		Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	50		Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	100		Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	50		Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	300		Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	1,000		Redacted
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive	0		Redacted

	interventions that are based on evidence and/or meet the minimum standards required)			
KP_PREV_DSD	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	800		Redacted
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	200		Redacted
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0		Redacted
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their	34,856		Redacted



	test results during the past 12 months			
HTC_TST_DSD	By Test Result: Negative	33,462		Redacted
HTC_TST_DSD	By Test Result: Positive	1,394		Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	34,856		Redacted
HTC_TST_DSD	Age/sex: <1 Male	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	1,220		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	523		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	871		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	1,743		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	4,357		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	6,971		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	1,743		Redacted
HTC_TST_DSD	Age/sex: <1 Female	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	1,220		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	523		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	871		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	1,743		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	4,357		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	6,971		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	1,743		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	34,856		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,614		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	14,814		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,614		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	14,814		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	5,228		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	29,628		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex	34,856		Redacted



	disaggregates			
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	1,500		Redacted
OVC_ACC_DSD	Sex: Male	750		Redacted
OVC_ACC_DSD	Sex: Female	750		Redacted
OVC_ACC_DSD	Sum of Sex disaggregates	1,500		Redacted
OVC_ACC_DSD	Age: <1	30		Redacted
OVC_ACC_DSD	Age: 1-4	180		Redacted
OVC_ACC_DSD	Age: 5-9	375		Redacted
OVC_ACC_DSD	Age: 10-14	540		Redacted
OVC_ACC_DSD	Age: 15-17	300		Redacted
OVC_ACC_DSD	Age: 18+	75		Redacted
OVC_ACC_DSD	Sum of Age disaggregates	1,500		Redacted
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	3,000		Redacted
OVC_SERV_DSD	Sex: Male	1,500		Redacted
OVC_SERV_DSD	Sex: Female	1,500		Redacted
OVC_SERV_DSD	Sum of Sex disaggregates	3,000		Redacted
OVC_SERV_DSD	Age: <1	60		Redacted
OVC_SERV_DSD	Age: 1-4	360		Redacted
OVC_SERV_DSD	Age: 5-9	750		Redacted
OVC_SERV_DSD	Age: 10-14	1,080		Redacted
OVC_SERV_DSD	Age: 15-17	600		Redacted
OVC_SERV_DSD	Age: 18+	150		Redacted
OVC_SERV_DSD	Sum of Age disaggregates	3,000		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	26,139		Redacted
CARE_CURR_DS	Age/sex: <1 Male	41		Redacted

D				
CARE_CURR_DS D	Age/sex: 1-4 Male	283		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	479		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	376		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	200		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	371		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	5,584		Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	1,931		Redacted
CARE_CURR_DS D	Age/sex: <1 Female	41		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	269		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	495		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	373		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	331		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	1,374		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	11,735		Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	2,256		Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	26,139		Redacted
CARE_CURR_DS	Aggregated Age/sex - USE WITH HQ	1,179		Redacted

D	PERMISSION ONLY: <15 Male			
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	8,086		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,178		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	15,696		Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	26,139		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	4,753		Redacted
CARE_NEW_DSD	Age/sex: <1 Male	7		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	52		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	87		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	68		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	31		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	129		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	1,099		Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	211		Redacted
CARE_NEW_DSD	Age/sex: <1 Female	7		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	49		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	90		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	69		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	71		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	131		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	1,971		Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	681		Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	4,753		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	214		Redacted

CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	1,470		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	215		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	2,854		Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	4,753		Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	4,127		Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	5,503		Redacted
FN_THER_DSD	Age: <1	13		Redacted
FN_THER_DSD	Age: 1-4	89		Redacted
FN_THER_DSD	Age: 5-14	278		Redacted
FN_THER_DSD	Age: 15-17	84		Redacted
FN_THER_DSD	Age: 18+	3,663		Redacted
FN_THER_DSD	Sum of Age disaggregates	4,127		Redacted
FN_THER_DSD	Aggregated Age: <18	464		Redacted
FN_THER_DSD	Aggregated Age: 18+	3,663		Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	4,127		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,176		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,307		Redacted
TB_ART_DSD	Age: 0-4	29		Redacted
TB_ART_DSD	Age: 5-14	79		Redacted
TB_ART_DSD	Age: 15+	1,068		Redacted
TB_ART_DSD	Male	635		Redacted

TB_ART_DSD	Female	541		Redacted
TB_ART_DSD	Sum of Sex disaggregates	1,176		Redacted
TB_ART_DSD	Newly tested	705		Redacted
TB_ART_DSD	Known HIV-positive	471		Redacted
TB_ART_DSD	Sum of Test Status disaggregates	1,176		Redacted
TB_ART_DSD	Aggregated Age: <15	108		Redacted
TB_ART_DSD	Aggregated Age: 15+	1,068		Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	1,176		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	738		Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	923		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	554		Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	184		Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	738		Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	37		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	20,305		Redacted
TX_CURR_DSD	Age/Sex: <1 Male	32		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	214		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	670		Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	6,466		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	32		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	214		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	669		Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	12,008		Redacted

TX_CURR_DSD	Sum of age/sex disaggregates	1,831		Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	74		Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	73		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	32		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	32		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	916		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	6,466		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	915		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	12,008		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,831		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	18,474		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	20,305		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	64		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,639		Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	77		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	44		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	77		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	58		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	27		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	50		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	756		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	261		Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	77		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	44		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	77		Redacted

TX_NEW_DSD	By Age/Sex: 10-14 Female	59		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	43		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	178		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	1,519		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	292		Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	3,639		Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	77		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	256		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,094		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	77		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	257		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	2,032		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	3,639		Redacted
TX_NEW_DSD	Pregnancy status	291		Redacted
TX_NEW_DSD	Breastfeeding status	32		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,134		Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	3,688		Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	78		Redacted

TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	211		Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,846		Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	91		Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	249		Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,348		Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	289		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12	2,846		Redacted



	months after initiating ART)			
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	340		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,348		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	577		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	679		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	3		Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	3		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	3		Redacted
FPINT_SITE_DSD	Number of service delivery points	7		Redacted

	supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services			
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	9		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	7		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0		Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	7		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	9		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	0		Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	9		Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	7		Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	7		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last	24,832		Redacted



	clinical visit to an HIV care facility during the reporting period			
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	26,139		Redacted
TB_SCREEN_DSD	Age: <1	79		Redacted
TB_SCREEN_DSD	Age: 1-4	536		Redacted
TB_SCREEN_DSD	Age: 5-9	946		Redacted
TB_SCREEN_DSD	Age: 10-14	728		Redacted
TB_SCREEN_DSD	Age: 15-19	502		Redacted
TB_SCREEN_DSD	Age: 20-24	1,674		Redacted
TB_SCREEN_DSD	Age: 25-49	16,444		Redacted
TB_SCREEN_DSD	Age: 50+	3,923		Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	2,791		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	2,289		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	22,543		Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	24,832		Redacted
TB_SCREEN_DSD	Sex: Male	8,809		Redacted
TB_SCREEN_DSD	Sex: Female	16,023		Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	24,832		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 12664</b>	<b>Mechanism Name: Clinical Services</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Medical and Research Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



<b>Total All Funding Sources: 1,191,863</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,191,863

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	238,373
Gender: GBV	29,797
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	29,797
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID: 12664</b>
----------------------------



<b>Mechanism Name:</b>	<b>Clinical Services</b>		
<b>Prime Partner Name:</b>	<b>African Medical and Research Foundation</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	152,274	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	49,990	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	22,708	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	23,614	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	120,882	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	817,891	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	4,504	0

### Implementing Mechanism Indicator Information

<b>Indicator Number</b>	<b>Label</b>	<b>2015</b>	<b>2016</b>	<b>Planning Budget Targets</b>
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	364		Redacted

PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	364		Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	273		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	128		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	145		Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	91		Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	364		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	273		Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	4,379		Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	4,379		Redacted
PMTCT_STAT_DS D	By: Known positives at entry	171		Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	193		Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	364		Redacted

HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	25,123		Redacted
HTC_TST_DSD	By Test Result: Negative	24,118		Redacted
HTC_TST_DSD	By Test Result: Positive	1,005		Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	25,123		Redacted
HTC_TST_DSD	Age/sex: <1 Male	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	879		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	377		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	628		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	1,256		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	3,140		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	5,025		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	1,256		Redacted
HTC_TST_DSD	Age/sex: <1 Female	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	879		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	377		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	628		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	1,256		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	3,140		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	5,025		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	1,257		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	25,123		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,884		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	10,677		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,884		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	10,678		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	3,768		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	21,355		Redacted



HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	25,123		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	4,067		Redacted
CARE_CURR_DS D	Age/sex: <1 Male	6		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	44		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	74		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	59		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	31		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	58		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	869		Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	300		Redacted
CARE_CURR_DS D	Age/sex: <1 Female	6		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	42		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	77		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	58		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	52		Redacted
CARE_CURR_DS	Age/sex: 20-24 Female	214		Redacted



D				
CARE_CURR_DS D	Age/sex: 25-49 Female	1,826		Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	351		Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	4,067		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	183		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,258		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	183		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	2,443		Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	4,067		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	739		Redacted
CARE_NEW_DSD	Age/sex: <1 Male	1		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	8		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	14		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	10		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	5		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	20		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	172		Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	32		Redacted
CARE_NEW_DSD	Age/sex: <1 Female	2		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	7		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	13		Redacted

CARE_NEW_DSD	Age/sex: 10-14 Female	11		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	11		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	20		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	307		Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	106		Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	739		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	33		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	229		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	33		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	444		Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	739		Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	642		Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	856		Redacted
FN_THER_DSD	Age: <1	2		Redacted
FN_THER_DSD	Age: 1-4	14		Redacted
FN_THER_DSD	Age: 5-14	43		Redacted
FN_THER_DSD	Age: 15-17	13		Redacted
FN_THER_DSD	Age: 18+	570		Redacted
FN_THER_DSD	Sum of Age disaggregates	642		Redacted
FN_THER_DSD	Aggregated Age: <18	72		Redacted
FN_THER_DSD	Aggregated Age: 18+	570		Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	642		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	183		Redacted

TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	203		Redacted
TB_ART_DSD	Age: 0-4	5		Redacted
TB_ART_DSD	Age: 5-14	12		Redacted
TB_ART_DSD	Age: 15+	166		Redacted
TB_ART_DSD	Male	99		Redacted
TB_ART_DSD	Female	84		Redacted
TB_ART_DSD	Sum of Sex disaggregates	183		Redacted
TB_ART_DSD	Newly tested	110		Redacted
TB_ART_DSD	Known HIV-positive	73		Redacted
TB_ART_DSD	Sum of Test Status disaggregates	183		Redacted
TB_ART_DSD	Aggregated Age: <15	17		Redacted
TB_ART_DSD	Aggregated Age: 15+	166		Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	183		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	291		Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	364		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	218		Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	73		Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	291		Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	15		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	2,780		Redacted
TX_CURR_DSD	Age/Sex: <1 Male	4		Redacted

TX_CURR_DSD	Age/Sex: 1-4 Male	29		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	92		Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	885		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	4		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	29		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	92		Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	1,645		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	250		Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	65		Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	64		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	4		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	4		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	125		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	885		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	125		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	1,645		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	250		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	2,530		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	2,780		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	8		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	661		Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	14		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	8		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	14		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	11		Redacted

TX_NEW_DSD	By Age/Sex: 15-19 Male	5		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	9		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	138		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	47		Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	14		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	8		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	14		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	11		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	8		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	32		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	275		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	53		Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	661		Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	14		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	47		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	199		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	14		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	47		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	368		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	661		Redacted
TX_NEW_DSD	Pregnancy status	115		Redacted
TX_NEW_DSD	Breastfeeding status	13		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	569		Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months	670		Redacted

	prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up			
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	14		Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	38		Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	517		Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	17		Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	45		Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to	608		Redacted

	follow-up)			
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	52		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	517		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	62		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	608		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	227		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	267		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing	4		Redacted

	facilities with capacity to perform clinical laboratory tests			
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	4		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	4		Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	3		Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	4		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	3		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0		Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	3		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	4		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	0		Redacted



FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	4		Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	3		Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	3		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	3,864		Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	4,067		Redacted
TB_SCREEN_DSD	Age: <1	12		Redacted
TB_SCREEN_DSD	Age: 1-4	83		Redacted
TB_SCREEN_DSD	Age: 5-9	147		Redacted
TB_SCREEN_DSD	Age: 10-14	114		Redacted
TB_SCREEN_DSD	Age: 15-19	78		Redacted
TB_SCREEN_DSD	Age: 20-24	260		Redacted
TB_SCREEN_DSD	Age: 25-49	2,560		Redacted
TB_SCREEN_DSD	Age: 50+	610		Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	434		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	356		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	3,508		Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	3,864		Redacted
TB_SCREEN_DSD	Sex: Male	1,371		Redacted
TB_SCREEN_DSD	Sex: Female	2,493		Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	3,864		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 13025</b>	<b>Mechanism Name: Integrated HIV Prevention</b>
----------------------------	--



	<b>Interventions Including Male Circumcision</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Impact Research and Development Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 6,707,884</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	6,707,884

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Gender: GBV	17,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Gender: Gender Equality	17,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms



Focus Area:	Increase gender-equitable access to income and productive resources, including education
Condom programming	27,170
Human Resources for Health	1,200,000

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	13025		
<b>Mechanism Name:</b>	Integrated HIV Prevention Interventions Including Male Circumcision		
<b>Prime Partner Name:</b>	Impact Research and Development Organization		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	6,457,144	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	75,068	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	IDUP	175,672	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	159	424	Redacted

KP_MAT_DSD	Sex: Male	127	390	Redacted
KP_MAT_DSD	Sex: Female	32	34	Redacted
KP_MAT_DSD	Sum of Sex disaggregates	159	424	Redacted
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	375		Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	337		Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	38		Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	375		Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	337		Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	38		Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	38		Redacted
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more	38		Redacted

	moderate medical device-related AE(s), but no severe medical device-related AE(s)			
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	0		Redacted
VMMC_CIRC_DS D	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	93,778	102,212	Redacted
VMMC_CIRC_DS D	By Age: 1-9	0	0	Redacted
VMMC_CIRC_DS D	By Age: 10-14	37,980	0	Redacted
VMMC_CIRC_DS D	By Age: 15-19	37,511	51,114	Redacted
VMMC_CIRC_DS D	By Age: 20-24	9,378	30,670	Redacted
VMMC_CIRC_DS D	By Age: 25-49	8,909		Redacted
VMMC_CIRC_DS D	By Age: 50+	0	0	Redacted
VMMC_CIRC_DS D	Sum of age disaggregates	93,778	81,784	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	5,627	1,226	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	87,214	83,815	Redacted
VMMC_CIRC_DS D	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	937	17,171	Redacted

VMMC_CIRC_DS D	By circumcision technique: Surgical VMMC	84,400	102,212	Redacted
VMMC_CIRC_DS D	By circumcision technique: Device-based VMMC	9,378	0	Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	93,778	41,028	Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	61,184	Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	529	733	Redacted
KP_PREV_DSD	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	423	672	Redacted
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	106	61	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	93,778	42,371	Redacted

HTC_TST_DSD	By Test Result: Negative	88,151	40,398	Redacted
HTC_TST_DSD	By Test Result: Positive	5,627	1,973	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	93,778	42,371	Redacted
HTC_TST_DSD	Age/sex: <1 Male	469		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	0		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	0		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	37,511		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	37,511		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	9,378		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	8,909		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	0		Redacted
HTC_TST_DSD	Age/sex: <1 Female	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	0		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	0		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	0		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	0		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	0		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	0		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	0		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	93,778		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	37,980	7,447	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	55,798	25,533	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	1,314	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0	8,077	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	37,980	8,761	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	55,798	33,610	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	93,778	42,371	Redacted



### Implementing Mechanism Details

<b>Mechanism ID: 13028</b>	<b>Mechanism Name: TA for Implementation and Expansion of Blood Safety Activities in Kenya</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Community Housing Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	13028		
<b>Mechanism Name:</b>	TA for Implementation and Expansion of Blood Safety Activities in Kenya		
<b>Prime Partner Name:</b>	Community Housing Foundation		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>





Prevention	HMBL	0	0
------------	------	---	---

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 13050</b>	<b>Mechanism Name: Coptic Hospital / University of Washington Collaborative HIV Care Program</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Coptic Hospital	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 4,941,356</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	4,941,356

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	988,271
Gender: GBV	123,534
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation



Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	123,534
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	13050		
<b>Mechanism Name:</b>	Coptic Hospital / University of Washington Collaborative HIV Care		
<b>Prime Partner Name:</b>	Program Coptic Hospital		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	603,852	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	190,701	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	61,528	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	28,084	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>

Prevention	MTCT	1,001,952	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	3,048,462	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	6,777	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	430		Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	430		Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	323		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	151		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	172		Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy)	107		Redacted

	and delivery)			
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	430		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	323		Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,016		Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	1,016		Redacted
PMTCT_STAT_DS D	By: Known positives at entry	202		Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	228		Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	430		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	18,742		Redacted
HTC_TST_DSD	By Test Result: Negative	17,992		Redacted
HTC_TST_DSD	By Test Result: Positive	750		Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	18,742		Redacted
HTC_TST_DSD	Age/sex: <1 Male	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	656		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	281		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	469		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	937		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	2,343		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	3,748		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	937		Redacted

HTC_TST_DSD	Age/sex: <1 Female	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	656		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	281		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	469		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	937		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	2,343		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	3,748		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	937		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	18,742		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,406		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	7,965		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,406		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	7,965		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	2,812		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	15,930		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	18,742		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	14,891		Redacted
CARE_CURR_DS D	Age/sex: <1 Male	23		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	161		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	273		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	215		Redacted

CARE_CURR_DS D	Age/sex: 15-19 Male	114		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	212		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	3,181		Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	1,099		Redacted
CARE_CURR_DS D	Age/sex: <1 Female	23		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	153		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	282		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	214		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	189		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	783		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	6,685		Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	1,284		Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	14,891		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	672		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	4,606		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	672		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	8,941		Redacted

CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	14,891		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	2,708		Redacted
CARE_NEW_DSD	Age/sex: <1 Male	4		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	29		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	50		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	39		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	18		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	73		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	626		Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	121		Redacted
CARE_NEW_DSD	Age/sex: <1 Female	4		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	28		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	51		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	39		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	40		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	75		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	1,123		Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	388		Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	2,708		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	122		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	838		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	122		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	1,626		Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	2,708		Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or	2,351		Redacted

	supplementary food during the reporting period.			
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	3,135		Redacted
FN_THER_DSD	Age: <1	7		Redacted
FN_THER_DSD	Age: 1-4	51		Redacted
FN_THER_DSD	Age: 5-14	158		Redacted
FN_THER_DSD	Age: 15-17	48		Redacted
FN_THER_DSD	Age: 18+	2,087		Redacted
FN_THER_DSD	Sum of Age disaggregates	2,351		Redacted
FN_THER_DSD	Aggregated Age: <18	264		Redacted
FN_THER_DSD	Aggregated Age: 18+	2,087		Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	2,351		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	670		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	745		Redacted
TB_ART_DSD	Age: 0-4	17		Redacted
TB_ART_DSD	Age: 5-14	45		Redacted
TB_ART_DSD	Age: 15+	608		Redacted
TB_ART_DSD	Male	362		Redacted
TB_ART_DSD	Female	308		Redacted
TB_ART_DSD	Sum of Sex disaggregates	670		Redacted
TB_ART_DSD	Newly tested	402		Redacted
TB_ART_DSD	Known HIV-positive	268		Redacted
TB_ART_DSD	Sum of Test Status disaggregates	670		Redacted
TB_ART_DSD	Aggregated Age: <15	62		Redacted



TB_ART_DSD	Aggregated Age: 15+	608		Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	670		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	344		Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	430		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	258		Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	86		Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	344		Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	17		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	13,621		Redacted
TX_CURR_DSD	Age/Sex: <1 Male	21		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	143		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	449		Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	4,338		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	21		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	144		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	449		Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	8,056		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	1,227		Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	87		Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART)	86		Redacted

	[CURRENT]		
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	21	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	21	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	613	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	4,338	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	614	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	8,056	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,227	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	12,394	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	13,621	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	42	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,115	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	24	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	13	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	23	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	18	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	8	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	15	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	232	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	80	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	24	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	13	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	24	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	18	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	13	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	55	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	466	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	89	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,115	Redacted

TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	24		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	78		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	335		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	24		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	79		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	623		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,115		Redacted
TX_NEW_DSD	Pregnancy status	135		Redacted
TX_NEW_DSD	Breastfeeding status	15		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	961		Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,130		Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	24		Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	65		Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating	872		Redacted

	ART)			
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	28		Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	76		Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,026		Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	89		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	872		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and	104		Redacted

	those lost to follow-up)			
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,026		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	268		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	316		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	3		Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	3		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	3		Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	3		Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	3		Redacted
FPINT_SITE_DSD	By site support type: Direct Service	3		Redacted

	Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services			
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0		Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	3		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	3		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	0		Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	3		Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	3		Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	3		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	14,147		Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	14,891		Redacted



TB_SCREEN_DSD	Age: <1	45		Redacted
TB_SCREEN_DSD	Age: 1-4	305		Redacted
TB_SCREEN_DSD	Age: 5-9	539		Redacted
TB_SCREEN_DSD	Age: 10-14	415		Redacted
TB_SCREEN_DSD	Age: 15-19	286		Redacted
TB_SCREEN_DSD	Age: 20-24	954		Redacted
TB_SCREEN_DSD	Age: 25-49	9,368		Redacted
TB_SCREEN_DSD	Age: 50+	2,235		Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	1,590		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	1,304		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	12,843		Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	14,147		Redacted
TB_SCREEN_DSD	Sex: Male	5,019		Redacted
TB_SCREEN_DSD	Sex: Female	9,128		Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	14,147		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 13061</b>	<b>Mechanism Name: Advancement of Public Health Practices in Kenya</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: MINISTRY OF PUBLIC HEALTH AND SANITATION	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 7,951,009</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	7,951,009



**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Key Populations: MSM and TG	40,000
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Gender: Gender Equality	117,026
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Key Populations: FSW	55,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Gender: GBV	117,026
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care





Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Condom programming	20,000
Human Resources for Health	896,201
Economic Strengthening	5,000
Condom procurement	15,000

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	13061		
<b>Mechanism Name:</b>	Advancement of Public Health Practices in Kenya		
<b>Prime Partner Name:</b>	MINISTRY OF PUBLIC HEALTH AND SANITATION		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	296,261	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	560,708	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	69,216	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	600,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>

Governance and Systems	HVSI	1,900,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	640,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	80,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HMIN	200,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	50,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	100,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	IDUP	50,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	1,730,051	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	1,423,303	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	251,470	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	80	13	Redacted
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	15		Redacted
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	65		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	80		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	1,460	8	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	300		Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	1,160		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	1,460		Redacted
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	75		Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	7,000	8	Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	7,000	8	Redacted

LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	5,250	6	Redacted
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	255	8	Redacted
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	80	8	Redacted
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	60	6	Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	6	1	Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	6	1	Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	6	1	Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	6	1	Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	6	1	Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	6	1	Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that perform this testing	1,450		Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that participate in this PT program	1,450		Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert	1,088		Redacted



	MTB/RIF, Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program			
--	--	--	--	--

**Implementing Mechanism Details**

<b>Mechanism ID: 13121</b>	<b>Mechanism Name: Partnership in Advanced Clinical Education (PACE)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Maryland	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**



<b>Mechanism ID:</b> 13121			
<b>Mechanism Name:</b> Partnership in Advanced Clinical Education (PACE)			
<b>Prime Partner Name:</b> University of Maryland			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	300		Redacted
HRH_PRE	By Graduates: Doctors	200		Redacted
HRH_PRE	By Graduates: Nurses	25		Redacted
HRH_PRE	By Graduates: Laboratory professionals	50		Redacted
HRH_PRE	By Graduates: Other	25		Redacted
HRH_PRE	Sum of Graduates disaggregated	300		Redacted
HRH_PRE	By new graduates who are licensed	200		Redacted

	and registered: Doctors			
HRH_PRE	By new graduates who are licensed and registered: Nurses	25		Redacted
HRH_PRE	By new graduates who are licensed and registered: Laboratorians	50		Redacted
HRH_PRE	By new graduates who are licensed and registered: Other (where applicable)	25		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 13164</b>	<b>Mechanism Name: Strengthening Public Health Laboratory Systems in Kenya</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	13164		
<b>Mechanism Name:</b>	Strengthening Public Health Laboratory Systems in Kenya		
<b>Prime Partner Name:</b>	Management Sciences for Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	15		Redacted
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	15		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	15		Redacted
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific	75		Redacted





	proficiency testing (PT) program			
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	255		Redacted
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	63		Redacted
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	47		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 13179</b>	<b>Mechanism Name: Emory University</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Association of Schools of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 595,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	595,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	100,000
----------------------------	---------

### Key Issues



(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 13179			
<b>Mechanism Name:</b> Emory University			
<b>Prime Partner Name:</b> Association of Schools of Public Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	595,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 13210	<b>Mechanism Name:</b> Strengthening Laboratory Accreditation Services in Kenya
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Global Healthcare Public Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 0	
<b>Applied Pipeline Amount:</b> 0	
Funding Source	Funding Amount
GHP-State	0

**Sub Partner Name(s)**

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 13210			
<b>Mechanism Name:</b> Strengthening Laboratory Accreditation Services in Kenya			
<b>Prime Partner Name:</b> Global Healthcare Public Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	0		Redacted
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	0		Redacted



LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	0		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	0		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 13287</b>	<b>Mechanism Name: Establishment of Medical Waste Management Systems in Kenya</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Program for Appropriate Technology in Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 13287
----------------------------



<b>Mechanism Name:</b>	<b>Establishment of Medical Waste Management Systems in Kenya</b>		
<b>Prime Partner Name:</b>	<b>Program for Appropriate Technology in Health</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HMIN	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 13302</b>	<b>Mechanism Name: HIV Prevention Activities for Youth and General Population</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Hope Worldwide	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 454,093</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	454,093

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Gender: GBV	20,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic



	Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	20,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	13302		
<b>Mechanism Name:</b>	HIV Prevention Activities for Youth and General Population		
<b>Prime Partner Name:</b>	Hope Worldwide		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVAB	134,523	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	15,804	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	303,766	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	86,253	14,612	Redacted
PP_PREV_DSD	Total number of people in the target population	334,634	33,443	Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	29,634		Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	30,003	2,122	Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	14,043	5,784	Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	12,573	6,706	Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	86,253	14,612	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	27,237	7,393	Redacted
HTC_TST_DSD	By Test Result: Negative	26,148		Redacted
HTC_TST_DSD	By Test Result: Positive	1,089		Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	27,237		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	13,618		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	13,619		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	27,237		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	27,237	4,764	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	27,237	4,764	Redacted



HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	27,237	6,186	Redacted
GEND_GBV_DSD	Number of people receiving post-GBV care	1,840	4,313	Redacted
GEND_GBV_DSD	Age: 10-14	368		Redacted
GEND_GBV_DSD	Age: 15-17	1,472		Redacted
GEND_GBV_DSD	Sum of Age disaggregates	1,840		Redacted
GEND_GBV_DSD	Sex: Male	90		Redacted
GEND_GBV_DSD	Sex: Female	1,750		Redacted
GEND_GBV_DSD	Sum of Sex disaggregates	1,840		Redacted
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	400		Redacted
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	1,600		Redacted
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	15		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 13307</b>	<b>Mechanism Name: Prevention for Youth and General Population</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Impact Research and Development Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,070,435</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,070,435





**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	400,000
Key Populations: MSM and TG	142,307
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Key Populations: FSW	188,680
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Gender: GBV	50,000
Focus Area:	GBV Prevention

Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	184,744
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Capacity building

## Key Issues

(No data provided.)



### Budget Code Information

<b>Mechanism ID:</b>	13307		
<b>Mechanism Name:</b>	Prevention for Youth and General Population		
<b>Prime Partner Name:</b>	Impact Research and Development Organization		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	324,786	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	1,745,649	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	206,447	64,932	Redacted
PP_PREV_DSD	Total number of people in the target population	800,937	101,839	Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	78,495	0	Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	383	2,250	Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	1,534	5,412	Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	78,982	0	Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	10,781	20,811	Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	35,506	23,742	Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	766	6,119	Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	206,447	64,932	Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level	2,541	6,481	Redacted

	HIV preventive interventions that are based on evidence and/or meet the minimum standards required			
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,208	5,484	Redacted
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	333	997	Redacted
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	133		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	48,894	68,979	Redacted
HTC_TST_DSD	By Test Result: Negative	46,938	50,035	Redacted
HTC_TST_DSD	By Test Result: Positive	1,956	2,580	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	48,894	52,615	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	305		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	1,579		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	1,704		Redacted

HTC_TST_DSD	Age/sex: 50+ Male	180		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	12,772		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	30,261		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	1,981		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	112		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	48,894		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,768	31,506	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	45,126	37,473	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	48,894	68,979	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	48,894	68,979	Redacted
GEND_GBV_DSD	Number of people receiving post-GBV care	2,440	7,465	Redacted
GEND_GBV_DSD	Age: 0-9	0		Redacted
GEND_GBV_DSD	Age: 10-14	488		Redacted
GEND_GBV_DSD	Age: 15-17	1,952		Redacted
GEND_GBV_DSD	Age: 18-24	0		Redacted
GEND_GBV_DSD	Age: 25+	0		Redacted
GEND_GBV_DSD	Sum of Age disaggregates	2,440		Redacted
GEND_GBV_DSD	Sex: Male	0		Redacted
GEND_GBV_DSD	Sex: Female	2,440		Redacted
GEND_GBV_DSD	Sum of Sex disaggregates	2,440		Redacted
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	2,440	4,223	Redacted
GEND_NORM_DS D	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	2,875	22,316	Redacted
GEND_NORM_DS D	By Age: 20-24	575		Redacted
GEND_NORM_DS	By Age: 25+	2,300		Redacted



D				
GEND_NORM_DS D	Sum of Age disaggregates	2,875		Redacted
GEND_NORM_DS D	By Sex: Male	1,917		Redacted
GEND_NORM_DS D	By Sex: Female	958		Redacted
GEND_NORM_DS D	Sum of Sex disaggregates	2,875		Redacted
GEND_NORM_DS D	By type of activity: Small Group	2,875		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 13309</b>	<b>Mechanism Name: Kenya Medical Research Institute</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Kenya Medical Research Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

## Key Issues

(No data provided.)

## Budget Code Information

<b>Mechanism ID:</b> 13309			
<b>Mechanism Name:</b> Kenya Medical Research Institute			
<b>Prime Partner Name:</b> Kenya Medical Research Institute			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,228		Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	1,228		Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	921		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	430		Redacted
PMTCT_ARV_DS	Sub-Disag of Life-long ART: Already on	491		Redacted



D	treatment at the beginning of the current pregnancy			
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	307		Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	1,228		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	921		Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	4,270		Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	4,270		Redacted
PMTCT_STAT_DS D	By: Known positives at entry	577		Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	651		Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	1,228		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	62,196		Redacted
HTC_TST_DSD	By Test Result: Negative	59,708		Redacted
HTC_TST_DSD	By Test Result: Positive	2,488		Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	62,196		Redacted
HTC_TST_DSD	Age/sex: <1 Male	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	2,177		Redacted

HTC_TST_DSD	Age/sex: 5-9 Male	933		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	1,555		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	3,110		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	7,775		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	12,438		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	3,110		Redacted
HTC_TST_DSD	Age/sex: <1 Female	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	2,177		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	933		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	1,555		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	3,110		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	7,775		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	12,438		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	3,110		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	62,196		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	4,665		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	26,433		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	4,665		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	26,433		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	9,330		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	52,866		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	62,196		Redacted
GEND_GBV_DSD	Number of people receiving post-GBV care	720		Redacted
GEND_GBV_DSD	Age: 0-9	115		Redacted
GEND_GBV_DSD	Age: 10-14	108		Redacted
GEND_GBV_DSD	Age: 15-17	65		Redacted
GEND_GBV_DSD	Age: 18-24	252		Redacted

GEND_GBVDSD	Age: 25+	180		Redacted
GEND_GBVDSD	Sum of Age disaggregates	720		Redacted
GEND_GBVDSD	Sex: Male	172		Redacted
GEND_GBVDSD	Sex: Female	548		Redacted
GEND_GBVDSD	Sum of Sex disaggregates	720		Redacted
GEND_GBVDSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	302		Redacted
GEND_GBVDSD	By type of service: Sexual Violence (Post-Rape Care)	418		Redacted
GEND_GBVDSD	By PEP service provision (related to sexual violence services provided)	576		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	8,454		Redacted
CARE_CURR_DS D	Age/sex: <1 Male	13		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	92		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	155		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	122		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	65		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	120		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	1,806		Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	624		Redacted
CARE_CURR_DS	Age/sex: <1 Female	13		Redacted

D				
CARE_CURR_DS D	Age/sex: 1-4 Female	87		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	160		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	121		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	107		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	444		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	3,795		Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	730		Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	8,454		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	382		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,615		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	381		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	5,076		Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	8,454		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	1,537		Redacted
CARE_NEW_DSD	Age/sex: <1 Male	2		Redacted

CARE_NEW_DSD	Age/sex: 1-4 Male	17		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	28		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	22		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	10		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	42		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	356		Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	68		Redacted
CARE_NEW_DSD	Age/sex: <1 Female	2		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	16		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	29		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	22		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	23		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	42		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	637		Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	221		Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	1,537		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	69		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	476		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	69		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	923		Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	1,537		Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	1,335		Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	1,780		Redacted
FN_THER_DSD	Age: <1	4		Redacted
FN_THER_DSD	Age: 1-4	29		Redacted
FN_THER_DSD	Age: 5-14	90		Redacted
FN_THER_DSD	Age: 15-17	27		Redacted

FN_THER_DSD	Age: 18+	1,185		Redacted
FN_THER_DSD	Sum of Age disaggregates	1,335		Redacted
FN_THER_DSD	Aggregated Age: <18	150		Redacted
FN_THER_DSD	Aggregated Age: 18+	1,185		Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	1,335		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	380		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	423		Redacted
TB_ART_DSD	Age: 0-4	9		Redacted
TB_ART_DSD	Age: 5-14	26		Redacted
TB_ART_DSD	Age: 15+	345		Redacted
TB_ART_DSD	Male	205		Redacted
TB_ART_DSD	Female	175		Redacted
TB_ART_DSD	Sum of Sex disaggregates	380		Redacted
TB_ART_DSD	Newly tested	228		Redacted
TB_ART_DSD	Known HIV-positive	152		Redacted
TB_ART_DSD	Sum of Test Status disaggregates	380		Redacted
TB_ART_DSD	Aggregated Age: <15	35		Redacted
TB_ART_DSD	Aggregated Age: 15+	345		Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	380		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	982		Redacted
PMTCT_EID_DSD	Number of HIV-positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	1,228		Redacted

PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	737		Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	245		Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	982		Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	49		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	7,281		Redacted
TX_CURR_DSD	Age/Sex: <1 Male	11		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	77		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	240		Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	2,319		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	11		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	77		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	240		Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	4,306		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	656		Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	82		Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	81		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	11		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	11		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	328		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	2,319		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	328		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	4,306		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	656		Redacted

TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	6,625		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	7,281		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	22		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,389		Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	29		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	17		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	29		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	23		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	10		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	19		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	288		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	101		Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	29		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	17		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	29		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	22		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	16		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	68		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	580		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	112		Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,389		Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	29		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	98		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	418		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	29		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	97		Redacted



TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	776		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,389		Redacted
TX_NEW_DSD	Pregnancy status	387		Redacted
TX_NEW_DSD	Breastfeeding status	43		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,197		Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,408		Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	30		Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	81		Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,086		Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	35		Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number	95		Redacted

	of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,278		Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	110		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,086		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	130		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,278		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status	767		Redacted

	(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)			
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	903		Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	17		Redacted
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	7		Redacted
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	10		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	17		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	10		Redacted
LAB_CAP_DSD	By clinical laboratories	0		Redacted
LAB_CAP_DSD	By Point-of-care testing sites	0		Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	0		Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	10		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	10		Redacted
LAB_PT_DSD	Percentage of laboratories and POC	75		Redacted

	testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program			
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	255		Redacted
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	54		Redacted
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	41		Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that perform this testing	1,450		Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that participate in this PT program	25		Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	19		Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	2		Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	2		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family	2		Redacted

	planning services			
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0		Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	2		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	2		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	0		Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	2		Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	2		Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	2		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	8,032		Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	8,454		Redacted
TB_SCREEN_DSD	Age: <1	26		Redacted
TB_SCREEN_DSD	Age: 1-4	173		Redacted
TB_SCREEN_DSD	Age: 5-9	306		Redacted
TB_SCREEN_DSD	Age: 10-14	236		Redacted



TB_SCREEN_DSD	Age: 15-19	162		Redacted
TB_SCREEN_DSD	Age: 20-24	541		Redacted
TB_SCREEN_DSD	Age: 25-49	5,319		Redacted
TB_SCREEN_DSD	Age: 50+	1,269		Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	903		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	741		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	7,291		Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	8,032		Redacted
TB_SCREEN_DSD	Sex: Male	2,849		Redacted
TB_SCREEN_DSD	Sex: Female	5,183		Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	8,032		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 13312</b>	<b>Mechanism Name: Afyainfo</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,675,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,675,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)



(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 13312			
<b>Mechanism Name:</b> Afyainfo			
<b>Prime Partner Name:</b> Abt Associates			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	2,675,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID:</b> 13340	<b>Mechanism Name:</b> APHIAPlus Rift Valley
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 12,675,778	
<b>Applied Pipeline Amount:</b> 0	
Funding Source	Funding Amount
GHP-State	12,675,778



**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 13340			
<b>Mechanism Name:</b> APHIAPlus Rift Valley			
<b>Prime Partner Name:</b> FHI 360			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	1,605,737	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	3,083,734	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	530,107	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	250,686	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	550,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Prevention	CIRC	208,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	1,453,818	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	37,756	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	1,396,632	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	3,247,473	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	311,835	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	188	
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	196	
PMTCT_ARV_DSD	Life-long ART (including Option B+)	156	
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	78	
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current	78	

	pregnancy		
PMTCT_ARV_DSD	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	
PMTCT_ARV_DSD	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	32	
PMTCT_ARV_DSD	Single-dose nevirapine (with or without tail)	0	
PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	188	
PMTCT_ARV_DSD	Sum of New and Current disaggregates	156	
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	4,507	
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	4,694	
PMTCT_ARV_TA	Life-long ART (including Option B+)	3,756	
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	1,878	
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	1,878	
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	751	
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0	
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	4,507	
PMTCT_ARV_TA	Sum of New and Current disaggregates	3,756	
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for	6,152	

	HIV and received their results)		
PMTCT_STAT_DSD	Number of new ANC and L&D clients	6,275	
PMTCT_STAT_DSD	By: Known positives at entry	78	
PMTCT_STAT_DSD	By: Number of new positives identified	117	
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	195	
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	23	
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	3	
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	20	
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	1,018	
VMMC_CIRC_DSD	By Age: <1	0	
VMMC_CIRC_DSD	By Age: 1-9	0	
VMMC_CIRC_DSD	By Age: 10-14	102	
VMMC_CIRC_DSD	By Age: 15-19	305	
VMMC_CIRC_DSD	By Age: 20-24	407	
VMMC_CIRC_DSD	By Age: 25-49	153	
VMMC_CIRC_DSD	By Age: 50+	51	
VMMC_CIRC_DSD	Sum of age disaggregates	1,018	
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	1,018	
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	48,000	
PP_PREV_DSD	Total number of people in the target population	186,233	
PP_PREV_DSD	Age/sex: 10-14 Male	0	

PP_PREV_DSD	Age/sex: 15-19 Male	0	
PP_PREV_DSD	Age/sex: 20-24 Male	0	
PP_PREV_DSD	Age/sex: 25-49 Male	0	
PP_PREV_DSD	Age/sex: 50+ Male	0	
PP_PREV_DSD	Age/sex: 10-14 Female	0	
PP_PREV_DSD	Age/sex: 15-19 Female	10,500	
PP_PREV_DSD	Age/sex: 20-24 Female	37,500	
PP_PREV_DSD	Age/sex: 25-49 Female	0	
PP_PREV_DSD	Age/sex: 50+ Female	0	
PP_PREV_DSD	Sum of Age/Sex disaggregates	48,000	
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	2,130	
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,819	
KP_PREV_DSD	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	
KP_PREV_DSD	By key population type: Men who have sex	311	

	with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)		
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	148,298	
HTC_TST_DSD	By Test Result: Negative	142,366	
HTC_TST_DSD	By Test Result: Positive	5,932	
HTC_TST_DSD	Sum of Test Result disaggregates	148,298	
HTC_TST_DSD	Age/sex: <1 Male	0	
HTC_TST_DSD	Age/sex: 1-4 Male	5,190	
HTC_TST_DSD	Age/sex: 5-9 Male	2,224	
HTC_TST_DSD	Age/sex: 10-14 Male	3,707	
HTC_TST_DSD	Age/sex: 15-19 Male	7,415	
HTC_TST_DSD	Age/sex: 20-24 Male	18,537	
HTC_TST_DSD	Age/sex: 25-49 Male	29,660	
HTC_TST_DSD	Age/sex: 50+ Male	7,415	
HTC_TST_DSD	Age/sex: <1 Female	0	
HTC_TST_DSD	Age/sex: 1-4 Female	5,190	
HTC_TST_DSD	Age/sex: 5-9 Female	2,224	
HTC_TST_DSD	Age/sex: 10-14 Female	3,707	
HTC_TST_DSD	Age/sex: 15-19 Female	7,415	
HTC_TST_DSD	Age/sex: 20-24 Female	18,537	
HTC_TST_DSD	Age/sex: 25-49 Female	29,660	

HTC_TST_DSD	Age/sex: 50+ Female	7,417	
HTC_TST_DSD	Sum of Age/Sex disaggregates	148,298	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	11,122	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	63,027	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	11,122	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	63,027	
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	22,244	
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	126,054	
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	148,298	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	196,580	
HTC_TST_TA	By Test Result: Negative	188,717	
HTC_TST_TA	By Test Result: Positive	7,863	
HTC_TST_TA	Sum of Test Result disaggregates	196,580	
HTC_TST_TA	Age/sex: <1 Male	0	
HTC_TST_TA	Age/sex: 1-4 Male	6,880	
HTC_TST_TA	Age/sex: 5-9 Male	2,949	
HTC_TST_TA	Age/sex: 10-14 Male	4,915	
HTC_TST_TA	Age/sex: 15-19 Male	9,829	
HTC_TST_TA	Age/sex: 20-24 Male	24,573	
HTC_TST_TA	Age/sex: 25-49 Male	39,316	
HTC_TST_TA	Age/sex: 50+ Male	9,829	
HTC_TST_TA	Age/sex: <1 Female	0	
HTC_TST_TA	Age/sex: 1-4 Female	6,880	
HTC_TST_TA	Age/sex: 5-9 Female	2,949	
HTC_TST_TA	Age/sex: 10-14 Female	4,915	
HTC_TST_TA	Age/sex: 15-19 Female	9,829	
HTC_TST_TA	Age/sex: 20-24 Female	24,573	

HTC_TST_TA	Age/sex: 25-49 Female	39,316	
HTC_TST_TA	Age/sex: 50+ Female	9,827	
HTC_TST_TA	Sum of Age/Sex disaggregates	196,580	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	14,744	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	83,547	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	14,744	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	83,545	
HTC_TST_TA	Sum of Aggregated Age/Sex <15	29,488	
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	167,092	
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	196,580	
GEND_GBV_DSD	Number of people receiving post-GBV care	1,210	
GEND_GBV_DSD	Age: 0-9	210	
GEND_GBV_DSD	Age: 10-14	500	
GEND_GBV_DSD	Age: 15-17	500	
GEND_GBV_DSD	Sum of Age disaggregates	1,210	
GEND_GBV_DSD	Sex: Male	60	
GEND_GBV_DSD	Sex: Female	1,150	
GEND_GBV_DSD	Sum of Sex disaggregates	1,210	
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	1,210	
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	44,353	
GEND_NORM_DSD	By Age: 0-9	0	
GEND_NORM_DSD	By Age: 10-14	0	
GEND_NORM_DSD	By Age: 15-19	0	
GEND_NORM_DSD	By Age: 20-24	11,088	
GEND_NORM_DSD	By Age: 25+	33,265	
GEND_NORM_DSD	Sum of Age disaggregates	44,353	



GEND_NORM_DSD	By Sex: Male	33,265	
GEND_NORM_DSD	By Sex: Female	11,088	
GEND_NORM_DSD	Sum of Sex disaggregates	44,353	
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	9,477	
OVC_ACC_DSD	Sex: Male	4,644	
OVC_ACC_DSD	Sex: Female	4,833	
OVC_ACC_DSD	Sum of Sex disaggregates	9,477	
OVC_ACC_DSD	Age: <1	0	
OVC_ACC_DSD	Age: 1-4	569	
OVC_ACC_DSD	Age: 5-9	1,895	
OVC_ACC_DSD	Age: 10-14	3,033	
OVC_ACC_DSD	Age: 15-17	2,085	
OVC_ACC_DSD	Age: 18+	1,895	
OVC_ACC_DSD	Sum of Age disaggregates	9,477	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	89,000	
OVC_SERV_DSD	Sex: Male	43,610	
OVC_SERV_DSD	Sex: Female	45,390	
OVC_SERV_DSD	Sum of Sex disaggregates	89,000	
OVC_SERV_DSD	Age: <1	0	
OVC_SERV_DSD	Age: 1-4	5,340	
OVC_SERV_DSD	Age: 5-9	17,800	
OVC_SERV_DSD	Age: 10-14	28,480	
OVC_SERV_DSD	Age: 15-17	19,580	
OVC_SERV_DSD	Age: 18+	17,800	
OVC_SERV_DSD	Sum of Age disaggregates	89,000	
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count	29,013	



	OR viral load		
CARE_CURR_DSD	Age/sex: <1 Male	254	
CARE_CURR_DSD	Age/sex: 1-4 Male	203	
CARE_CURR_DSD	Age/sex: 5-9 Male	305	
CARE_CURR_DSD	Age/sex: 10-14 Male	508	
CARE_CURR_DSD	Age/sex: 15-19 Male	2,031	
CARE_CURR_DSD	Age/sex: 20-24 Male	3,554	
CARE_CURR_DSD	Age/sex: 25-49 Male	3,047	
CARE_CURR_DSD	Age/sex: 50+ Male	254	
CARE_CURR_DSD	Age/sex: <1 Female	471	
CARE_CURR_DSD	Age/sex: 1-4 Female	377	
CARE_CURR_DSD	Age/sex: 5-9 Female	566	
CARE_CURR_DSD	Age/sex: 10-14 Female	943	
CARE_CURR_DSD	Age/sex: 15-19 Female	3,772	
CARE_CURR_DSD	Age/sex: 20-24 Female	6,600	
CARE_CURR_DSD	Age/sex: 25-49 Female	5,657	
CARE_CURR_DSD	Age/sex: 50+ Female	471	
CARE_CURR_DSD	Sun of Age/Sex disaggregates	29,013	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,269	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	8,886	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,357	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	16,501	
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	29,013	
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	8,243	

CARE_NEW_DSD	Age/sex: <1 Male	72	
CARE_NEW_DSD	Age/sex: 1-4 Male	58	
CARE_NEW_DSD	Age/sex: 5-9 Male	87	
CARE_NEW_DSD	Age/sex: 10-14 Male	144	
CARE_NEW_DSD	Age/sex: 15-19 Male	577	
CARE_NEW_DSD	Age/sex: 20-24 Male	1,010	
CARE_NEW_DSD	Age/sex: 25-49 Male	866	
CARE_NEW_DSD	Age/sex: 50+ Male	72	
CARE_NEW_DSD	Age/sex: <1 Female	134	
CARE_NEW_DSD	Age/sex: 1-4 Female	107	
CARE_NEW_DSD	Age/sex: 5-9 Female	161	
CARE_NEW_DSD	Age/sex: 10-14 Female	268	
CARE_NEW_DSD	Age/sex: 15-19 Female	1,071	
CARE_NEW_DSD	Age/sex: 20-24 Female	1,875	
CARE_NEW_DSD	Age/sex: 25-49 Female	1,607	
CARE_NEW_DSD	Age/sex: 50+ Female	134	
CARE_NEW_DSD	Sum of Age/sex disaggregates	8,243	
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	361	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	2,524	
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	670	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	4,688	
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	8,243	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	2,640	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	2,640	
TB_ART_DSD	Age: 0-4	132	
TB_ART_DSD	Age: 5-14	240	
TB_ART_DSD	Age: 15+	2,268	

TB_ART_DSD	Male	1,465	
TB_ART_DSD	Female	1,175	
TB_ART_DSD	Sum of Sex disaggregates	2,640	
TB_ART_DSD	Newly tested	1,958	
TB_ART_DSD	Known HIV-positive	682	
TB_ART_DSD	Sum of Test Status disaggregates	2,640	
TB_ART_DSD	Aggregated Age: <15	355	
TB_ART_DSD	Aggregated Age: 15+	2,285	
TB_ART_DSD	Sum of Aggregated Age disaggregates	2,640	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	5,275	
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	5,383	
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	4,748	
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	527	
PMTCT_EID_DSD	Sum of Infant Age disaggregates	5,275	
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	264	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	23,259	
TX_CURR_DSD	Age/Sex: <1 Male	204	
TX_CURR_DSD	Age/Sex: 1-4 Male	163	
TX_CURR_DSD	Age/Sex: 5-14 Male	651	
TX_CURR_DSD	Age/Sex: 15+ Male	7,123	
TX_CURR_DSD	Age/Sex: <1 Female	378	
TX_CURR_DSD	Age/Sex: 1-4 Female	302	
TX_CURR_DSD	Age/Sex: 5-14 Female	1,210	
TX_CURR_DSD	Age/Sex: 15+ Female	13,228	

TX_CURR_DSD	Sum of age/sex disaggregates	2,908	
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	13	
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	57	
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	204	
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	378	
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	814	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	7,123	
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	680	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	14,642	
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,494	
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	21,765	
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	23,259	
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	582	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	6,702	
TX_NEW_DSD	By Age/Sex: <1 Male	59	
TX_NEW_DSD	By Age/Sex: 1-4 Male	47	
TX_NEW_DSD	By Age/Sex: 5-9 Male	70	
TX_NEW_DSD	By Age/Sex: 10-14 Male	117	
TX_NEW_DSD	By Age/Sex: 15-19 Male	469	
TX_NEW_DSD	By Age/Sex: 20-24 Male	821	
TX_NEW_DSD	By Age/Sex: 25-49 Male	704	
TX_NEW_DSD	By Age/Sex: 50+ Male	59	
TX_NEW_DSD	By Age/Sex: <1 Female	109	
TX_NEW_DSD	By Age/Sex: 1-4 Female	87	
TX_NEW_DSD	By Age/Sex: 5-9 Female	131	
TX_NEW_DSD	By Age/Sex: 10-14 Female	218	
TX_NEW_DSD	By Age/Sex: 15-19 Female	871	

TX_NEW_DSD	By Age/Sex: 20-24 Female	1,525	
TX_NEW_DSD	By Age/Sex: 25-49 Female	1,305	
TX_NEW_DSD	By Age/Sex: 50+ Female	110	
TX_NEW_DSD	Sum of Age/Sex disaggregates	6,702	
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	59	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	235	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	2,053	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	109	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	436	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	3,812	
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	6,536	
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	5,696	
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	6,702	
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	50	
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	40	
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	60	
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have	99	

	died, those who have stopped ART, and those lost to follow-up)		
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	399	
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	698	
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	93	
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	74	
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	111	
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	185	
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	598	

TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	50	
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	5	
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	0	
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	5	
LAB_ACC_DSD	Sum of Support Type disaggregates	5	
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	0	
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	0	
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	0	
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	



FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	0	
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	29,013	
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	29,013	
TB_SCREEN_DSD	Age: <1	725	
TB_SCREEN_DSD	Age: 1-4	580	
TB_SCREEN_DSD	Age: 5-9	870	
TB_SCREEN_DSD	Age: 10-14	1,451	
TB_SCREEN_DSD	Age: 15-19	5,803	
TB_SCREEN_DSD	Age: 20-24	10,155	
TB_SCREEN_DSD	Age: 25-49	8,704	
TB_SCREEN_DSD	Age: 50+	725	
TB_SCREEN_DSD	Sum of Age disaggregates	9,429	
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	3,627	
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	25,386	
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	29,013	
TB_SCREEN_DSD	Sex: Male	10,155	
TB_SCREEN_DSD	Sex: Female	18,858	
TB_SCREEN_DSD	Sum of Sex disaggregates	29,013	

### Implementing Mechanism Details

<b>Mechanism ID: 13346</b>	<b>Mechanism Name: Support Services for HIV Pandemic</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: World Health Organization	





Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 281,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	281,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	5,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	13346
<b>Mechanism Name:</b>	Support Services for HIV Pandemic
<b>Prime Partner Name:</b>	World Health Organization



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	35,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	60,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	36,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	125,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	25,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 13354</b>	<b>Mechanism Name: Kenya Conference of Catholic Bishops (KCCB)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Kenya Episcopal Conference	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



<b>Total All Funding Sources: 11,216,756</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	11,216,756

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	1,570,346
Gender: GBV	280,419
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	280,419
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID: 13354</b>
----------------------------



<b>Mechanism Name:</b>	<b>Kenya Conference of Catholic Bishops (KCCB)</b>		
<b>Prime Partner Name:</b>	<b>Kenya Episcopal Conference</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	2,615,572	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	890,426	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	510,314	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	708,487	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	608,803	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	5,790,929	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	92,225	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,922		Redacted

PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	1,922		Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	1,441		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	673		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	768		Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	481		Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	1,922		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	1,441		Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	19,142		Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	19,142		Redacted
PMTCT_STAT_DS D	By: Known positives at entry	904		Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	1,018		Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	1,922		Redacted

HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	93,219		Redacted
HTC_TST_DSD	By Test Result: Negative	89,490		Redacted
HTC_TST_DSD	By Test Result: Positive	3,729		Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	93,219		Redacted
HTC_TST_DSD	Age/sex: <1 Male	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	3,263		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	1,398		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	2,330		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	4,661		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	11,652		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	18,644		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	4,661		Redacted
HTC_TST_DSD	Age/sex: <1 Female	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	3,263		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	1,398		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	2,330		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	4,661		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	11,652		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	18,644		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	4,662		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	93,219		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	6,991		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	39,618		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	6,991		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	39,619		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	13,982		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	79,237		Redacted



HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	93,219		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	53,135		Redacted
CARE_CURR_DS D	Age/sex: <1 Male	83		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	576		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	973		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	765		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	408		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	755		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	11,351		Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	3,922		Redacted
CARE_CURR_DS D	Age/sex: <1 Female	83		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	576		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	973		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	765		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	673		Redacted
CARE_CURR_DS	Age/sex: 20-24 Female	2,793		Redacted

D				
CARE_CURR_DS D	Age/sex: 25-49 Female	23,854		Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	4,585		Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	53,135		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,397		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	16,436		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,397		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	31,905		Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	53,135		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	9,661		Redacted
CARE_NEW_DSD	Age/sex: <1 Male	15		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	105		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	177		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	139		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	63		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	262		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	2,234		Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	430		Redacted
CARE_NEW_DSD	Age/sex: <1 Female	15		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	99		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	183		Redacted



CARE_NEW_DSD	Age/sex: 10-14 Female	139		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	144		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	267		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	4,006		Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	1,383		Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	9,661		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	436		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	2,989		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	436		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	5,800		Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	9,661		Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	8,390		Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	11,186		Redacted
FN_THER_DSD	Age: <1	27		Redacted
FN_THER_DSD	Age: 1-4	181		Redacted
FN_THER_DSD	Age: 5-14	565		Redacted
FN_THER_DSD	Age: 15-17	170		Redacted
FN_THER_DSD	Age: 18+	7,447		Redacted
FN_THER_DSD	Sum of Age disaggregates	8,390		Redacted
FN_THER_DSD	Aggregated Age: <18	943		Redacted
FN_THER_DSD	Aggregated Age: 18+	7,447		Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	8,390		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	2,391		Redacted

TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	2,657		Redacted
TB_ART_DSD	Age: 0-4	59		Redacted
TB_ART_DSD	Age: 5-14	161		Redacted
TB_ART_DSD	Age: 15+	2,171		Redacted
TB_ART_DSD	Male	1,291		Redacted
TB_ART_DSD	Female	1,100		Redacted
TB_ART_DSD	Sum of Sex disaggregates	2,391		Redacted
TB_ART_DSD	Newly tested	1,435		Redacted
TB_ART_DSD	Known HIV-positive	956		Redacted
TB_ART_DSD	Sum of Test Status disaggregates	2,391		Redacted
TB_ART_DSD	Aggregated Age: <15	220		Redacted
TB_ART_DSD	Aggregated Age: 15+	2,171		Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	2,391		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,537		Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	1,922		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,153		Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	384		Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,537		Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	77		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	52,332		Redacted
TX_CURR_DSD	Age/Sex: <1 Male	82		Redacted

TX_CURR_DSD	Age/Sex: 1-4 Male	553		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	1,725		Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	16,664		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	82		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	553		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	1,725		Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	30,948		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	4,720		Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	1		Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	1		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	82		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	82		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	2,360		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	16,664		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	2,360		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	30,948		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	4,720		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	47,612		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	52,332		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	164		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	6,184		Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	131		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	74		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	131		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	100		Redacted

TX_NEW_DSD	By Age/Sex: 15-19 Male	46		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	85		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	1,283		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	445		Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	131		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	74		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	130		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	101		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	73		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	302		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	2,582		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	496		Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	6,184		Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	131		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	436		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,859		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	131		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	436		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	3,453		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	6,184		Redacted
TX_NEW_DSD	Pregnancy status	605		Redacted
TX_NEW_DSD	Breastfeeding status	67		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	5,327		Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months	6,267		Redacted

	prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up			
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	132		Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	359		Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,836		Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	155		Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	422		Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to	5,690		Redacted

	follow-up)			
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	491		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,836		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	578		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,690		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,201		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,413		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing	57		Redacted

	facilities with capacity to perform clinical laboratory tests			
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	57		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	57		Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	44		Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	57		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	44		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0		Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	44		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	57		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	0		Redacted

FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	57		Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	44		Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	44		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	50,478		Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	53,135		Redacted
TB_SCREEN_DSD	Age: <1	161		Redacted
TB_SCREEN_DSD	Age: 1-4	1,089		Redacted
TB_SCREEN_DSD	Age: 5-9	1,922		Redacted
TB_SCREEN_DSD	Age: 10-14	1,480		Redacted
TB_SCREEN_DSD	Age: 15-19	1,021		Redacted
TB_SCREEN_DSD	Age: 20-24	3,403		Redacted
TB_SCREEN_DSD	Age: 25-49	33,427		Redacted
TB_SCREEN_DSD	Age: 50+	7,975		Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	5,673		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	4,652		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	45,826		Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	50,478		Redacted
TB_SCREEN_DSD	Sex: Male	17,907		Redacted
TB_SCREEN_DSD	Sex: Female	32,571		Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	50,478		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 13366</b>	<b>Mechanism Name: Expanding High Quality HIV</b>
----------------------------	---





	<b>Prevention, Care and Treatment within Faith-Based Health Facilities</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Christian Health Association of Kenya	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 7,203,953</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	7,203,953

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	1,440,791
Gender: GBV	180,099
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	180,099
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation



Sub Area:	Monitoring and Evaluation
-----------	---------------------------

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	13366		
<b>Mechanism Name:</b>	Expanding High Quality HIV Prevention, Care and Treatment within Faith-Based Health Facilities		
<b>Prime Partner Name:</b>	Christian Health Association of Kenya		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	1,649,611	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	529,857	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	201,757	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	415,826	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	382,005	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	3,830,812	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	194,085	0

## Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	2,065		Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	2,065		Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	1,549		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	723		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	826		Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	516		Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	2,065		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	1,549		Redacted

PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	22,918		Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	22,918		Redacted
PMTCT_STAT_DS D	By: Known positives at entry	971		Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	1,094		Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	2,065		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	183,228		Redacted
HTC_TST_DSD	By Test Result: Negative	175,899		Redacted
HTC_TST_DSD	By Test Result: Positive	7,329		Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	183,228		Redacted
HTC_TST_DSD	Age/sex: <1 Male	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	6,413		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	2,748		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	4,581		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	9,161		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	22,904		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	36,646		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	9,161		Redacted
HTC_TST_DSD	Age/sex: <1 Female	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	6,413		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	2,748		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	4,581		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	9,161		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	22,904		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	36,646		Redacted

HTC_TST_DSD	Age/sex: 50+ Female	9,161		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	183,228		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	13,742		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	77,872		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	13,742		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	77,872		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	27,484		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	155,744		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	183,228		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	46,940		Redacted
CARE_CURR_DS D	Age/sex: <1 Male	73		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	509		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	860		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	676		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	360		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	667		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	10,028		Redacted
CARE_CURR_DS	Age/sex: 50+ Male	3,465		Redacted

D				
CARE_CURR_DS D	Age/sex: <1 Female	73		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	483		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	889		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	673		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	595		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	2,467		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	21,072		Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	4,050		Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	46,940		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,118		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	14,520		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,118		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	28,184		Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	46,940		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO	8,535		Redacted

	staging) OR CD4 count OR viral load			
CARE_NEW_DSD	Age/sex: <1 Male	13		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	88		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	162		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	122		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	56		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	231		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	1,974		Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	380		Redacted
CARE_NEW_DSD	Age/sex: <1 Female	13		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	92		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	156		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	124		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	127		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	235		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	3,539		Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	1,223		Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	8,535		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	385		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	2,641		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	385		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	5,124		Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	8,535		Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	7,412		Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	9,882		Redacted
FN_THER_DSD	Age: <1	24		Redacted
FN_THER_DSD	Age: 1-4	160		Redacted

FN_THER_DSD	Age: 5-14	500		Redacted
FN_THER_DSD	Age: 15-17	150		Redacted
FN_THER_DSD	Age: 18+	6,578		Redacted
FN_THER_DSD	Sum of Age disaggregates	7,412		Redacted
FN_THER_DSD	Aggregated Age: <18	834		Redacted
FN_THER_DSD	Aggregated Age: 18+	6,578		Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	7,412		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	2,112		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	2,347		Redacted
TB_ART_DSD	Age: 0-4	52		Redacted
TB_ART_DSD	Age: 5-14	143		Redacted
TB_ART_DSD	Age: 15+	1,917		Redacted
TB_ART_DSD	Male	1,140		Redacted
TB_ART_DSD	Female	972		Redacted
TB_ART_DSD	Sum of Sex disaggregates	2,112		Redacted
TB_ART_DSD	Newly tested	1,267		Redacted
TB_ART_DSD	Known HIV-positive	845		Redacted
TB_ART_DSD	Sum of Test Status disaggregates	2,112		Redacted
TB_ART_DSD	Aggregated Age: <15	195		Redacted
TB_ART_DSD	Aggregated Age: 15+	1,917		Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	2,112		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,652		Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting	2,061		Redacted



	period (include known HIV-positive women at entry into PMTCT)			
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,239		Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	413		Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,652		Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	83		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	45,830		Redacted
TX_CURR_DSD	Age/Sex: <1 Male	71		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	484		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	1,511		Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	14,594		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	71		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	484		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	1,511		Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	27,104		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	4,132		Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	1		Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	1		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	71		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	71		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	2,066		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	14,594		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	2,066		Redacted

TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	27,104		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	4,132		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	41,698		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	45,830		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	142		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	5,640		Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	119		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	67		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	119		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	92		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	42		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	78		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	1,171		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	405		Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	119		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	67		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	119		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	92		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	66		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	276		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	2,354		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	454		Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	5,640		Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	119		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	397		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,696		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	119		Redacted

TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	397		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	3,150		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	5,640		Redacted
TX_NEW_DSD	Pregnancy status	650		Redacted
TX_NEW_DSD	Breastfeeding status	72		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	4,813		Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	5,663		Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	119		Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	324		Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,370		Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to	140		Redacted

	follow-up)			
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	382		Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,141		Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	444		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,369		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	522		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and	5,141		Redacted

	those lost to follow-up)			
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	725		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	853		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	30		Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	30		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	30		Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	43		Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	57		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	43		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of	0		Redacted

	service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services			
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	43		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	57		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	0		Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	57		Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	43		Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	43		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	44,593		Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	46,940		Redacted
TB_SCREEN_DSD	Age: <1	142		Redacted
TB_SCREEN_DSD	Age: 1-4	962		Redacted
TB_SCREEN_DSD	Age: 5-9	1,698		Redacted
TB_SCREEN_DSD	Age: 10-14	1,308		Redacted
TB_SCREEN_DSD	Age: 15-19	902		Redacted
TB_SCREEN_DSD	Age: 20-24	3,006		Redacted



TB_SCREEN_DSD	Age: 25-49	29,530		Redacted
TB_SCREEN_DSD	Age: 50+	7,045		Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	5,012		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	4,110		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	40,483		Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	44,593		Redacted
TB_SCREEN_DSD	Sex: Male	15,819		Redacted
TB_SCREEN_DSD	Sex: Female	28,774		Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	44,593		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 13385</b>	<b>Mechanism Name: Prevention for MARPS</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Manitoba	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 3,170,311</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	3,170,311

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	500,000
Key Populations: MSM and TG	300,000



Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Key Populations: FSW	1,481,900
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Gender: GBV	50,000
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation

## Key Issues





(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 13385			
<b>Mechanism Name:</b> Prevention for MARPS			
<b>Prime Partner Name:</b> University of Manitoba			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	296,170	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	97,228	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	44,166	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	166,080	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	1,535,856	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	IDUP	256,831	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	55,564	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	687,781	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	30,635	0

## Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	295		Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	295		Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	221		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	103		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	118		Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	74		Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	295		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	221		Redacted
PMTCT_STAT_DS	Number of pregnant women with known	1,283		Redacted

D	HIV status (includes women who were tested for HIV and received their results)			
PMTCT_STAT_DS D	Number of new ANC and L&D clients	1,283		Redacted
PMTCT_STAT_DS D	By: Known positives at entry	139		Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	156		Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	295		Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	14,300		Redacted
PP_PREV_DSD	Total number of people in the target population	17,800		Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	2,860		Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	11,440		Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	14,300		Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	43,162		Redacted
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	40,221		Redacted
KP_PREV_DSD	By key population type: Males who inject drugs ( Male PWID) (Numerator:	1,144		Redacted

	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)			
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	286		Redacted
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,511		Redacted
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	604		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	51,901		Redacted
HTC_TST_DSD	By Test Result: Negative	49,825		Redacted
HTC_TST_DSD	By Test Result: Positive	2,076		Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	51,901		Redacted

HTC_TST_DSD	Age/sex: <1 Male	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	0		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	0		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	0		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	102		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	1,682		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	3,971		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	255		Redacted
HTC_TST_DSD	Age/sex: <1 Female	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	0		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	0		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	0		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	918		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	9,178		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	27,535		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	8,260		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	51,901		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	6,010		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	45,891		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	0		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	51,901		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	51,901		Redacted
GEND_GBV_DSD	Number of people receiving post-GBV care	50		Redacted
GEND_GBV_DSD	Age: 18-24	20		Redacted
GEND_GBV_DSD	Age: 25+	30		Redacted

GEND_GBVDSD	Sum of Age disaggregates	50		Redacted
GEND_GBVDSD	Sex: Male	5		Redacted
GEND_GBVDSD	Sex: Female	45		Redacted
GEND_GBVDSD	Sum of Sex disaggregates	50		Redacted
GEND_GBVDSD	By type of service: Sexual Violence (Post-Rape Care)	50		Redacted
GEND_GBVDSD	By PEP service provision (related to sexual violence services provided)	50		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	12,188		Redacted
CARE_CURR_DS D	Age/sex: <1 Male	19		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	132		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	223		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	175		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	93		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	173		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	2,604		Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	900		Redacted
CARE_CURR_DS D	Age/sex: <1 Female	19		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	125		Redacted
CARE_CURR_DS	Age/sex: 5-9 Female	231		Redacted

D				
CARE_CURR_DS D	Age/sex: 10-14 Female	174		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	154		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	641		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	5,472		Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	1,053		Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	12,188		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	549		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,770		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	549		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	7,320		Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	12,188		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	2,215		Redacted
CARE_NEW_DSD	Age/sex: <1 Male	3		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	24		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	40		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	33		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	14		Redacted

CARE_NEW_DSD	Age/sex: 20-24 Male	60		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	512		Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	99		Redacted
CARE_NEW_DSD	Age/sex: <1 Female	3		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	23		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	42		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	32		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	33		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	61		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	918		Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	318		Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	2,215		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	100		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	685		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	100		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	1,330		Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	2,215		Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	1,925		Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	2,566		Redacted
FN_THER_DSD	Age: <1	6		Redacted
FN_THER_DSD	Age: 1-4	42		Redacted
FN_THER_DSD	Age: 5-14	130		Redacted
FN_THER_DSD	Age: 15-17	39		Redacted
FN_THER_DSD	Age: 18+	1,708		Redacted
FN_THER_DSD	Sum of Age disaggregates	1,925		Redacted
FN_THER_DSD	Aggregated Age: <18	217		Redacted
FN_THER_DSD	Aggregated Age: 18+	1,708		Redacted



FN_THER_DSD	Sum of Aggregated Age disaggregates	1,925		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	548		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	609		Redacted
TB_ART_DSD	Age: 0-4	14		Redacted
TB_ART_DSD	Age: 5-14	36		Redacted
TB_ART_DSD	Age: 15+	498		Redacted
TB_ART_DSD	Male	296		Redacted
TB_ART_DSD	Female	252		Redacted
TB_ART_DSD	Sum of Sex disaggregates	548		Redacted
TB_ART_DSD	Newly tested	329		Redacted
TB_ART_DSD	Known HIV-positive	219		Redacted
TB_ART_DSD	Sum of Test Status disaggregates	548		Redacted
TB_ART_DSD	Aggregated Age: <15	50		Redacted
TB_ART_DSD	Aggregated Age: 15+	498		Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	548		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	236		Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	295		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	177		Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	59		Redacted

PMTCT_EID_DSD	Sum of Infant Age disaggregates	236		Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	12		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	7,363		Redacted
TX_CURR_DSD	Age/Sex: <1 Male	11		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	78		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	243		Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	2,345		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	11		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	78		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	243		Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	4,354		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	664		Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	57		Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	57		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	11		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	11		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	332		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	2,345		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	332		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	4,354		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	664		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	6,699		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	7,363		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	22		Redacted

TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,491		Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	31		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	18		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	31		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	25		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	11		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	21		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	309		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	107		Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	31		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	19		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	31		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	24		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	18		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	73		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	623		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	119		Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,491		Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	31		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	105		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	448		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	31		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	105		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	833		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,491		Redacted
TX_NEW_DSD	Pregnancy status	93		Redacted

TX_NEW_DSD	Breastfeeding status	10		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,284		Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,511		Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	31		Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	87		Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,166		Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	37		Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	102		Redacted

TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,372		Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	118		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,166		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	139		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,372		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	185		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults	218		Redacted

	and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)			
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	1		Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	1		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	1		Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	8		Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	10		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	8		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0		Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	8		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of	10		Redacted

	PEPFAR-supported HIV service delivery points			
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	0		Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	10		Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	8		Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	8		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	11,579		Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	12,188		Redacted
TB_SCREEN_DSD	Age: <1	37		Redacted
TB_SCREEN_DSD	Age: 1-4	250		Redacted
TB_SCREEN_DSD	Age: 5-9	441		Redacted
TB_SCREEN_DSD	Age: 10-14	340		Redacted
TB_SCREEN_DSD	Age: 15-19	234		Redacted
TB_SCREEN_DSD	Age: 20-24	781		Redacted
TB_SCREEN_DSD	Age: 25-49	7,668		Redacted
TB_SCREEN_DSD	Age: 50+	1,828		Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	1,302		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	1,068		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	10,511		Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	11,579		Redacted



TB_SCREEN_DSD	Sex: Male	4,108		Redacted
TB_SCREEN_DSD	Sex: Female	7,471		Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	11,579		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 13399</b>	<b>Mechanism Name: Partnership for Advanced Care and Treatment (PACT)</b>		
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement		
Prime Partner Name: University of Maryland			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: N/A			
G2G: No	Managing Agency:		

<b>Total All Funding Sources: 5,282,816</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	5,282,816

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	964,099
Renovation	160,000
Gender: GBV	125,100
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	125,100





Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 13399			
<b>Mechanism Name:</b> Partnership for Advanced Care and Treatment (PACT)			
<b>Prime Partner Name:</b> University of Maryland			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	716,581	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	216,739	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	36,814	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	82,588	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	IDUP	636,492	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Prevention	MTCT	675,786	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	2,914,883	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	2,933	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,274		Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	1,274		Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	955		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	446		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	509		Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy)	319		Redacted

	and delivery)			
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	1,274		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	955		Redacted
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	716		Redacted
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	716		Redacted
PMTCT_ARV_TA	Life-long ART (including Option B+)	537		Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	250		Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	287		Redacted
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	179		Redacted
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	716		Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	537		Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were	18,371		Redacted

	tested for HIV and received their results)			
PMTCT_STAT_DS D	Number of new ANC and L&D clients	18,371		Redacted
PMTCT_STAT_DS D	By: Known positives at entry	599		Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	675		Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	1,274		Redacted
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	1,430		Redacted
KP_MAT_DSD	Sex: Male	1,144		Redacted
KP_MAT_DSD	Sex: Female	286		Redacted
KP_MAT_DSD	Sum of Sex disaggregates	1,430		Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	3,338		Redacted
KP_PREV_DSD	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,670		Redacted
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum	668		Redacted

	standards required)			
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	99,808		Redacted
HTC_TST_DSD	By Test Result: Negative	95,816		Redacted
HTC_TST_DSD	By Test Result: Positive	3,992		Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	99,808		Redacted
HTC_TST_DSD	Age/sex: <1 Male	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	3,493		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	1,497		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	2,495		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	4,990		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	12,476		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	19,962		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	4,991		Redacted
HTC_TST_DSD	Age/sex: <1 Female	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	3,493		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	1,497		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	2,495		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	4,990		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	12,476		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	19,962		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	4,991		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	99,808		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	7,485		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	42,419		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	7,485		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	42,419		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	14,970		Redacted

HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	84,838		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	99,808		Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	14,520		Redacted
HTC_TST_TA	By Test Result: Negative	13,939		Redacted
HTC_TST_TA	By Test Result: Positive	581		Redacted
HTC_TST_TA	Sum of Test Result disaggregates	14,520		Redacted
HTC_TST_TA	Age/sex: <1 Male	0		Redacted
HTC_TST_TA	Age/sex: 1-4 Male	508		Redacted
HTC_TST_TA	Age/sex: 5-9 Male	218		Redacted
HTC_TST_TA	Age/sex: 10-14 Male	363		Redacted
HTC_TST_TA	Age/sex: 15-19 Male	726		Redacted
HTC_TST_TA	Age/sex: 20-24 Male	1,815		Redacted
HTC_TST_TA	Age/sex: 25-49 Male	2,904		Redacted
HTC_TST_TA	Age/sex: 50+ Male	726		Redacted
HTC_TST_TA	Age/sex: <1 Female	0		Redacted
HTC_TST_TA	Age/sex: 1-4 Female	508		Redacted
HTC_TST_TA	Age/sex: 5-9 Female	218		Redacted
HTC_TST_TA	Age/sex: 10-14 Female	363		Redacted
HTC_TST_TA	Age/sex: 15-19 Female	726		Redacted
HTC_TST_TA	Age/sex: 20-24 Female	1,815		Redacted
HTC_TST_TA	Age/sex: 25-49 Female	2,904		Redacted
HTC_TST_TA	Age/sex: 50+ Female	726		Redacted
HTC_TST_TA	Sum of Age/Sex disaggregates	14,520		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,089		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	6,171		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,089		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	6,171		Redacted

	PERMISSION ONLY: 15+ Female			
HTC_TST_TA	Sum of Aggregated Age/Sex <15	2,178		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	12,342		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	14,520		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	16,718		Redacted
CARE_CURR_DS D	Age/sex: <1 Male	26		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	181		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	306		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	241		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	128		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	238		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	3,571		Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	1,234		Redacted
CARE_CURR_DS D	Age/sex: <1 Female	26		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	172		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	317		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	239		Redacted

CARE_CURR_DS D	Age/sex: 15-19 Female	212		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	879		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	7,505		Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	1,443		Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	16,718		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	754		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	5,171		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	754		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	10,039		Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	16,718		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	3,576		Redacted
CARE_NEW_DSD	Age/sex: <1 Male	6		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	39		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	65		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	51		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	53		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	99		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	1,483		Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	512		Redacted



CARE_NEW_DSD	Age/sex: <1 Female	6		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	37		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	68		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	51		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	23		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	97		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	827		Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	159		Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	3,576		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	161		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	2,147		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	162		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	1,106		Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	3,576		Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	3,106		Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	4,141		Redacted
FN_THER_DSD	Age: <1	10		Redacted
FN_THER_DSD	Age: 1-4	67		Redacted
FN_THER_DSD	Age: 5-14	209		Redacted
FN_THER_DSD	Age: 15-17	64		Redacted
FN_THER_DSD	Age: 18+	2,756		Redacted
FN_THER_DSD	Sum of Age disaggregates	3,106		Redacted
FN_THER_DSD	Aggregated Age: <18	350		Redacted
FN_THER_DSD	Aggregated Age: 18+	2,756		Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	3,106		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented	752		Redacted

	HIV-positive status who are on ART during TB treatment during the reporting period			
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	836		Redacted
TB_ART_DSD	Age: 0-4	19		Redacted
TB_ART_DSD	Age: 5-14	50		Redacted
TB_ART_DSD	Age: 15+	683		Redacted
TB_ART_DSD	Male	406		Redacted
TB_ART_DSD	Female	346		Redacted
TB_ART_DSD	Sum of Sex disaggregates	752		Redacted
TB_ART_DSD	Newly tested	451		Redacted
TB_ART_DSD	Known HIV-positive	301		Redacted
TB_ART_DSD	Sum of Test Status disaggregates	752		Redacted
TB_ART_DSD	Aggregated Age: <15	69		Redacted
TB_ART_DSD	Aggregated Age: 15+	683		Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	752		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,592		Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	1,990		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,194		Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	398		Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,592		Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	80		Redacted

TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	12,706		Redacted
TX_CURR_DSD	Age/Sex: <1 Male	20		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	134		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	419		Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	4,046		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	20		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	134		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	419		Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	7,514		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	1,146		Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	72		Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	71		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	20		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	20		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	573		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	4,046		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	573		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	7,514		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,146		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	11,560		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	12,706		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	40		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,798		Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	80		Redacted



TX_NEW_DSD	By Age/Sex: 1-4 Male	45		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	80		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	62		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	28		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	52		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	789		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	273		Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	80		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	45		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	80		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	63		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	45		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	186		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	1,585		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	305		Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	3,798		Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	80		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	267		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,142		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	80		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	268		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	2,121		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	3,798		Redacted
TX_NEW_DSD	Pregnancy status	627		Redacted
TX_NEW_DSD	Breastfeeding status	70		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12	3,124		Redacted

	months after initiating ART			
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	3,675		Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	77		Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	211		Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,836		Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	91		Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	248		Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning	3,336		Redacted

	of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	288		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,836		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	339		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,336		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,202		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who	1,415		Redacted

	have died, those who have stopped ART, and those lost to follow-up)			
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	20		Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	7		Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	13		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	20		Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	31		Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	41		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	12		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	19		Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	31		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service	16		Redacted

	delivery points			
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	25		Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	41		Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	31		Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	31		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	15,882		Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	16,718		Redacted
TB_SCREEN_DSD	Age: <1	51		Redacted
TB_SCREEN_DSD	Age: 1-4	343		Redacted
TB_SCREEN_DSD	Age: 5-9	605		Redacted
TB_SCREEN_DSD	Age: 10-14	465		Redacted
TB_SCREEN_DSD	Age: 15-19	321		Redacted
TB_SCREEN_DSD	Age: 20-24	1,071		Redacted
TB_SCREEN_DSD	Age: 25-49	10,517		Redacted
TB_SCREEN_DSD	Age: 50+	2,509		Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	1,785		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	1,464		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	14,418		Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	15,882		Redacted
TB_SCREEN_DSD	Sex: Male	5,634		Redacted





TB_SCREEN_DSD	Sex: Female	10,248		Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	15,882		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 13474</b>	<b>Mechanism Name: HIV Prevention for MARPS</b>			
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement			
Prime Partner Name: Hope Worldwide				
Agreement Start Date: Redacted	Agreement End Date: Redacted			
TBD: No	New Mechanism: No			
Global Fund / Multilateral Engagement: N/A				
G2G: No	Managing Agency:			

<b>Total All Funding Sources: 266,309</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	266,309

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	46,650
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs



Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Key Populations: FSW	202,994
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Gender: GBV	20,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	20,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms



Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 13474			
<b>Mechanism Name:</b> HIV Prevention for MARPS			
<b>Prime Partner Name:</b> Hope Worldwide			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	121,662	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	140,347	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	4,300	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
KP_PREV_DSD	Number of key populations reached with individual and/or small group level	14,604	3,905	Redacted

	HIV preventive interventions that are based on evidence and/or meet the minimum standards required			
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	13,937	3,776	Redacted
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	667	86	Redacted
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	266		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	15,122	20,278	Redacted
HTC_TST_DSD	By Test Result: Negative	14,517	19,811	Redacted
HTC_TST_DSD	By Test Result: Positive	605	467	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	15,122	20,278	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	76		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	304		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	380		Redacted

HTC_TST_DSD	Age/sex: 15-19 Female	1,436		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	5,745		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	6,463		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	718		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	15,122		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	760	6,002	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	14,362	11,979	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	15,122	17,981	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	15,122	20,278	Redacted
GEND_GBV_DSD	Number of people receiving post-GBV care	85		Redacted
GEND_GBV_DSD	Age: 15-17	10		Redacted
GEND_GBV_DSD	Age: 18-24	35		Redacted
GEND_GBV_DSD	Age: 25+	40		Redacted
GEND_GBV_DSD	Sum of Age disaggregates	85		Redacted
GEND_GBV_DSD	Sex: Male	5		Redacted
GEND_GBV_DSD	Sex: Female	80		Redacted
GEND_GBV_DSD	Sum of Sex disaggregates	85		Redacted
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	40		Redacted
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	45		Redacted
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	45		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	942	300	Redacted

CARE_CURR_DS D	Age/sex: <1 Male	0		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	0		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	0		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	0		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	8		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	15	3	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	221	60	Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	76		Redacted
CARE_CURR_DS D	Age/sex: <1 Female	0		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	0		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	0		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	0		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	13	2	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	54	53	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	465	182	Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	90		Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	942	300	Redacted

CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	320		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	622		Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	942		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	171	75	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	1		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	5	4	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	44	19	Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	8		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	3	1	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	5	14	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	78	37	Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	27		Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	171	75	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	0		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	58		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	113		Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	171		Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	149		Redacted

FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	198		Redacted
FN_THER_DSD	Age: 15-17	2		Redacted
FN_THER_DSD	Age: 18+	147		Redacted
FN_THER_DSD	Sum of Age disaggregates	149		Redacted
FN_THER_DSD	Aggregated Age: <18	2		Redacted
FN_THER_DSD	Aggregated Age: 18+	147		Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	149		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	42	9	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	47	9	Redacted
TB_ART_DSD	Age: 15+	42		Redacted
TB_ART_DSD	Male	23	2	Redacted
TB_ART_DSD	Female	19	7	Redacted
TB_ART_DSD	Sum of Sex disaggregates	42	9	Redacted
TB_ART_DSD	Newly tested	25		Redacted
TB_ART_DSD	Known HIV-positive	17	8	Redacted
TB_ART_DSD	Sum of Test Status disaggregates	42	8	Redacted
TB_ART_DSD	Aggregated Age: 15+	42		Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	42		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	195	270	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	0		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	0		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	0		Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	68		Redacted



TX_CURR_DSD	Age/Sex: <1 Female	0		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	0		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	0		Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	127		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	0	270	Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	19		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	0		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	0		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	0		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	68		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	0		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	127		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	0		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	195		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	195		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	0		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	107	59	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	0		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	0		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	0		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	0		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	1	1	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	2	4	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	25	13	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	9		Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	0		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	0		Redacted

TX_NEW_DSD	By Age/Sex: 5-9 Female	0		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	0		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	1	2	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	6	12	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	53	27	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	10		Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	107	59	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	0		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	0		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	37		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	0		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	0		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	70		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	107		Redacted
TX_NEW_DSD	Pregnancy status	0	1	Redacted
TX_NEW_DSD	Breastfeeding status	0	0	Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	4	5	Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	5	5	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family	4		Redacted

	planning services			
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0		Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	4		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	5		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	0		Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	5		Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	4		Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	4		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	895	300	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	942	300	Redacted
TB_SCREEN_DSD	Age: 15-19	21	1	Redacted
TB_SCREEN_DSD	Age: 20-24	79		Redacted
TB_SCREEN_DSD	Age: 25-49	626		Redacted
TB_SCREEN_DSD	Age: 50+	169		Redacted



TB_SCREEN_DSD	Sum of Age disaggregates	21	300	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	895		Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	895		Redacted
TB_SCREEN_DSD	Sex: Male	317	85	Redacted
TB_SCREEN_DSD	Sex: Female	578	215	Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	895	300	Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 13481</b>	<b>Mechanism Name: Prevention for MARPS-Central and Eastern</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Nairobi	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 1,477,331</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,477,331

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	112,363
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current



	PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	555,034
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Human Resources for Health	674,176
Gender: GBV	18,727
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Condom programming	74,908

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 13481
----------------------------



<b>Mechanism Name:</b>	Prevention for MARPS-Central and Eastern		
<b>Prime Partner Name:</b>	University of Nairobi		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	51,458	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	14,979	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	429	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	145,461	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	786,328	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	IDUP	194,846	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	283,025	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	805	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PP_PREV_DSD	Number of the target population who	1,420		Redacted

	completed a standardized HIV prevention intervention including the minimum components during the reporting period.			
PP_PREV_DSD	Total number of people in the target population	5,509		Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	710		Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	710		Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	1,420		Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	17,448		Redacted
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	16,537		Redacted
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	911		Redacted
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on	364		Redacted

	evidence and/or meet the minimum standards required)			
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	25,525		Redacted
HTC_TST_DSD	By Test Result: Negative	24,504		Redacted
HTC_TST_DSD	By Test Result: Positive	1,021		Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	25,525		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	114		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	455		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	569		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	2,439		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	9,755		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	10,974		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	1,219		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	25,525		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,138		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	24,387		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	25,525		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	25,525		Redacted
GEND_GBV_DSD	Number of people receiving post-GBV care	1,470		Redacted
GEND_GBV_DSD	Age: 10-14	284		Redacted
GEND_GBV_DSD	Age: 15-17	1,136		Redacted
GEND_GBV_DSD	Age: 18-24	25		Redacted
GEND_GBV_DSD	Age: 25+	25		Redacted
GEND_GBV_DSD	Sum of Age disaggregates	1,470		Redacted
GEND_GBV_DSD	Sex: Male	334		Redacted
GEND_GBV_DSD	Sex: Female	1,136		Redacted
GEND_GBV_DSD	Sum of Sex disaggregates	1,470		Redacted



GEND_GBVDSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	284		Redacted
GEND_GBVDSD	By type of service: Sexual Violence (Post-Rape Care)	1,136		Redacted
GEND_GBVDSD	By PEP service provision (related to sexual violence services provided)	50		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	440		Redacted
CARE_CURR_DS D	Age/sex: <1 Male	0		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	0		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	0		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	0		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	4		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	7		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	103		Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	36		Redacted
CARE_CURR_DS D	Age/sex: <1 Female	0		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	0		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	0		Redacted

CARE_CURR_DS D	Age/sex: 10-14 Female	0		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	6		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	25		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	217		Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	42		Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	440		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	150		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	290		Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	440		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	80		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	1		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	2		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	20		Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	4		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	1		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	2		Redacted

CARE_NEW_DSD	Age/sex: 25-49 Female	37		Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	13		Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	80		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	0		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	27		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	53		Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	80		Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	70		Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	93		Redacted
FN_THER_DSD	Age: 15-17	2		Redacted
FN_THER_DSD	Age: 18+	68		Redacted
FN_THER_DSD	Sum of Age disaggregates	70		Redacted
FN_THER_DSD	Aggregated Age: <18	2		Redacted
FN_THER_DSD	Aggregated Age: 18+	68		Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	70		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	20		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	22		Redacted
TB_ART_DSD	Age: 0-4	0		Redacted
TB_ART_DSD	Age: 5-14	0		Redacted
TB_ART_DSD	Age: 15+	20		Redacted
TB_ART_DSD	Male	11		Redacted

TB_ART_DSD	Female	9		Redacted
TB_ART_DSD	Sum of Sex disaggregates	20		Redacted
TB_ART_DSD	Newly tested	12		Redacted
TB_ART_DSD	Known HIV-positive	8		Redacted
TB_ART_DSD	Sum of Test Status disaggregates	20		Redacted
TB_ART_DSD	Aggregated Age: <15	0		Redacted
TB_ART_DSD	Aggregated Age: 15+	20		Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	20		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	704		Redacted
TX_CURR_DSD	Age/Sex: <1 Male	0		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	0		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	0		Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	246		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	0		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	0		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	0		Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	458		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	0		Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	1		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	0		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	0		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	0		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	246		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	0		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	458		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	0		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	704		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex	704		Redacted

	disaggregates			
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	0		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	453		Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	0		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	0		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	0		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	0		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	4		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	7		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	110		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	38		Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	0		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	0		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	0		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	0		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	6		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	26		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	220		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	42		Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	453		Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	0		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	0		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	159		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	0		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	0		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	294		Redacted

TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	453		Redacted
TX_NEW_DSD	Pregnancy status	0		Redacted
TX_NEW_DSD	Breastfeeding status	0		Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	8		Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	10		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	8		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0		Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	8		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	10		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	0		Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	10		Redacted

FPINT_SITE_DSD	Service delivery type: Clinical	8		Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	8		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	418		Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	440		Redacted
TB_SCREEN_DSD	Age: <1	0		Redacted
TB_SCREEN_DSD	Age: 1-4	0		Redacted
TB_SCREEN_DSD	Age: 5-9	0		Redacted
TB_SCREEN_DSD	Age: 10-14	0		Redacted
TB_SCREEN_DSD	Age: 15-19	10		Redacted
TB_SCREEN_DSD	Age: 20-24	37		Redacted
TB_SCREEN_DSD	Age: 25-49	293		Redacted
TB_SCREEN_DSD	Age: 50+	78		Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	10		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	0		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	418		Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	418		Redacted
TB_SCREEN_DSD	Sex: Male	142		Redacted
TB_SCREEN_DSD	Sex: Female	276		Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	418		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 13543</b>	<b>Mechanism Name: PAMOJA</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 13,541,789</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	13,541,789

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	3,227,706
Gender: GBV	336,219
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Implementation
Gender: Gender Equality	336,219
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation





Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Economic Strengthening	139,451
Education	139,451

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	13543		
<b>Mechanism Name:</b>	PAMOJA		
<b>Prime Partner Name:</b>	Elizabeth Glaser Pediatric AIDS Foundation		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	2,176,917	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	464,835	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	750,172	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	459,096	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and	HLAB	100,000	0

Systems			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	2,226,021	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	805,581	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	1,339,067	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	4,442,175	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	777,925	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	5,482		Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	5,482		Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	4,112		Redacted
PMTCT_ARV_DS	Sub-Disag of Life-long ART: Newly	1,919		Redacted

D	initiated on treatment during the current pregnancy			
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	2,193		Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	1,370		Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	5,482		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	4,112		Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	46,955		Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	46,955		Redacted
PMTCT_STAT_DS D	By: Known positives at entry	2,577		Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	2,905		Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	5,482		Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	2,038		Redacted
PP_PREV_DSD	Total number of people in the target	6,440		Redacted

	population			
PP_PREV_DSD	Age/sex: 10-14 Male	766		Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	253		Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	766		Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	253		Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	2,038		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	333,678		Redacted
HTC_TST_DSD	By Test Result: Negative	320,331		Redacted
HTC_TST_DSD	By Test Result: Positive	13,347		Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	333,678		Redacted
HTC_TST_DSD	Age/sex: <1 Male	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	11,679		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	5,005		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	8,342		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	16,684		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	41,709		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	66,735		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	16,685		Redacted
HTC_TST_DSD	Age/sex: <1 Female	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	11,679		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	5,005		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	8,342		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	16,684		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	41,709		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	66,735		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	16,685		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	333,678		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	25,026		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ	141,813		Redacted

	PERMISSION ONLY: 15+ Male			
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	25,026		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	141,813		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	50,052		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	283,626		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	333,678		Redacted
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	500		Redacted
OVC_ACC_DSD	Sex: Male	250		Redacted
OVC_ACC_DSD	Sex: Female	250		Redacted
OVC_ACC_DSD	Sum of Sex disaggregates	500		Redacted
OVC_ACC_DSD	Age: <1	10		Redacted
OVC_ACC_DSD	Age: 1-4	60		Redacted
OVC_ACC_DSD	Age: 5-9	125		Redacted
OVC_ACC_DSD	Age: 10-14	180		Redacted
OVC_ACC_DSD	Age: 15-17	100		Redacted
OVC_ACC_DSD	Age: 18+	25		Redacted
OVC_ACC_DSD	Sum of Age disaggregates	500		Redacted
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	11,500		Redacted
OVC_SERV_DSD	Sex: Male	5,750		Redacted
OVC_SERV_DSD	Sex: Female	5,750		Redacted
OVC_SERV_DSD	Sum of Sex disaggregates	11,500		Redacted
OVC_SERV_DSD	Age: <1	230		Redacted
OVC_SERV_DSD	Age: 1-4	1,380		Redacted
OVC_SERV_DSD	Age: 5-9	2,875		Redacted
OVC_SERV_DSD	Age: 10-14	4,140		Redacted
OVC_SERV_DSD	Age: 15-17	2,300		Redacted



OVC_SERV_DSD	Age: 18+	575		Redacted
OVC_SERV_DSD	Sum of Age disaggregates	11,500		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	52,763		Redacted
CARE_CURR_DS D	Age/sex: <1 Male	82		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	572		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	966		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	760		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	405		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	750		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	11,272		Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	3,894		Redacted
CARE_CURR_DS D	Age/sex: <1 Female	82		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	543		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	1,000		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	755		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	670		Redacted
CARE_CURR_DS	Age/sex: 20-24 Female	2,773		Redacted

D				
CARE_CURR_DS D	Age/sex: 25-49 Female	23,687		Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	4,552		Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	52,763		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,380		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	16,321		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,380		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	31,682		Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	52,763		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	9,594		Redacted
CARE_NEW_DSD	Age/sex: <1 Male	15		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	99		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	182		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	137		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	63		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	260		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	2,218		Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	426		Redacted
CARE_NEW_DSD	Age/sex: <1 Female	15		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	104		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	176		Redacted

CARE_NEW_DSD	Age/sex: 10-14 Female	138		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	143		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	265		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	3,978		Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	1,375		Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	9,594		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	433		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	2,967		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	433		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	5,761		Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	9,594		Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	8,331		Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	11,108		Redacted
FN_THER_DSD	Age: <1	27		Redacted
FN_THER_DSD	Age: 1-4	180		Redacted
FN_THER_DSD	Age: 5-14	560		Redacted
FN_THER_DSD	Age: 15-17	169		Redacted
FN_THER_DSD	Age: 18+	7,395		Redacted
FN_THER_DSD	Sum of Age disaggregates	8,331		Redacted
FN_THER_DSD	Aggregated Age: <18	936		Redacted
FN_THER_DSD	Aggregated Age: 18+	7,395		Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	8,331		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	2,374		Redacted



TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	2,638		Redacted
TB_ART_DSD	Age: 0-4	59		Redacted
TB_ART_DSD	Age: 5-14	160		Redacted
TB_ART_DSD	Age: 15+	2,155		Redacted
TB_ART_DSD	Male	1,282		Redacted
TB_ART_DSD	Female	1,092		Redacted
TB_ART_DSD	Sum of Sex disaggregates	2,374		Redacted
TB_ART_DSD	Newly tested	1,424		Redacted
TB_ART_DSD	Known HIV-positive	950		Redacted
TB_ART_DSD	Sum of Test Status disaggregates	2,374		Redacted
TB_ART_DSD	Aggregated Age: <15	219		Redacted
TB_ART_DSD	Aggregated Age: 15+	2,155		Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	2,374		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	4,386		Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	5,482		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	3,289		Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	1,097		Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	4,386		Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	219		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	31,402		Redacted
TX_CURR_DSD	Age/Sex: <1 Male	49		Redacted

TX_CURR_DSD	Age/Sex: 1-4 Male	331		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	1,036		Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	10,000		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	49		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	331		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	1,035		Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	18,571		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	2,831		Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	1		Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	1		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	49		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	49		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,416		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	10,000		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,415		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	18,571		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	2,831		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	28,571		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	31,402		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	98		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	5,432		Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	115		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	65		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	115		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	88		Redacted

TX_NEW_DSD	By Age/Sex: 15-19 Male	40		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	75		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	1,128		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	390		Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	115		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	65		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	115		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	88		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	64		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	266		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	2,267		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	436		Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	5,432		Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	115		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	383		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,633		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	115		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	383		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	3,033		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	5,432		Redacted
TX_NEW_DSD	Pregnancy status	1,727		Redacted
TX_NEW_DSD	Breastfeeding status	192		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,279		Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months	3,858		Redacted

	prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up			
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	81		Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	221		Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,977		Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	96		Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	260		Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to	3,502		Redacted

	follow-up)			
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	302		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,977		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	356		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,502		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,003		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,533		Redacted
FPINT_SITE_DSD	Number of service delivery points	114		Redacted

	supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services			
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	152		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	114		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0		Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	114		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	152		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	0		Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	152		Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	114		Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	114		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last	50,125		Redacted



	clinical visit to an HIV care facility during the reporting period			
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	52,763		Redacted
TB_SCREEN_DSD	Age: <1	160		Redacted
TB_SCREEN_DSD	Age: 1-4	1,082		Redacted
TB_SCREEN_DSD	Age: 5-9	1,908		Redacted
TB_SCREEN_DSD	Age: 10-14	1,470		Redacted
TB_SCREEN_DSD	Age: 15-19	1,014		Redacted
TB_SCREEN_DSD	Age: 20-24	3,379		Redacted
TB_SCREEN_DSD	Age: 25-49	33,195		Redacted
TB_SCREEN_DSD	Age: 50+	7,917		Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	5,634		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	4,620		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	45,505		Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	50,125		Redacted
TB_SCREEN_DSD	Sex: Male	4,620		Redacted
TB_SCREEN_DSD	Sex: Female	45,505		Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	50,125		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 13545</b>	<b>Mechanism Name: Peace Corps</b>
Funding Agency: PC	Procurement Type: USG Core
Prime Partner Name: U.S. Peace Corps	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



<b>Total All Funding Sources: 484,386</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	484,386

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Gender: GBV	1,000
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Economic Strengthening	5,000
Education	10,000
Gender: Gender Equality	1,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building
Water	20,000

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 13545</b>			
<b>Mechanism Name: Peace Corps</b>			
<b>Prime Partner Name: U.S. Peace Corps</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>





Care	HKID	65,680	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVAB	386,073	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	32,633	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 13546</b>	<b>Mechanism Name: Kisumu West</b>
Funding Agency: DOD	Procurement Type: Cooperative Agreement
Prime Partner Name: Henry Jackson Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,875,556</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,875,556

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Food and Nutrition: Policy, Tools, and Service	50,000
--	--------



Delivery	
Food and Nutrition: Commodities	50,000
Key Populations: FSW	15,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Gender: Gender Equality	5,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 13546			
<b>Mechanism Name:</b> Kisumu West			
<b>Prime Partner Name:</b> Henry Jackson Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	395,237	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	215,117	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	134,694	0

Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	77,651	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	850,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	125,811	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	158,644	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	917,840	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	562	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,199	763
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	1,199	809
PMTCT_ARV_DSD	Life-long ART (including Option B+)	899	
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	524	597

PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	375	55
PMTCT_ARV_DSD	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	300	
PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	1,199	
PMTCT_ARV_DSD	Sum of New and Current disaggregates	899	652
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	8,020	3,071
PMTCT_STAT_DSD	Number of new ANC and L&D clients	8,020	3,071
PMTCT_STAT_DSD	By: Known positives at entry	619	80
PMTCT_STAT_DSD	By: Number of new positives identified	700	811
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	1,319	891
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	18,995	41,704
HTC_TST_DSD	By Test Result: Negative	18,235	34,486
HTC_TST_DSD	By Test Result: Positive	760	1,883
HTC_TST_DSD	Sum of Test Result disaggregates	18,995	36,369
HTC_TST_DSD	Age/sex: <1 Male	0	
HTC_TST_DSD	Age/sex: 1-4 Male	664	
HTC_TST_DSD	Age/sex: 5-9 Male	285	
HTC_TST_DSD	Age/sex: 10-14 Male	475	
HTC_TST_DSD	Age/sex: 15-19 Male	950	
HTC_TST_DSD	Age/sex: 20-24 Male	2,374	
HTC_TST_DSD	Age/sex: 25-49 Male	3,799	
HTC_TST_DSD	Age/sex: 50+ Male	950	
HTC_TST_DSD	Age/sex: <1 Female	0	
HTC_TST_DSD	Age/sex: 1-4 Female	665	
HTC_TST_DSD	Age/sex: 5-9 Female	285	
HTC_TST_DSD	Age/sex: 10-14 Female	475	

HTC_TST_DSD	Age/sex: 15-19 Female	950	
HTC_TST_DSD	Age/sex: 20-24 Female	2,374	
HTC_TST_DSD	Age/sex: 25-49 Female	3,799	
HTC_TST_DSD	Age/sex: 50+ Female	950	
HTC_TST_DSD	Sum of Age/Sex disaggregates	18,995	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,424	4,155
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	8,073	11,660
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,425	4,158
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	8,073	11,663
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	2,849	8,313
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	16,146	23,323
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	18,995	31,636
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	4,200	4,100
OVC_ACC_DSD	Sex: Male	2,100	
OVC_ACC_DSD	Sex: Female	2,100	
OVC_ACC_DSD	Sum of Sex disaggregates	4,200	
OVC_ACC_DSD	Age: <1	84	
OVC_ACC_DSD	Age: 1-4	504	
OVC_ACC_DSD	Age: 5-9	1,050	
OVC_ACC_DSD	Age: 10-14	1,512	
OVC_ACC_DSD	Age: 15-17	840	
OVC_ACC_DSD	Age: 18+	210	
OVC_ACC_DSD	Sum of Age disaggregates	4,200	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	4,200	5,079
OVC_SERV_DSD	Sex: Male	2,100	

OVC_SERV_DSD	Sex: Female	2,100	
OVC_SERV_DSD	Sum of Sex disaggregates	4,200	
OVC_SERV_DSD	Age: <1	42	
OVC_SERV_DSD	Age: 1-4	462	
OVC_SERV_DSD	Age: 5-9	1,008	
OVC_SERV_DSD	Age: 10-14	1,449	
OVC_SERV_DSD	Age: 15-17	819	
OVC_SERV_DSD	Age: 18+	420	
OVC_SERV_DSD	Sum of Age disaggregates	4,200	
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	9,537	10,275
CARE_CURR_DSD	Age/sex: <1 Male	15	23
CARE_CURR_DSD	Age/sex: 1-4 Male	103	158
CARE_CURR_DSD	Age/sex: 5-9 Male	175	272
CARE_CURR_DSD	Age/sex: 10-14 Male	137	214
CARE_CURR_DSD	Age/sex: 15-19 Male	73	68
CARE_CURR_DSD	Age/sex: 20-24 Male	136	126
CARE_CURR_DSD	Age/sex: 25-49 Male	2,038	1,901
CARE_CURR_DSD	Age/sex: 50+ Male	704	656
CARE_CURR_DSD	Age/sex: <1 Female	15	22
CARE_CURR_DSD	Age/sex: 1-4 Female	98	155
CARE_CURR_DSD	Age/sex: 5-9 Female	180	281
CARE_CURR_DSD	Age/sex: 10-14 Female	136	214
CARE_CURR_DSD	Age/sex: 15-19 Female	121	107
CARE_CURR_DSD	Age/sex: 20-24 Female	501	447
CARE_CURR_DSD	Age/sex: 25-49 Female	4,282	3,818
CARE_CURR_DSD	Age/sex: 50+ Female	823	733
CARE_CURR_DSD	Sun of Age/Sex disaggregates	9,537	9,195
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ	429	550

	PERMISSION ONLY: <15 Male		
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,951	2,365
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	429	552
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	5,728	4,393
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	9,537	7,860
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	1,716	2,149
CARE_NEW_DSD	Age/sex: <1 Male	27	7
CARE_NEW_DSD	Age/sex: 1-4 Male	15	38
CARE_NEW_DSD	Age/sex: 5-9 Male	27	68
CARE_NEW_DSD	Age/sex: 10-14 Male	20	53
CARE_NEW_DSD	Age/sex: 15-19 Male	13	17
CARE_NEW_DSD	Age/sex: 20-24 Male	25	28
CARE_NEW_DSD	Age/sex: 25-49 Male	372	434
CARE_NEW_DSD	Age/sex: 50+ Male	128	152
CARE_NEW_DSD	Age/sex: <1 Female	27	7
CARE_NEW_DSD	Age/sex: 1-4 Female	15	38
CARE_NEW_DSD	Age/sex: 5-9 Female	27	71
CARE_NEW_DSD	Age/sex: 10-14 Female	20	53
CARE_NEW_DSD	Age/sex: 15-19 Female	21	26
CARE_NEW_DSD	Age/sex: 20-24 Female	88	102
CARE_NEW_DSD	Age/sex: 25-49 Female	748	883
CARE_NEW_DSD	Age/sex: 50+ Female	143	169
CARE_NEW_DSD	Sum of Age/sex disaggregates	1,716	2,146
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	89	80
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	538	425

CARE_NEW_DSD	Aggregated Age/sex: <15 Female	89	83
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	1,000	790
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	1,716	1,378
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	2,720	
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	2,720	
FN_THER_DSD	Age: <1	9	
FN_THER_DSD	Age: 1-4	59	
FN_THER_DSD	Age: 5-14	183	
FN_THER_DSD	Age: 15-17	55	
FN_THER_DSD	Age: 18+	2,414	
FN_THER_DSD	Sum of Age disaggregates	2,720	
FN_THER_DSD	Aggregated Age: <18	306	
FN_THER_DSD	Aggregated Age: 18+	2,414	
FN_THER_DSD	Sum of Aggregated Age disaggregates	2,720	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	587	162
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	587	162
TB_ART_DSD	Age: 0-4	14	
TB_ART_DSD	Age: 5-14	40	
TB_ART_DSD	Age: 15+	533	
TB_ART_DSD	Male	317	
TB_ART_DSD	Female	270	
TB_ART_DSD	Sum of Sex disaggregates	587	
TB_ART_DSD	Newly tested	352	



TB_ART_DSD	Known HIV-positive	235	
TB_ART_DSD	Sum of Test Status disaggregates	587	
TB_ART_DSD	Aggregated Age: <15	54	
TB_ART_DSD	Aggregated Age: 15+	533	
TB_ART_DSD	Sum of Aggregated Age disaggregates	587	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	424	693
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	1,199	
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	240	90
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	184	
PMTCT_EID_DSD	Sum of Infant Age disaggregates	424	90
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	24	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	9,654	9,141
TX_CURR_DSD	Age/Sex: <1 Male	11	26
TX_CURR_DSD	Age/Sex: 1-4 Male	78	168
TX_CURR_DSD	Age/Sex: 5-14 Male	243	522
TX_CURR_DSD	Age/Sex: 15+ Male	3,213	
TX_CURR_DSD	Age/Sex: <1 Female	11	25
TX_CURR_DSD	Age/Sex: 1-4 Female	78	164
TX_CURR_DSD	Age/Sex: 5-14 Female	243	532
TX_CURR_DSD	Age/Sex: 15+ Female	5,777	
TX_CURR_DSD	Sum of age/sex disaggregates	664	9,140
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	0	

TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	0	
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	11	18
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	11	17
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	332	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	3,213	2,199
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	332	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	5,777	4,080
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	664	
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	8,990	6,279
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	9,654	6,279
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	22	1,001
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	933	2,231
TX_NEW_DSD	By Age/Sex: <1 Male	14	7
TX_NEW_DSD	By Age/Sex: 1-4 Male	8	41
TX_NEW_DSD	By Age/Sex: 5-9 Male	14	69
TX_NEW_DSD	By Age/Sex: 10-14 Male	11	53
TX_NEW_DSD	By Age/Sex: 15-19 Male	7	18
TX_NEW_DSD	By Age/Sex: 20-24 Male	13	33
TX_NEW_DSD	By Age/Sex: 25-49 Male	203	475
TX_NEW_DSD	By Age/Sex: 50+ Male	70	157
TX_NEW_DSD	By Age/Sex: <1 Female	14	7
TX_NEW_DSD	By Age/Sex: 1-4 Female	8	41
TX_NEW_DSD	By Age/Sex: 5-9 Female	14	71
TX_NEW_DSD	By Age/Sex: 10-14 Female	11	54
TX_NEW_DSD	By Age/Sex: 15-19 Female	11	26
TX_NEW_DSD	By Age/Sex: 20-24 Female	48	105
TX_NEW_DSD	By Age/Sex: 25-49 Female	409	902
TX_NEW_DSD	By Age/Sex: 50+ Female	78	172

TX_NEW_DSD	Sum of Age/Sex disaggregates	933	2,231
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	14	5
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	47	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	293	493
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	14	5
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	47	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	546	915
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	933	1,408
TX_NEW_DSD	Pregnancy status	166	
TX_NEW_DSD	Breastfeeding status	18	
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	793	6,203
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	933	6,203
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	20	
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	53	
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	793	
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those	23	

	lost to follow-up)		
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	63	
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	933	
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	73	
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	793	
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	86	
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	933	
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	260	

TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	260	
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	2	
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	2	
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	0	
LAB_ACC_DSD	Sum of Support Type disaggregates	2	
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	7	
LAB_CAP_DSD	By clinical laboratories	2	
LAB_CAP_DSD	By Point-of-care testing sites	0	
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	5	
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	2	
LAB_CAP_DSD	Sum of Site Support Type disaggregates	7	
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	7,630	5,927
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count	9,537	10,275



	OR viral load		
TB_SCREEN_DSD	Age: <1	24	
TB_SCREEN_DSD	Age: 1-4	165	
TB_SCREEN_DSD	Age: 5-9	291	
TB_SCREEN_DSD	Age: 10-14	224	
TB_SCREEN_DSD	Age: 15-19	154	
TB_SCREEN_DSD	Age: 20-24	514	
TB_SCREEN_DSD	Age: 25-49	5,053	
TB_SCREEN_DSD	Age: 50+	1,205	
TB_SCREEN_DSD	Sum of Age disaggregates	858	
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	703	
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	6,927	
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	7,630	
TB_SCREEN_DSD	Sex: Male	2,747	
TB_SCREEN_DSD	Sex: Female	4,883	
TB_SCREEN_DSD	Sum of Sex disaggregates	7,630	

### Implementing Mechanism Details

<b>Mechanism ID: 13548</b>	<b>Mechanism Name: Health Commodities &amp; Services Management Project</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,189,818</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>



GHP-State	1,189,818
-----------	-----------

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	13548		
<b>Mechanism Name:</b>	Health Commodities & Services Management Project		
<b>Prime Partner Name:</b>	Management Sciences for Health		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	124,445	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	200,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	575,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	290,373	0

**Implementing Mechanism Indicator Information**

Indicator Number	Label	2015	2016
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	
PMTCT_ARV_TA	Life-long ART (including Option B+)	0	
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	0	
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	0	
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0	
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	0	
PMTCT_ARV_TA	Sum of New and Current disaggregates	0	
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	



PMTCT_STAT_DSD	Number of new ANC and L&D clients	0	
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	0	
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	0	
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0	
PP_PREV_DSD	Total number of people in the target population	0	
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	0	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	
HTC_TST_TA	By Test Result: Negative	0	
HTC_TST_TA	By Test Result: Positive	0	
HTC_TST_TA	Sum of Test Result disaggregates	0	
HTC_TST_TA	Age/sex: <1 Male	0	
HTC_TST_TA	Age/sex: 1-4 Male	0	
HTC_TST_TA	Age/sex: 5-9 Male	0	

HTC_TST_TA	Age/sex: 10-14 Male	0	
HTC_TST_TA	Age/sex: 15-19 Male	0	
HTC_TST_TA	Age/sex: 20-24 Male	0	
HTC_TST_TA	Age/sex: 25-49 Male	0	
HTC_TST_TA	Age/sex: 50+ Male	0	
HTC_TST_TA	Age/sex: <1 Female	0	
HTC_TST_TA	Age/sex: 1-4 Female	0	
HTC_TST_TA	Age/sex: 5-9 Female	0	
HTC_TST_TA	Age/sex: 10-14 Female	0	
HTC_TST_TA	Age/sex: 15-19 Female	0	
HTC_TST_TA	Age/sex: 20-24 Female	0	
HTC_TST_TA	Age/sex: 25-49 Female	0	
HTC_TST_TA	Age/sex: 50+ Female	0	
HTC_TST_TA	Sum of Age/Sex disaggregates	0	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	0	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0	
HTC_TST_TA	Sum of Aggregated Age/Sex <15	0	
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	0	
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	0	
GEND_GBV_DSD	Number of people receiving post-GBV care	0	
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	0	
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	0	
OVC_SERV_DSD	Number of active beneficiaries served by	0	

	PEPFAR OVC programs for children and families affected by HIV/AIDS		
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	0	
CARE_NEW_DSD	Age/sex: <1 Male	0	
CARE_NEW_DSD	Age/sex: 1-4 Male	0	
CARE_NEW_DSD	Age/sex: 5-9 Male	0	
CARE_NEW_DSD	Age/sex: 10-14 Male	0	
CARE_NEW_DSD	Age/sex: 15-19 Male	0	
CARE_NEW_DSD	Age/sex: 20-24 Male	0	
CARE_NEW_DSD	Age/sex: 25-49 Male	0	
CARE_NEW_DSD	Age/sex: 50+ Male	0	
CARE_NEW_DSD	Age/sex: <1 Female	0	
CARE_NEW_DSD	Age/sex: 1-4 Female	0	
CARE_NEW_DSD	Age/sex: 5-9 Female	0	
CARE_NEW_DSD	Age/sex: 10-14 Female	0	
CARE_NEW_DSD	Age/sex: 15-19 Female	0	
CARE_NEW_DSD	Age/sex: 20-24 Female	0	
CARE_NEW_DSD	Age/sex: 25-49 Female	0	
CARE_NEW_DSD	Age/sex: 50+ Female	0	
CARE_NEW_DSD	Sum of Age/sex disaggregates	0	
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	0	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	0	
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	0	

CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	0	
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	0	
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	0	
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	0	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	0	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	0	
TB_ART_DSD	Age: 0-4	0	
TB_ART_DSD	Age: 5-14	0	
TB_ART_DSD	Age: 15+	0	
TB_ART_DSD	Male	1,850	
TB_ART_DSD	Female	2,000	
TB_ART_DSD	Sum of Sex disaggregates	3,850	
TB_ART_DSD	Newly tested	1,221	
TB_ART_DSD	Known HIV-positive	1,831	
TB_ART_DSD	Sum of Test Status disaggregates	3,052	
TB_ART_DSD	Aggregated Age: <15	28	
TB_ART_DSD	Aggregated Age: 15+	3,024	
TB_ART_DSD	Sum of Aggregated Age disaggregates	3,052	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	0	
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into	0	

	PMTCT)		
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	0	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	0	
TX_NEW_DSD	By Age/Sex: <1 Male	0	
TX_NEW_DSD	By Age/Sex: 1-4 Male	0	
TX_NEW_DSD	By Age/Sex: 5-9 Male	0	
TX_NEW_DSD	By Age/Sex: 10-14 Male	0	
TX_NEW_DSD	By Age/Sex: 15-19 Male	0	
TX_NEW_DSD	By Age/Sex: 20-24 Male	0	
TX_NEW_DSD	By Age/Sex: 25-49 Male	0	
TX_NEW_DSD	By Age/Sex: 50+ Male	0	
TX_NEW_DSD	By Age/Sex: <1 Female	0	
TX_NEW_DSD	By Age/Sex: 1-4 Female	0	
TX_NEW_DSD	By Age/Sex: 5-9 Female	0	
TX_NEW_DSD	By Age/Sex: 10-14 Female	0	
TX_NEW_DSD	By Age/Sex: 15-19 Female	0	
TX_NEW_DSD	By Age/Sex: 20-24 Female	0	
TX_NEW_DSD	By Age/Sex: 25-49 Female	0	
TX_NEW_DSD	By Age/Sex: 50+ Female	0	
TX_NEW_DSD	Sum of Age/Sex disaggregates	0	
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	0	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	0	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	0	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	0	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	0	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	0	
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	0	
TX_RET_DSD	Number of adults and children who are still	0	

	alive and on treatment at 12 months after initiating ART		
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	0	
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of	0	

	adults and children who are still alive and on treatment at 12 months after initiating ART)		
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	0	
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical	0	

	laboratory tests		
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	0	
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	0	
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	0	
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	0	
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	
TB_SCREEN_DSD	Age: <1	0	
TB_SCREEN_DSD	Age: 1-4	0	
TB_SCREEN_DSD	Age: 5-9	0	
TB_SCREEN_DSD	Age: 10-14	0	
TB_SCREEN_DSD	Age: 15-19	0	
TB_SCREEN_DSD	Age: 20-24	0	
TB_SCREEN_DSD	Age: 25-49	0	
TB_SCREEN_DSD	Age: 50+	0	





TB_SCREEN_DSD	Sum of Age disaggregates	0	
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	0	
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	0	
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	0	
TB_SCREEN_DSD	Sex: Male	0	
TB_SCREEN_DSD	Sex: Female	0	
TB_SCREEN_DSD	Sum of Sex disaggregates	0	

### Implementing Mechanism Details

<b>Mechanism ID: 13588</b>	<b>Mechanism Name: APHIAplus Nyanza/Western</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Program for Appropriate Technology in Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 31,814,620</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	31,814,620

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)



## Key Issues

(No data provided.)

## Budget Code Information

<b>Mechanism ID:</b> 13588			
<b>Mechanism Name:</b> APHIAplus Nyanza/Western			
<b>Prime Partner Name:</b> Program for Appropriate Technology in Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	3,780,399	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	7,846,192	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	463,181	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	729,889	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	650,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	2,264,384	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	566,744	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	2,851,483	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Prevention	HVOP	308,735	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	2,715,299	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	7,307,904	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	2,330,410	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	10,405	
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	10,405	
PMTCT_ARV_DSD	Life-long ART (including Option B+)	10,405	
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	6,243	
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	4,162	
PMTCT_ARV_DSD	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	
PMTCT_ARV_DSD	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	1,573	

PMTCT_ARV_DSD	Single-dose nevirapine (with or without tail)	0	
PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	11,978	
PMTCT_ARV_DSD	Sum of New and Current disaggregates	10,405	
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	
PMTCT_ARV_TA	Life-long ART (including Option B+)	0	
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	0	
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	0	
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0	
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	0	
PMTCT_ARV_TA	Sum of New and Current disaggregates	0	
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	182,507	
PMTCT_STAT_DSD	Number of new ANC and L&D clients	182,507	
PMTCT_STAT_DSD	By: Known positives at entry	4,162	
PMTCT_STAT_DSD	By: Number of new positives identified	6,243	
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	10,405	
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least	0	

	6 months		
KP_MAT_DSD	Sex: Male	0	
KP_MAT_DSD	Sex: Female	0	
KP_MAT_DSD	Sum of Sex disaggregates	0	
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	16	
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	0	
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	0	
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	0	
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	16	
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	16	
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	0	
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	8	
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by	8	

	maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)		
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	0	
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	45,000	
VMMC_CIRC_DSD	By Age: 1-9	1,739	
VMMC_CIRC_DSD	By Age: 10-14	9,664	
VMMC_CIRC_DSD	By Age: 15-19	16,931	
VMMC_CIRC_DSD	By Age: 20-24	8,700	
VMMC_CIRC_DSD	By Age: 25-49	7,669	
VMMC_CIRC_DSD	By Age: 50+	297	
VMMC_CIRC_DSD	Sum of age disaggregates	45,000	
VMMC_CIRC_DSD	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	604	
VMMC_CIRC_DSD	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	37,220	
VMMC_CIRC_DSD	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	5,335	
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	42,159	
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	1,000	
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	26,327	
VMMC_CIRC_DSD	By follow-up status: Number of surgically	16,832	

	circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery		
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	161,531	
PP_PREV_DSD	Total number of people in the target population	626,682	
PP_PREV_DSD	Age/sex: 10-14 Male	50,852	
PP_PREV_DSD	Age/sex: 20-24 Male	4,000	
PP_PREV_DSD	Age/sex: 25-49 Male	4,250	
PP_PREV_DSD	Age/sex: 50+ Male	0	
PP_PREV_DSD	Age/sex: 10-14 Female	50,000	
PP_PREV_DSD	Age/sex: 15-19 Female	25,000	
PP_PREV_DSD	Age/sex: 20-24 Female	27,429	
PP_PREV_DSD	Age/sex: 25-49 Female	0	
PP_PREV_DSD	Age/sex: 50+ Female	0	
PP_PREV_DSD	Sum of Age/Sex disaggregates	161,531	
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	28,241	
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	27,197	
KP_PREV_DSD	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions	0	

	that are based on evidence and/or meet the minimum standards required)		
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,500	
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	250	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	658,954	
HTC_TST_DSD	By Test Result: Negative	632,596	
HTC_TST_DSD	By Test Result: Positive	26,358	
HTC_TST_DSD	Sum of Test Result disaggregates	658,954	
HTC_TST_DSD	Age/sex: <1 Male	0	
HTC_TST_DSD	Age/sex: 1-4 Male	23,063	
HTC_TST_DSD	Age/sex: 5-9 Male	9,884	
HTC_TST_DSD	Age/sex: 10-14 Male	16,474	
HTC_TST_DSD	Age/sex: 15-19 Male	32,948	
HTC_TST_DSD	Age/sex: 20-24 Male	82,369	



HTC_TST_DSD	Age/sex: 25-49 Male	131,791	
HTC_TST_DSD	Age/sex: 50+ Male	32,948	
HTC_TST_DSD	Age/sex: <1 Female	0	
HTC_TST_DSD	Age/sex: 1-4 Female	23,063	
HTC_TST_DSD	Age/sex: 5-9 Female	9,884	
HTC_TST_DSD	Age/sex: 10-14 Female	16,474	
HTC_TST_DSD	Age/sex: 15-19 Female	32,948	
HTC_TST_DSD	Age/sex: 20-24 Female	82,369	
HTC_TST_DSD	Age/sex: 25-49 Female	131,791	
HTC_TST_DSD	Age/sex: 50+ Female	32,948	
HTC_TST_DSD	Sum of Age/Sex disaggregates	658,954	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	49,422	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	280,055	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	49,422	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	280,055	
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	98,844	
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	560,110	
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	658,954	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	
HTC_TST_TA	By Test Result: Negative	0	
HTC_TST_TA	By Test Result: Positive	0	
HTC_TST_TA	Sum of Test Result disaggregates	0	
HTC_TST_TA	Age/sex: <1 Male	0	
HTC_TST_TA	Age/sex: 1-4 Male	0	
HTC_TST_TA	Age/sex: 5-9 Male	0	
HTC_TST_TA	Age/sex: 10-14 Male	0	
HTC_TST_TA	Age/sex: 15-19 Male	0	

HTC_TST_TA	Age/sex: 20-24 Male	0	
HTC_TST_TA	Age/sex: 25-49 Male	0	
HTC_TST_TA	Age/sex: 50+ Male	0	
HTC_TST_TA	Age/sex: <1 Female	0	
HTC_TST_TA	Age/sex: 1-4 Female	0	
HTC_TST_TA	Age/sex: 5-9 Female	0	
HTC_TST_TA	Age/sex: 10-14 Female	0	
HTC_TST_TA	Age/sex: 15-19 Female	0	
HTC_TST_TA	Age/sex: 20-24 Female	0	
HTC_TST_TA	Age/sex: 25-49 Female	0	
HTC_TST_TA	Age/sex: 50+ Female	0	
HTC_TST_TA	Sum of Age/Sex disaggregates	0	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	0	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0	
HTC_TST_TA	Sum of Aggregated Age/Sex <15	0	
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	0	
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	0	
GEND_GBV_DSD	Number of people receiving post-GBV care	8,550	
GEND_GBV_DSD	Age: 0-9	300	
GEND_GBV_DSD	Age: 10-14	400	
GEND_GBV_DSD	Age: 15-17	450	
GEND_GBV_DSD	Age: 18-24	2,200	
GEND_GBV_DSD	Age: 25+	5,200	
GEND_GBV_DSD	Sum of Age disaggregates	8,550	
GEND_GBV_DSD	Sex: Male	3,250	
GEND_GBV_DSD	Sex: Female	5,300	

GEND_GBVDSD	Sum of Sex disaggregates	8,550	
GEND_GBVDSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	5,832	
GEND_GBVDSD	By type of service: Sexual Violence (Post-Rape Care)	893	
GEND_GBVDSD	By PEP service provision (related to sexual violence services provided)	1,018	
GEND_NORMDSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	40,000	
GEND_NORMDSD	By Age: 0-9	3,000	
GEND_NORMDSD	By Age: 10-14	4,000	
GEND_NORMDSD	By Age: 15-19	6,000	
GEND_NORMDSD	By Age: 20-24	10,000	
GEND_NORMDSD	By Age: 25+	17,000	
GEND_NORMDSD	Sum of Age disaggregates	40,000	
GEND_NORMDSD	By Sex: Male	15,000	
GEND_NORMDSD	By Sex: Female	25,000	
GEND_NORMDSD	Sum of Sex disaggregates	40,000	
GEND_NORMDSD	By type of activity: Individual	4,500	
GEND_NORMDSD	By type of activity: Small Group	14,000	
GEND_NORMDSD	By type of activity: Community-level	21,500	
OVC_ACCDSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	3,000	
OVC_ACCDSD	Sex: Male	1,800	
OVC_ACCDSD	Sex: Female	1,200	
OVC_ACCDSD	Sum of Sex disaggregates	3,000	
OVC_ACCDSD	Age: <1	250	
OVC_ACCDSD	Age: 1-4	350	
OVC_ACCDSD	Age: 5-9	850	
OVC_ACCDSD	Age: 10-14	820	
OVC_ACCDSD	Age: 15-17	730	

OVC_ACC_DSD	Age: 18+	0	
OVC_ACC_DSD	Sum of Age disaggregates	3,000	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	180,000	
OVC_SERV_DSD	Sex: Male	92,000	
OVC_SERV_DSD	Sex: Female	88,000	
OVC_SERV_DSD	Sum of Sex disaggregates	180,000	
OVC_SERV_DSD	Age: <1	2,500	
OVC_SERV_DSD	Age: 1-4	3,500	
OVC_SERV_DSD	Age: 5-9	28,000	
OVC_SERV_DSD	Age: 10-14	77,000	
OVC_SERV_DSD	Age: 15-17	69,000	
OVC_SERV_DSD	Age: 18+	0	
OVC_SERV_DSD	Sum of Age disaggregates	180,000	
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	109,130	
CARE_CURR_DSD	Age/sex: <1 Male	1,091	
CARE_CURR_DSD	Age/sex: 1-4 Male	1,091	
CARE_CURR_DSD	Age/sex: 5-9 Male	1,091	
CARE_CURR_DSD	Age/sex: 10-14 Male	1,091	
CARE_CURR_DSD	Age/sex: 15-19 Male	2,182	
CARE_CURR_DSD	Age/sex: 20-24 Male	17,461	
CARE_CURR_DSD	Age/sex: 25-49 Male	17,461	
CARE_CURR_DSD	Age/sex: 50+ Male	2,182	
CARE_CURR_DSD	Age/sex: <1 Female	1,637	
CARE_CURR_DSD	Age/sex: 1-4 Female	1,637	
CARE_CURR_DSD	Age/sex: 5-9 Female	1,637	
CARE_CURR_DSD	Age/sex: 10-14 Female	1,637	
CARE_CURR_DSD	Age/sex: 15-19 Female	3,275	

CARE_CURR_DSD	Age/sex: 20-24 Female	26,191	
CARE_CURR_DSD	Age/sex: 25-49 Female	26,191	
CARE_CURR_DSD	Age/sex: 50+ Female	3,275	
CARE_CURR_DSD	Sun of Age/Sex disaggregates	109,130	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	4,364	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	39,286	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	6,548	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	58,932	
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	109,130	
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	19,846	
CARE_NEW_DSD	Age/sex: <1 Male	199	
CARE_NEW_DSD	Age/sex: 1-4 Male	199	
CARE_NEW_DSD	Age/sex: 5-9 Male	199	
CARE_NEW_DSD	Age/sex: 10-14 Male	199	
CARE_NEW_DSD	Age/sex: 15-19 Male	397	
CARE_NEW_DSD	Age/sex: 20-24 Male	3,175	
CARE_NEW_DSD	Age/sex: 25-49 Male	3,175	
CARE_NEW_DSD	Age/sex: 50+ Male	397	
CARE_NEW_DSD	Age/sex: <1 Female	298	
CARE_NEW_DSD	Age/sex: 1-4 Female	298	
CARE_NEW_DSD	Age/sex: 5-9 Female	298	
CARE_NEW_DSD	Age/sex: 10-14 Female	298	
CARE_NEW_DSD	Age/sex: 15-19 Female	595	
CARE_NEW_DSD	Age/sex: 20-24 Female	4,762	

CARE_NEW_DSD	Age/sex: 25-49 Female	4,762	
CARE_NEW_DSD	Age/sex: 50+ Female	595	
CARE_NEW_DSD	Sum of Age/sex disaggregates	19,846	
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	796	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	7,144	
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	1,192	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	10,714	
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	19,846	
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	0	
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	0	
FN_THER_DSD	Age: <1	0	
FN_THER_DSD	Age: 1-4	0	
FN_THER_DSD	Age: 5-14	0	
FN_THER_DSD	Age: 15-17	0	
FN_THER_DSD	Age: 18+	0	
FN_THER_DSD	Sum of Age disaggregates	0	
FN_THER_DSD	Aggregated Age: <18	0	
FN_THER_DSD	Aggregated Age: 18+	0	
FN_THER_DSD	Sum of Aggregated Age disaggregates	0	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	3,570	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	4,462	
TB_ART_DSD	Age: 0-4	171	
TB_ART_DSD	Age: 5-14	257	

TB_ART_DSD	Age: 15+	3,142	
TB_ART_DSD	Male	1,428	
TB_ART_DSD	Female	2,142	
TB_ART_DSD	Sum of Sex disaggregates	3,570	
TB_ART_DSD	Newly tested	1,427	
TB_ART_DSD	Known HIV-positive	2,143	
TB_ART_DSD	Sum of Test Status disaggregates	3,570	
TB_ART_DSD	Aggregated Age: <15	428	
TB_ART_DSD	Aggregated Age: 15+	3,142	
TB_ART_DSD	Sum of Aggregated Age disaggregates	3,570	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	10,405	
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	10,405	
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	7,284	
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	3,121	
PMTCT_EID_DSD	Sum of Infant Age disaggregates	10,405	
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	350	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	82,343	
TX_CURR_DSD	Age/Sex: <1 Male	1,037	
TX_CURR_DSD	Age/Sex: 1-4 Male	1,037	
TX_CURR_DSD	Age/Sex: 5-14 Male	1,037	
TX_CURR_DSD	Age/Sex: 15+ Male	26,217	
TX_CURR_DSD	Age/Sex: <1 Female	1,556	
TX_CURR_DSD	Age/Sex: 1-4 Female	1,556	
TX_CURR_DSD	Age/Sex: 5-14 Female	1,556	

TX_CURR_DSD	Age/Sex: 15+ Female	48,347	
TX_CURR_DSD	Sum of age/sex disaggregates	7,779	
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	9	
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	64	
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	1,037	
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	1,556	
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	3,111	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	26,217	
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	4,668	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	48,347	
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	7,779	
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	74,564	
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	82,343	
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	2,593	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	14,546	
TX_NEW_DSD	By Age/Sex: <1 Male	260	
TX_NEW_DSD	By Age/Sex: 1-4 Male	239	
TX_NEW_DSD	By Age/Sex: 5-9 Male	239	
TX_NEW_DSD	By Age/Sex: 10-14 Male	239	
TX_NEW_DSD	By Age/Sex: 15-19 Male	420	
TX_NEW_DSD	By Age/Sex: 20-24 Male	1,678	
TX_NEW_DSD	By Age/Sex: 25-49 Male	1,678	
TX_NEW_DSD	By Age/Sex: 50+ Male	420	
TX_NEW_DSD	By Age/Sex: <1 Female	374	
TX_NEW_DSD	By Age/Sex: 1-4 Female	363	
TX_NEW_DSD	By Age/Sex: 5-9 Female	363	
TX_NEW_DSD	By Age/Sex: 10-14 Female	363	



TX_NEW_DSD	By Age/Sex: 15-19 Female	791	
TX_NEW_DSD	By Age/Sex: 20-24 Female	3,164	
TX_NEW_DSD	By Age/Sex: 25-49 Female	3,164	
TX_NEW_DSD	By Age/Sex: 50+ Female	791	
TX_NEW_DSD	Sum of Age/Sex disaggregates	14,546	
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	260	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	977	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	4,196	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	374	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	1,463	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	7,910	
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	14,546	
TX_NEW_DSD	Pregnancy status	0	
TX_NEW_DSD	Breastfeeding status	0	
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	13,091	
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	14,546	
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	655	
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	655	
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11,782	
TX_RET_DSD	Age: 0-4 (Denominator: Total number of	728	

	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	728	
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	13,091	
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,310	
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11,782	
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,456	
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	13,091	
TX_RET_DSD	Pregnancy and breastfeeding status	1,178	

	(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,309	
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	10	
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	5	
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	5	
LAB_ACC_DSD	Sum of Support Type disaggregates	10	
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	48	
LAB_CAP_DSD	By clinical laboratories	17	
LAB_CAP_DSD	By Point-of-care testing sites	7	
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	24	
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	24	
LAB_CAP_DSD	Sum of Site Support Type disaggregates	48	
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT)	0	

	program		
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	0	
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	0	
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0	
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	0	
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	0	
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0	
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	0	
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	0	
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0	
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	0	
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	0	
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0	
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that perform this testing	0	
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of	0	

	laboratories that participate in this PT program		
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0	
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	0	
HRH_PRE	By Graduates: Doctors	0	
HRH_PRE	By Graduates: Nurses	0	
HRH_PRE	By Graduates: Midwives	0	
HRH_PRE	By Graduates: Social service workers	0	
HRH_PRE	By Graduates: Laboratory professionals	0	
HRH_PRE	By Graduates: Other	0	
HRH_PRE	Sum of Graduates disaggregated	0	
HRH_PRE	By new graduates who are licensed and registered: Doctors	0	
HRH_PRE	By new graduates who are licensed and registered: Nurses	0	
HRH_PRE	By new graduates who are licensed and registered: Midwives	0	
HRH_PRE	By new graduates who are licensed and registered: Social service workers	0	
HRH_PRE	By new graduates who are licensed and registered: Laboratorians	0	
HRH_PRE	By new graduates who are licensed and registered: Other (where applicable)	0	
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV	0	

	service delivery points: PMTCT, Care and Treatment		
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	0	
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	0	
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	0	
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	0	
FPINT_SITE_DSD	Service delivery type: Community	0	
FPINT_SITE_DSD	Service delivery type: Clinical	0	
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	0	
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	79,367	
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	109,130	
TB_SCREEN_DSD	Age: <1	400	



TB_SCREEN_DSD	Age: 1-4	1,000	
TB_SCREEN_DSD	Age: 5-9	1,200	
TB_SCREEN_DSD	Age: 10-14	2,000	
TB_SCREEN_DSD	Age: 15-19	7,200	
TB_SCREEN_DSD	Age: 20-24	31,467	
TB_SCREEN_DSD	Age: 25-49	31,500	
TB_SCREEN_DSD	Age: 50+	4,600	
TB_SCREEN_DSD	Sum of Age disaggregates	11,800	
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	4,600	
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	74,767	
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	79,367	
TB_SCREEN_DSD	Sex: Male	31,747	
TB_SCREEN_DSD	Sex: Female	47,620	
TB_SCREEN_DSD	Sum of Sex disaggregates	79,367	

### Implementing Mechanism Details

<b>Mechanism ID: 13636</b>	<b>Mechanism Name: APHIAplus Central/Eastern</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 12,297,301</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	12,297,301

### Sub Partner Name(s)



(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 13636			
<b>Mechanism Name:</b> APHIAplus Central/Eastern			
<b>Prime Partner Name:</b> JHPIEGO			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1,312,724	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	5,147,162	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	420,541	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	156,364	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	500,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	986,633	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	815,449	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,456,286	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	502,142	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	113	
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	118	
PMTCT_ARV_DSD	Life-long ART (including Option B+)	94	
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	47	
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	47	
PMTCT_ARV_DSD	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	
PMTCT_ARV_DSD	Maternal AZT (prophylaxis component of	19	

	WHO Option A during pregnancy and delivery)		
PMTCT_ARV_DSD	Single-dose nevirapine (with or without tail)	0	
PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	113	
PMTCT_ARV_DSD	Sum of New and Current disaggregates	94	
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	3,280	
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	3,424	
PMTCT_ARV_TA	Life-long ART (including Option B+)	2,952	
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	1,640	
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	1,312	
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	328	
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0	
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	3,280	
PMTCT_ARV_TA	Sum of New and Current disaggregates	2,952	
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	3,783	
PMTCT_STAT_DSD	Number of new ANC and L&D clients	3,859	
PMTCT_STAT_DSD	By: Known positives at entry	68	
PMTCT_STAT_DSD	By: Number of new positives identified	86	
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	154	

KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	0	
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	0	
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	
PP_PREV_DSD	Age/sex: 15-19 Male	0	
PP_PREV_DSD	Sum of Age/Sex disaggregates	0	
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	7,217	
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	7,095	
KP_PREV_DSD	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	

KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	122	
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	434,288	
HTC_TST_TA	By Test Result: Negative	416,916	
HTC_TST_TA	By Test Result: Positive	17,372	
HTC_TST_TA	Sum of Test Result disaggregates	434,288	
HTC_TST_TA	Age/sex: <1 Male	0	
HTC_TST_TA	Age/sex: 1-4 Male	15,200	
HTC_TST_TA	Age/sex: 5-9 Male	6,514	
HTC_TST_TA	Age/sex: 10-14 Male	10,857	
HTC_TST_TA	Age/sex: 15-19 Male	21,714	
HTC_TST_TA	Age/sex: 20-24 Male	54,286	
HTC_TST_TA	Age/sex: 25-49 Male	86,858	
HTC_TST_TA	Age/sex: 50+ Male	21,714	
HTC_TST_TA	Age/sex: <1 Female	0	
HTC_TST_TA	Age/sex: 1-4 Female	15,200	
HTC_TST_TA	Age/sex: 5-9 Female	6,514	

HTC_TST_TA	Age/sex: 10-14 Female	10,857	
HTC_TST_TA	Age/sex: 15-19 Female	21,714	
HTC_TST_TA	Age/sex: 20-24 Female	54,286	
HTC_TST_TA	Age/sex: 25-49 Female	86,857	
HTC_TST_TA	Age/sex: 50+ Female	21,717	
HTC_TST_TA	Sum of Age/Sex disaggregates	434,288	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	32,572	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	184,572	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	32,572	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	184,572	
HTC_TST_TA	Sum of Aggregated Age/Sex <15	65,144	
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	369,144	
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	434,288	
GEND_GBV_DSD	Number of people receiving post-GBV care	986	
GEND_GBV_DSD	Age: 0-9	86	
GEND_GBV_DSD	Age: 10-14	450	
GEND_GBV_DSD	Age: 15-17	450	
GEND_GBV_DSD	Age: 18-24	0	
GEND_GBV_DSD	Age: 25+	0	
GEND_GBV_DSD	Sum of Age disaggregates	986	
GEND_GBV_DSD	Sex: Male	50	
GEND_GBV_DSD	Sex: Female	936	
GEND_GBV_DSD	Sum of Sex disaggregates	986	
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	986	
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	1,100	
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets	29,431	



	minimum criteria		
GEND_NORM_DSD	By Age: 0-9	0	
GEND_NORM_DSD	By Age: 10-14	0	
GEND_NORM_DSD	By Age: 15-19	0	
GEND_NORM_DSD	By Age: 20-24	7,358	
GEND_NORM_DSD	By Age: 25+	22,073	
GEND_NORM_DSD	Sum of Age disaggregates	29,431	
GEND_NORM_DSD	By Sex: Male	22,073	
GEND_NORM_DSD	By Sex: Female	7,358	
GEND_NORM_DSD	Sum of Sex disaggregates	29,431	
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	31,656	
OVC_ACC_DSD	Sex: Male	14,274	
OVC_ACC_DSD	Sex: Female	17,382	
OVC_ACC_DSD	Sum of Sex disaggregates	31,656	
OVC_ACC_DSD	Age: <1	0	
OVC_ACC_DSD	Age: 1-4	217	
OVC_ACC_DSD	Age: 5-9	1,582	
OVC_ACC_DSD	Age: 10-14	25,325	
OVC_ACC_DSD	Age: 15-17	4,432	
OVC_ACC_DSD	Age: 18+	100	
OVC_ACC_DSD	Sum of Age disaggregates	31,656	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	134,824	
OVC_SERV_DSD	Sex: Male	67,412	
OVC_SERV_DSD	Sex: Female	67,412	
OVC_SERV_DSD	Sum of Sex disaggregates	134,824	
OVC_SERV_DSD	Age: <1	0	
OVC_SERV_DSD	Age: 1-4	1,347	
OVC_SERV_DSD	Age: 5-9	6,736	



OVC_SERV_DSD	Age: 10-14	107,779	
OVC_SERV_DSD	Age: 15-17	18,861	
OVC_SERV_DSD	Age: 18+	101	
OVC_SERV_DSD	Sum of Age disaggregates	134,824	
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	2,599	
CARE_CURR_DSD	Age/sex: <1 Male	2	
CARE_CURR_DSD	Age/sex: 1-4 Male	12	
CARE_CURR_DSD	Age/sex: 5-9 Male	37	
CARE_CURR_DSD	Age/sex: 10-14 Male	97	
CARE_CURR_DSD	Age/sex: 15-19 Male	106	
CARE_CURR_DSD	Age/sex: 20-24 Male	141	
CARE_CURR_DSD	Age/sex: 25-49 Male	268	
CARE_CURR_DSD	Age/sex: 50+ Male	190	
CARE_CURR_DSD	Age/sex: <1 Female	3	
CARE_CURR_DSD	Age/sex: 1-4 Female	15	
CARE_CURR_DSD	Age/sex: 5-9 Female	47	
CARE_CURR_DSD	Age/sex: 10-14 Female	121	
CARE_CURR_DSD	Age/sex: 15-19 Female	234	
CARE_CURR_DSD	Age/sex: 20-24 Female	312	
CARE_CURR_DSD	Age/sex: 25-49 Female	593	
CARE_CURR_DSD	Age/sex: 50+ Female	421	
CARE_CURR_DSD	Sun of Age/Sex disaggregates	2,599	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	149	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	704	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	186	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ	1,560	

	PERMISSION ONLY: 15+ Female		
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	2,599	
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	7,886	
CARE_NEW_DSD	Age/sex: <1 Male	3	
CARE_NEW_DSD	Age/sex: 1-4 Male	15	
CARE_NEW_DSD	Age/sex: 5-9 Male	78	
CARE_NEW_DSD	Age/sex: 10-14 Male	215	
CARE_NEW_DSD	Age/sex: 15-19 Male	117	
CARE_NEW_DSD	Age/sex: 20-24 Male	468	
CARE_NEW_DSD	Age/sex: 25-49 Male	1,055	
CARE_NEW_DSD	Age/sex: 50+ Male	703	
CARE_NEW_DSD	Age/sex: <1 Female	3	
CARE_NEW_DSD	Age/sex: 1-4 Female	10	
CARE_NEW_DSD	Age/sex: 5-9 Female	190	
CARE_NEW_DSD	Age/sex: 10-14 Female	353	
CARE_NEW_DSD	Age/sex: 15-19 Female	374	
CARE_NEW_DSD	Age/sex: 20-24 Female	1,169	
CARE_NEW_DSD	Age/sex: 25-49 Female	1,870	
CARE_NEW_DSD	Age/sex: 50+ Female	1,263	
CARE_NEW_DSD	Sum of Age/sex disaggregates	7,886	
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	310	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	2,344	
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	372	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	4,860	
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	7,886	
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	0	



FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	0	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	450	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	450	
TB_ART_DSD	Age: 0-4	0	
TB_ART_DSD	Age: 5-14	95	
TB_ART_DSD	Age: 15+	355	
TB_ART_DSD	Male	202	
TB_ART_DSD	Female	248	
TB_ART_DSD	Sum of Sex disaggregates	450	
TB_ART_DSD	Newly tested	157	
TB_ART_DSD	Known HIV-positive	293	
TB_ART_DSD	Sum of Test Status disaggregates	450	
TB_ART_DSD	Aggregated Age: <15	45	
TB_ART_DSD	Aggregated Age: 15+	405	
TB_ART_DSD	Sum of Aggregated Age disaggregates	450	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,250	
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	2,500	
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,800	
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	450	

PMTCT_EID_DSD	Sum of Infant Age disaggregates	2,250	
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	90	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	1,964	
TX_CURR_DSD	Age/Sex: <1 Male	3	
TX_CURR_DSD	Age/Sex: 1-4 Male	27	
TX_CURR_DSD	Age/Sex: 5-14 Male	96	
TX_CURR_DSD	Age/Sex: 15+ Male	574	
TX_CURR_DSD	Age/Sex: <1 Female	2	
TX_CURR_DSD	Age/Sex: 1-4 Female	30	
TX_CURR_DSD	Age/Sex: 5-14 Female	124	
TX_CURR_DSD	Age/Sex: 15+ Female	1,108	
TX_CURR_DSD	Sum of age/sex disaggregates	282	
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	14	
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	86	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	5,586	
TX_NEW_DSD	By Age/Sex: <1 Male	78	
TX_NEW_DSD	By Age/Sex: 1-4 Male	61	
TX_NEW_DSD	By Age/Sex: 5-9 Male	84	
TX_NEW_DSD	By Age/Sex: 10-14 Male	67	
TX_NEW_DSD	By Age/Sex: 15-19 Male	78	
TX_NEW_DSD	By Age/Sex: 20-24 Male	184	
TX_NEW_DSD	By Age/Sex: 25-49 Male	1,162	
TX_NEW_DSD	By Age/Sex: 50+ Male	341	
TX_NEW_DSD	By Age/Sex: <1 Female	89	
TX_NEW_DSD	By Age/Sex: 1-4 Female	61	
TX_NEW_DSD	By Age/Sex: 5-9 Female	95	

TX_NEW_DSD	By Age/Sex: 10-14 Female	78	
TX_NEW_DSD	By Age/Sex: 15-19 Female	151	
TX_NEW_DSD	By Age/Sex: 20-24 Female	480	
TX_NEW_DSD	By Age/Sex: 25-49 Female	2,162	
TX_NEW_DSD	By Age/Sex: 50+ Female	408	
TX_NEW_DSD	Sum of Age/Sex disaggregates	5,579	
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	69	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	270	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,743	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	69	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	278	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	3,296	
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	5,587	
TX_NEW_DSD	Pregnancy status	300	
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	4,748	
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	5,586	
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	66	
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	52	
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	71	
TX_RET_DSD	Age: 0-4 (Denominator: Total number of	57	

	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	66	
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	157	
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	76	
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	52	
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	81	
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	66	
TX_RET_DSD	Pregnancy and breastfeeding status	988	

	(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	290	
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	7	
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	0	
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	7	
LAB_ACC_DSD	Sum of Support Type disaggregates	7	
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	134	
LAB_CAP_DSD	By clinical laboratories	0	
LAB_CAP_DSD	By Point-of-care testing sites	7	
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	0	
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	134	
LAB_CAP_DSD	Sum of Site Support Type disaggregates	134	
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT)	0	

	program		
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	0	
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	120	
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	134	
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	120	
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	120	
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	0	
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	134	
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	134	
FPINT_SITE_DSD	Service delivery type: Community	0	



FPINT_SITE_DSD	Service delivery type: Clinical	134	
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	134	
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	2,342	
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	2,599	
TB_SCREEN_DSD	Age: <1	5	
TB_SCREEN_DSD	Age: 1-4	17	
TB_SCREEN_DSD	Age: 5-9	80	
TB_SCREEN_DSD	Age: 10-14	121	
TB_SCREEN_DSD	Age: 15-19	319	
TB_SCREEN_DSD	Age: 20-24	425	
TB_SCREEN_DSD	Age: 25-49	1,274	
TB_SCREEN_DSD	Age: 50+	101	
TB_SCREEN_DSD	Sum of Age disaggregates	542	
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	225	
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	2,117	
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	2,342	
TB_SCREEN_DSD	Sex: Male	1,522	
TB_SCREEN_DSD	Sex: Female	820	
TB_SCREEN_DSD	Sum of Sex disaggregates	2,342	

### Implementing Mechanism Details

<b>Mechanism ID: 13701</b>	<b>Mechanism Name: KEMSA/FARA</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Kenya Medical Supplies Agency	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 134,769,375</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	134,769,375

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	13701		
<b>Mechanism Name:</b>	KEMSA/FARA		
<b>Prime Partner Name:</b>	Kenya Medical Supplies Agency		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	1,287,889	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	1,374,350	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>





Care	PDCS	268,361	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	1,350,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	200,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HMBL	850,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HMIN	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	8,001,515	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	3,317,356	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXD	89,783,410	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	20,298,770	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	8,037,724	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details



<b>Mechanism ID: 13802</b>	<b>Mechanism Name: Central Province Response Integration, Strengthening &amp; Sustainability Project (CRISSP)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Nairobi	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 2,402,505</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,402,505

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	13802		
<b>Mechanism Name:</b>	Central Province Response Integration, Strengthening & Sustainability Project (CRISSP)		
<b>Prime Partner Name:</b>	University of Nairobi		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Care	HBHC	311,837	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	102,025	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	45,189	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	127,749	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	195,827	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	1,587,913	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	31,965	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,175		Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	1,175		Redacted

PMTCT_ARV_DS D	Life-long ART (including Option B+)	881		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	411		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	470		Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	294		Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	1,175		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	881		Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	17,233		Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	17,233		Redacted
PMTCT_STAT_DS D	By: Known positives at entry	552		Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	623		Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	1,175		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	75,493		Redacted



HTC_TST_DSD	By Test Result: Negative	72,473		Redacted
HTC_TST_DSD	By Test Result: Positive	3,020		Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	75,493		Redacted
HTC_TST_DSD	Age/sex: <1 Male	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	2,642		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	1,133		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	1,887		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	3,774		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	9,437		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	15,099		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	3,774		Redacted
HTC_TST_DSD	Age/sex: <1 Female	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	2,642		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	1,133		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	1,887		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	3,774		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	9,437		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	15,099		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	3,775		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	75,493		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	5,662		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	32,084		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	5,662		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	32,085		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	11,324		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	64,169		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	75,493		Redacted

CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	10,152		Redacted
CARE_CURR_DS D	Age/sex: <1 Male	16		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	110		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	186		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	146		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	78		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	144		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	2,169		Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	749		Redacted
CARE_CURR_DS D	Age/sex: <1 Female	16		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	105		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	192		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	145		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	129		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	534		Redacted
CARE_CURR_DS	Age/sex: 25-49 Female	4,558		Redacted

D				
CARE_CURR_DS D	Age/sex: 50+ Female	875		Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	10,152		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	458		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,140		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	458		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	6,096		Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	10,152		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	1,846		Redacted
CARE_NEW_DSD	Age/sex: <1 Male	3		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	20		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	34		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	26		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	12		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	50		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	427		Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	83		Redacted
CARE_NEW_DSD	Age/sex: <1 Female	3		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	19		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	35		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	26		Redacted

CARE_NEW_DSD	Age/sex: 15-19 Female	27		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	51		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	766		Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	264		Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	1,846		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	83		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	572		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	83		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	1,108		Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	1,846		Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	1,603		Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	2,137		Redacted
FN_THER_DSD	Age: <1	5		Redacted
FN_THER_DSD	Age: 1-4	35		Redacted
FN_THER_DSD	Age: 5-14	108		Redacted
FN_THER_DSD	Age: 15-17	32		Redacted
FN_THER_DSD	Age: 18+	1,423		Redacted
FN_THER_DSD	Sum of Age disaggregates	1,603		Redacted
FN_THER_DSD	Aggregated Age: <18	180		Redacted
FN_THER_DSD	Aggregated Age: 18+	1,423		Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	1,603		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	457		Redacted
TB_ART_DSD	The number of registered new and	508		Redacted



	relapse TB cases with documented HIV-positive status during TB treatment during the reporting period			
TB_ART_DSD	Age: 0-4	11		Redacted
TB_ART_DSD	Age: 5-14	31		Redacted
TB_ART_DSD	Age: 15+	415		Redacted
TB_ART_DSD	Male	247		Redacted
TB_ART_DSD	Female	210		Redacted
TB_ART_DSD	Sum of Sex disaggregates	457		Redacted
TB_ART_DSD	Newly tested	274		Redacted
TB_ART_DSD	Known HIV-positive	183		Redacted
TB_ART_DSD	Sum of Test Status disaggregates	457		Redacted
TB_ART_DSD	Aggregated Age: <15	42		Redacted
TB_ART_DSD	Aggregated Age: 15+	415		Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	457		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	940		Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	1,175		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	705		Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	235		Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	940		Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	47		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	8,663		Redacted
TX_CURR_DSD	Age/Sex: <1 Male	14		Redacted

TX_CURR_DSD	Age/Sex: 1-4 Male	90		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	286		Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	2,759		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	14		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	91		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	286		Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	5,123		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	781		Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	1		Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	1		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	14		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	14		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	390		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	2,759		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	391		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	5,123		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	781		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	7,882		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	8,663		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	28		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,219		Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	26		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	15		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	25		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	20		Redacted

TX_NEW_DSD	By Age/Sex: 15-19 Male	9		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	17		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	253		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	87		Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	26		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	15		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	25		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	20		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	14		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	60		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	509		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	98		Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,219		Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	26		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	86		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	366		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	26		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	86		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	681		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,219		Redacted
TX_NEW_DSD	Pregnancy status	370		Redacted
TX_NEW_DSD	Breastfeeding status	41		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,050		Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months	1,235		Redacted

	prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up			
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	26		Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	71		Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	953		Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	31		Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	83		Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to	1,121		Redacted

	follow-up)			
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	97		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	953		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	114		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,121		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	734		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	864		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing	48		Redacted

	facilities with capacity to perform clinical laboratory tests			
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	48		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	48		Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	42		Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	56		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	42		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0		Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	42		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	56		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	0		Redacted

FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	56		Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	42		Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	42		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	9,645		Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	10,152		Redacted
TB_SCREEN_DSD	Age: <1	31		Redacted
TB_SCREEN_DSD	Age: 1-4	208		Redacted
TB_SCREEN_DSD	Age: 5-9	367		Redacted
TB_SCREEN_DSD	Age: 10-14	283		Redacted
TB_SCREEN_DSD	Age: 15-19	195		Redacted
TB_SCREEN_DSD	Age: 20-24	650		Redacted
TB_SCREEN_DSD	Age: 25-49	6,387		Redacted
TB_SCREEN_DSD	Age: 50+	1,524		Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	1,084		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	889		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	8,756		Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	9,645		Redacted
TB_SCREEN_DSD	Sex: Male	3,421		Redacted
TB_SCREEN_DSD	Sex: Female	6,224		Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	9,645		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 13805</b>	<b>Mechanism Name: International Training and</b>
----------------------------	---



	<b>Education Center for Health (ITECH)</b>
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Washington	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,500,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,500,000

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	13805		
<b>Mechanism Name:</b>	International Training and Education Center for Health (ITECH)		
<b>Prime Partner Name:</b>	University of Washington		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	2,500,000	0





## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

<b>Mechanism ID: 13868</b>	<b>Mechanism Name: Health Communication Marketing (Follow on)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 3,293,027</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	3,293,027

## Sub Partner Name(s)

(No data provided.)

## Cross-Cutting Budget Attribution(s)

(No data provided.)

## Key Issues

(No data provided.)

## Budget Code Information



<b>Mechanism ID:</b> 13868			
<b>Mechanism Name:</b> Health Communication Marketing (Follow on)			
<b>Prime Partner Name:</b> Population Services International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	189,686	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	54,856	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	197,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	1,300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	411,054	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	539,931	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	PDTX	0	0
-----------	------	---	---

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	
PMTCT_ARV_TA	Life-long ART (including Option B+)	0	
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	0	
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	0	
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0	
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	0	
PMTCT_ARV_TA	Sum of New and Current disaggregates	0	
PMTCT_STAT_DSD	Number of pregnant women with known HIV	0	

	status (includes women who were tested for HIV and received their results)		
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	0	
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	0	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	140,000	
HTC_TST_TA	By Test Result: Negative	134,400	
HTC_TST_TA	By Test Result: Positive	5,600	
HTC_TST_TA	Sum of Test Result disaggregates	140,000	
HTC_TST_TA	Age/sex: <1 Male	0	
HTC_TST_TA	Age/sex: 1-4 Male	4,900	
HTC_TST_TA	Age/sex: 5-9 Male	2,100	
HTC_TST_TA	Age/sex: 10-14 Male	3,500	
HTC_TST_TA	Age/sex: 15-19 Male	7,000	
HTC_TST_TA	Age/sex: 20-24 Male	17,500	
HTC_TST_TA	Age/sex: 25-49 Male	28,000	
HTC_TST_TA	Age/sex: 50+ Male	7,000	
HTC_TST_TA	Age/sex: <1 Female	0	
HTC_TST_TA	Age/sex: 1-4 Female	4,900	
HTC_TST_TA	Age/sex: 5-9 Female	2,100	

HTC_TST_TA	Age/sex: 10-14 Female	3,500	
HTC_TST_TA	Age/sex: 15-19 Female	7,000	
HTC_TST_TA	Age/sex: 20-24 Female	17,500	
HTC_TST_TA	Age/sex: 25-49 Female	28,000	
HTC_TST_TA	Age/sex: 50+ Female	7,000	
HTC_TST_TA	Sum of Age/Sex disaggregates	140,000	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	10,500	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	59,500	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	10,500	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	59,500	
HTC_TST_TA	Sum of Aggregated Age/Sex <15	21,000	
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	119,000	
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	140,000	
GEND_GBV_DSD	Number of people receiving post-GBV care	0	
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	0	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	0	
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count	957	

	OR viral load		
CARE_NEW_DSD	Age/sex: <1 Male	1	
CARE_NEW_DSD	Age/sex: 1-4 Male	1	
CARE_NEW_DSD	Age/sex: 5-9 Male	1	
CARE_NEW_DSD	Age/sex: 10-14 Male	1	
CARE_NEW_DSD	Age/sex: 15-19 Male	48	
CARE_NEW_DSD	Age/sex: 20-24 Male	50	
CARE_NEW_DSD	Age/sex: 25-49 Male	100	
CARE_NEW_DSD	Age/sex: 50+ Male	104	
CARE_NEW_DSD	Age/sex: <1 Female	2	
CARE_NEW_DSD	Age/sex: 1-4 Female	1	
CARE_NEW_DSD	Age/sex: 5-9 Female	1	
CARE_NEW_DSD	Age/sex: 10-14 Female	1	
CARE_NEW_DSD	Age/sex: 15-19 Female	96	
CARE_NEW_DSD	Age/sex: 20-24 Female	200	
CARE_NEW_DSD	Age/sex: 25-49 Female	300	
CARE_NEW_DSD	Age/sex: 50+ Female	50	
CARE_NEW_DSD	Sum of Age/sex disaggregates	957	
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	4	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	302	
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	5	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	646	
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	957	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	3,080	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	3,850	
TB_ART_DSD	Age: 0-4	20	
TB_ART_DSD	Age: 5-14	8	



TB_ART_DSD	Age: 15+	3,052	
TB_ART_DSD	Male	1,080	
TB_ART_DSD	Female	2,000	
TB_ART_DSD	Sum of Sex disaggregates	3,080	
TB_ART_DSD	Newly tested	1,221	
TB_ART_DSD	Known HIV-positive	1,859	
TB_ART_DSD	Sum of Test Status disaggregates	3,080	
TB_ART_DSD	Aggregated Age: <15	28	
TB_ART_DSD	Aggregated Age: 15+	3,052	
TB_ART_DSD	Sum of Aggregated Age disaggregates	3,080	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	0	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	891	
TX_NEW_DSD	By Age/Sex: <1 Male	10	
TX_NEW_DSD	By Age/Sex: 1-4 Male	10	
TX_NEW_DSD	By Age/Sex: 5-9 Male	10	
TX_NEW_DSD	By Age/Sex: 10-14 Male	11	
TX_NEW_DSD	By Age/Sex: 15-19 Male	40	
TX_NEW_DSD	By Age/Sex: 20-24 Male	100	
TX_NEW_DSD	By Age/Sex: 25-49 Male	100	
TX_NEW_DSD	By Age/Sex: 50+ Male	43	
TX_NEW_DSD	By Age/Sex: <1 Female	10	
TX_NEW_DSD	By Age/Sex: 1-4 Female	10	
TX_NEW_DSD	By Age/Sex: 5-9 Female	10	
TX_NEW_DSD	By Age/Sex: 10-14 Female	11	
TX_NEW_DSD	By Age/Sex: 15-19 Female	80	
TX_NEW_DSD	By Age/Sex: 20-24 Female	200	
TX_NEW_DSD	By Age/Sex: 25-49 Female	200	
TX_NEW_DSD	By Age/Sex: 50+ Female	46	
TX_NEW_DSD	Sum of Age/Sex disaggregates	891	
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	10	



TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	31	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	283	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	10	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	31	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	526	
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	871	
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	757	
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	891	
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	34	
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	36	
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	688	
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	40	
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have	42	



	died, those who have stopped ART, and those lost to follow-up)		
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	809	
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	70	
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	688	
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	62	
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	809	
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to	0	

	follow-up)		
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	3,850	
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	
TB_SCREEN_DSD	Age: <1	20	
TB_SCREEN_DSD	Age: 1-4	65	
TB_SCREEN_DSD	Age: 5-9	100	
TB_SCREEN_DSD	Age: 10-14	200	
TB_SCREEN_DSD	Age: 15-19	300	
TB_SCREEN_DSD	Age: 20-24	1,500	
TB_SCREEN_DSD	Age: 25-49	1,500	
TB_SCREEN_DSD	Age: 50+	165	
TB_SCREEN_DSD	Sum of Age disaggregates	685	

### Implementing Mechanism Details

<b>Mechanism ID: 13882</b>	<b>Mechanism Name: Integrated Program for both HIV infected and affected children and their households</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Children of God Relief Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,675,975</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>



GHP-State	1,675,975
-----------	-----------

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	13882		
<b>Mechanism Name:</b>	Integrated Program for both HIV infected and affected children and their households		
<b>Prime Partner Name:</b>	Children of God Relief Institute		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	29,087	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	516,123	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	50,611	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	159,774	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	38,046	0

Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	846,968	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	35,366	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	
PMTCT_STAT_DSD	Number of new ANC and L&D clients	0	
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	0	
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the	0	

	reporting period		
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	2,406	
PP_PREV_DSD	Total number of people in the target population	2,406	
PP_PREV_DSD	Age/sex: 10-14 Male	614	
PP_PREV_DSD	Age/sex: 15-19 Male	435	
PP_PREV_DSD	Age/sex: 20-24 Male	60	
PP_PREV_DSD	Age/sex: 25-49 Male	2	
PP_PREV_DSD	Age/sex: 50+ Male	6	
PP_PREV_DSD	Age/sex: 10-14 Female	652	
PP_PREV_DSD	Age/sex: 15-19 Female	491	
PP_PREV_DSD	Age/sex: 20-24 Female	53	
PP_PREV_DSD	Age/sex: 25-49 Female	1	
PP_PREV_DSD	Age/sex: 50+ Female	92	
PP_PREV_DSD	Sum of Age/Sex disaggregates	2,406	
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	0	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	2,278	
HTC_TST_DSD	By Test Result: Negative	2,123	
HTC_TST_DSD	By Test Result: Positive	155	
HTC_TST_DSD	Sum of Test Result disaggregates	2,278	
HTC_TST_DSD	Age/sex: <1 Male	42	
HTC_TST_DSD	Age/sex: 1-4 Male	72	
HTC_TST_DSD	Age/sex: 5-9 Male	189	
HTC_TST_DSD	Age/sex: 10-14 Male	154	

HTC_TST_DSD	Age/sex: 15-19 Male	125	
HTC_TST_DSD	Age/sex: 20-24 Male	259	
HTC_TST_DSD	Age/sex: 25-49 Male	248	
HTC_TST_DSD	Age/sex: 50+ Male	68	
HTC_TST_DSD	Age/sex: <1 Female	39	
HTC_TST_DSD	Age/sex: 1-4 Female	83	
HTC_TST_DSD	Age/sex: 5-9 Female	122	
HTC_TST_DSD	Age/sex: 10-14 Female	124	
HTC_TST_DSD	Age/sex: 15-19 Female	175	
HTC_TST_DSD	Age/sex: 20-24 Female	289	
HTC_TST_DSD	Age/sex: 25-49 Female	215	
HTC_TST_DSD	Age/sex: 50+ Female	74	
HTC_TST_DSD	Sum of Age/Sex disaggregates	2,278	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	457	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	700	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	369	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	752	
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	826	
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	1,452	
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	2,278	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	
GEND_GBV_DSD	Number of people receiving post-GBV care	0	
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	0	
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to	3,474	

	access HIV services		
OVC_ACC_DSD	Sex: Male	1,671	
OVC_ACC_DSD	Sex: Female	1,803	
OVC_ACC_DSD	Sum of Sex disaggregates	3,474	
OVC_ACC_DSD	Age: <1	158	
OVC_ACC_DSD	Age: 1-4	672	
OVC_ACC_DSD	Age: 5-9	896	
OVC_ACC_DSD	Age: 10-14	774	
OVC_ACC_DSD	Age: 15-17	880	
OVC_ACC_DSD	Age: 18+	94	
OVC_ACC_DSD	Sum of Age disaggregates	3,474	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	9,600	
OVC_SERV_DSD	Sex: Male	4,029	
OVC_SERV_DSD	Sex: Female	5,571	
OVC_SERV_DSD	Sum of Sex disaggregates	9,600	
OVC_SERV_DSD	Age: <1	0	
OVC_SERV_DSD	Age: 1-4	1,302	
OVC_SERV_DSD	Age: 5-9	1,367	
OVC_SERV_DSD	Age: 10-14	1,655	
OVC_SERV_DSD	Age: 15-17	2,187	
OVC_SERV_DSD	Age: 18+	3,089	
OVC_SERV_DSD	Sum of Age disaggregates	9,600	
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	3,474	
CARE_CURR_DSD	Age/sex: <1 Male	84	
CARE_CURR_DSD	Age/sex: 1-4 Male	324	
CARE_CURR_DSD	Age/sex: 5-9 Male	459	
CARE_CURR_DSD	Age/sex: 10-14 Male	528	

CARE_CURR_DSD	Age/sex: 15-19 Male	242	
CARE_CURR_DSD	Age/sex: 20-24 Male	25	
CARE_CURR_DSD	Age/sex: 25-49 Male	9	
CARE_CURR_DSD	Age/sex: 50+ Male	0	
CARE_CURR_DSD	Age/sex: <1 Female	74	
CARE_CURR_DSD	Age/sex: 1-4 Female	348	
CARE_CURR_DSD	Age/sex: 5-9 Female	437	
CARE_CURR_DSD	Age/sex: 10-14 Female	584	
CARE_CURR_DSD	Age/sex: 15-19 Female	300	
CARE_CURR_DSD	Age/sex: 20-24 Female	28	
CARE_CURR_DSD	Age/sex: 25-49 Female	29	
CARE_CURR_DSD	Age/sex: 50+ Female	3	
CARE_CURR_DSD	Sun of Age/Sex disaggregates	3,474	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,396	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	276	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,442	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	360	
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	3,474	
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	206	
CARE_NEW_DSD	Age/sex: <1 Male	45	
CARE_NEW_DSD	Age/sex: 1-4 Male	15	
CARE_NEW_DSD	Age/sex: 5-9 Male	27	
CARE_NEW_DSD	Age/sex: 10-14 Male	11	
CARE_NEW_DSD	Age/sex: 15-19 Male	2	



CARE_NEW_DSD	Age/sex: 20-24 Male	0	
CARE_NEW_DSD	Age/sex: 25-49 Male	0	
CARE_NEW_DSD	Age/sex: 50+ Male	0	
CARE_NEW_DSD	Age/sex: <1 Female	44	
CARE_NEW_DSD	Age/sex: 1-4 Female	31	
CARE_NEW_DSD	Age/sex: 5-9 Female	21	
CARE_NEW_DSD	Age/sex: 10-14 Female	10	
CARE_NEW_DSD	Age/sex: 15-19 Female	0	
CARE_NEW_DSD	Age/sex: 20-24 Female	0	
CARE_NEW_DSD	Age/sex: 25-49 Female	0	
CARE_NEW_DSD	Age/sex: 50+ Female	0	
CARE_NEW_DSD	Sum of Age/sex disaggregates	206	
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	97	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	2	
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	105	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	2	
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	206	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	140	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	140	
TB_ART_DSD	Age: 0-4	20	
TB_ART_DSD	Age: 5-14	78	
TB_ART_DSD	Age: 15+	42	
TB_ART_DSD	Male	70	
TB_ART_DSD	Female	70	
TB_ART_DSD	Sum of Sex disaggregates	140	
TB_ART_DSD	Newly tested	56	
TB_ART_DSD	Known HIV-positive	84	

TB_ART_DSD	Sum of Test Status disaggregates	140	
TB_ART_DSD	Aggregated Age: <15	98	
TB_ART_DSD	Aggregated Age: 15+	42	
TB_ART_DSD	Sum of Aggregated Age disaggregates	140	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	0	
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	0	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	2,626	
TX_CURR_DSD	Age/Sex: <1 Male	6	
TX_CURR_DSD	Age/Sex: 1-4 Male	165	
TX_CURR_DSD	Age/Sex: 5-14 Male	838	
TX_CURR_DSD	Age/Sex: 15+ Male	262	
TX_CURR_DSD	Age/Sex: <1 Female	10	
TX_CURR_DSD	Age/Sex: 1-4 Female	182	
TX_CURR_DSD	Age/Sex: 5-14 Female	841	
TX_CURR_DSD	Age/Sex: 15+ Female	322	
TX_CURR_DSD	Sum of age/sex disaggregates	2,042	
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	78	
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	51	
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	6	
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	10	
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,009	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	262	
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,033	

TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	322	
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	2,042	
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	584	
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	2,626	
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	16	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	137	
TX_NEW_DSD	By Age/Sex: <1 Male	9	
TX_NEW_DSD	By Age/Sex: 1-4 Male	11	
TX_NEW_DSD	By Age/Sex: 5-9 Male	12	
TX_NEW_DSD	By Age/Sex: 10-14 Male	22	
TX_NEW_DSD	By Age/Sex: 15-19 Male	12	
TX_NEW_DSD	By Age/Sex: 20-24 Male	0	
TX_NEW_DSD	By Age/Sex: 25-49 Male	0	
TX_NEW_DSD	By Age/Sex: 50+ Male	0	
TX_NEW_DSD	By Age/Sex: <1 Female	9	
TX_NEW_DSD	By Age/Sex: 1-4 Female	12	
TX_NEW_DSD	By Age/Sex: 5-9 Female	13	
TX_NEW_DSD	By Age/Sex: 10-14 Female	23	
TX_NEW_DSD	By Age/Sex: 15-19 Female	14	
TX_NEW_DSD	By Age/Sex: 20-24 Female	0	
TX_NEW_DSD	By Age/Sex: 25-49 Female	0	
TX_NEW_DSD	By Age/Sex: 50+ Female	0	
TX_NEW_DSD	Sum of Age/Sex disaggregates	137	
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	23	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	68	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	0	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	23	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	69	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+	0	

	Female		
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	137	
TX_NEW_DSD	Pregnancy status	0	
TX_NEW_DSD	Breastfeeding status	0	
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	123	
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	137	
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	37	
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	64	
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	24	
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	41	
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	70	
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the	26	

	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	101	
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	22	
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	111	
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	26	
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards	0	

	for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation		
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	0	
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	0	
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	0	
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	0	
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	3,474	
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	3,474	
TB_SCREEN_DSD	Age: <1	158	
TB_SCREEN_DSD	Age: 1-4	671	
TB_SCREEN_DSD	Age: 5-9	896	
TB_SCREEN_DSD	Age: 10-14	1,112	



TB_SCREEN_DSD	Age: 15-19	543	
TB_SCREEN_DSD	Age: 20-24	53	
TB_SCREEN_DSD	Age: 25-49	38	
TB_SCREEN_DSD	Age: 50+	3	
TB_SCREEN_DSD	Sum of Age disaggregates	3,380	
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	2,837	
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	637	
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	3,474	
TB_SCREEN_DSD	Sex: Male	1,671	
TB_SCREEN_DSD	Sex: Female	1,803	
TB_SCREEN_DSD	Sum of Sex disaggregates	3,474	

### Implementing Mechanism Details

<b>Mechanism ID: 13919</b>	<b>Mechanism Name: Laboratory Regulatory Support</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Clinical and Laboratory Standards Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 630,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	630,000

### Sub Partner Name(s)

(No data provided.)



### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 13919			
<b>Mechanism Name:</b> Laboratory Regulatory Support			
<b>Prime Partner Name:</b> Clinical and Laboratory Standards Institute			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	630,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	8	8	Redacted
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	8		Redacted
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	0		Redacted





LAB_ACC_DSD	Sum of Support Type disaggregates	8		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	8	5	Redacted
LAB_CAP_DSD	By clinical laboratories	0	5	Redacted
LAB_CAP_DSD	By Point-of-care testing sites	0		Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	0		Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	8		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	8		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 13922</b>	<b>Mechanism Name: Laboratory Leadership Training</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Field Epidemiology Network	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 13922			
<b>Mechanism Name:</b> Laboratory Leadership Training			
<b>Prime Partner Name:</b> African Field Epidemiology Network			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	8		Redacted
LAB_ACC_DSD	By site support type: Direct Service	8		Redacted



	Delivery (DSD)			
LAB_ACC_DSD	Sum of Support Type disaggregates	8		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	8		Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	8		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	8		Redacted
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	8		Redacted
HRH_PRE	By Graduates: Laboratory professionals	2		Redacted
HRH_PRE	By Graduates: Other	6		Redacted
HRH_PRE	Sum of Graduates disaggreagtes	8		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 14009</b>	<b>Mechanism Name: Kenya Nutrition and HIV Program Plus</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 3,587,100</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	3,587,100



**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	14009		
<b>Mechanism Name:</b>	Kenya Nutrition and HIV Program Plus		
<b>Prime Partner Name:</b>	FHI 360		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	2,699,265	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	484,496	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	403,339	0

**Implementing Mechanism Indicator Information**

Indicator Number	Label	2015	2016
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	

PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	
PMTCT_STAT_DSD	Number of new ANC and L&D clients	0	
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	0	
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	0	
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0	
PP_PREV_DSD	Total number of people in the target population	0	
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	0	

HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	
GEND_GBV_DSD	Number of people receiving post-GBV care	0	
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	0	
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	0	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	0	
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	0	
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	222,000	99,885
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	296,000	99,886
FN_THER_DSD	Age: <1	31,106	13,972
FN_THER_DSD	Age: 1-4	51,318	18,572

FN_THER_DSD	Age: 5-14	18,293	10,272
FN_THER_DSD	Age: 15-17	2,011	1,700
FN_THER_DSD	Age: 18+	119,272	55,342
FN_THER_DSD	Sum of Age disaggregates	222,000	99,858
FN_THER_DSD	Aggregated Age: <18	102,786	44,529
FN_THER_DSD	Aggregated Age: 18+	119,214	55,324
FN_THER_DSD	Sum of Aggregated Age disaggregates	222,000	99,853
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	0	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	0	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	0	
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	0	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	0	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	0	
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	0	
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	0	

LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	0	
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	0	
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	0	
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	0	
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	0	
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	0	
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	

### Implementing Mechanism Details





<b>Mechanism ID: 14012</b>	<b>Mechanism Name: AMPATHplus</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Moi Teaching and Referral Hospital	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 16,776,539</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	16,776,539

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	14012		
<b>Mechanism Name:</b>	AMPATHplus		
<b>Prime Partner Name:</b>	Moi Teaching and Referral Hospital		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	3,217,438	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Care	HKID	1,080,365	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	1,056,068	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	479,153	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	575,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	300,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVAB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	782,438	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	283,796	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	1,502,459	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	6,715,056	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	784,766	0

## Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	5,535	
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	5,535	
PMTCT_ARV_DSD	Life-long ART (including Option B+)	5,535	
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	2,762	
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	2,773	
PMTCT_ARV_DSD	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	
PMTCT_ARV_DSD	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	
PMTCT_ARV_DSD	Single-dose nevirapine (with or without tail)	0	
PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	5,535	
PMTCT_ARV_DSD	Sum of New and Current disaggregates	5,535	
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	100	
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	108	
PMTCT_ARV_TA	Life-long ART (including Option B+)	100	

PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	2	
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	98	
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	100	
PMTCT_ARV_TA	Sum of New and Current disaggregates	100	
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	106,080	
PMTCT_STAT_DSD	Number of new ANC and L&D clients	106,080	
PMTCT_STAT_DSD	By: Known positives at entry	2,762	
PMTCT_STAT_DSD	By: Number of new positives identified	2,773	
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	5,535	
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	0	
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	0	
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	12,236	

PP_PREV_DSD	Total number of people in the target population	47,471	
PP_PREV_DSD	Age/sex: 10-14 Male	2,100	
PP_PREV_DSD	Age/sex: 15-19 Male	0	
PP_PREV_DSD	Age/sex: 20-24 Male	1,750	
PP_PREV_DSD	Age/sex: 25-49 Male	2,000	
PP_PREV_DSD	Age/sex: 50+ Male	0	
PP_PREV_DSD	Age/sex: 10-14 Female	2,100	
PP_PREV_DSD	Age/sex: 15-19 Female	2,143	
PP_PREV_DSD	Age/sex: 20-24 Female	2,143	
PP_PREV_DSD	Age/sex: 25-49 Female	0	
PP_PREV_DSD	Age/sex: 50+ Female	0	
PP_PREV_DSD	Sum of Age/Sex disaggregates	12,236	
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	149	
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	149	
KP_PREV_DSD	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions	0	

	that are based on evidence and/or meet the minimum standards required)		
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	120,631	
HTC_TST_DSD	By Test Result: Negative	115,806	
HTC_TST_DSD	By Test Result: Positive	4,825	
HTC_TST_DSD	Sum of Test Result disaggregates	120,631	
HTC_TST_DSD	Age/sex: <1 Male	0	
HTC_TST_DSD	Age/sex: 1-4 Male	4,222	
HTC_TST_DSD	Age/sex: 5-9 Male	1,809	
HTC_TST_DSD	Age/sex: 10-14 Male	3,016	
HTC_TST_DSD	Age/sex: 15-19 Male	6,032	
HTC_TST_DSD	Age/sex: 20-24 Male	15,079	
HTC_TST_DSD	Age/sex: 25-49 Male	24,126	
HTC_TST_DSD	Age/sex: 50+ Male	6,032	
HTC_TST_DSD	Age/sex: <1 Female	0	
HTC_TST_DSD	Age/sex: 1-4 Female	4,222	
HTC_TST_DSD	Age/sex: 5-9 Female	1,809	
HTC_TST_DSD	Age/sex: 10-14 Female	3,016	

HTC_TST_DSD	Age/sex: 15-19 Female	6,032	
HTC_TST_DSD	Age/sex: 20-24 Female	15,079	
HTC_TST_DSD	Age/sex: 25-49 Female	24,126	
HTC_TST_DSD	Age/sex: 50+ Female	6,031	
HTC_TST_DSD	Sum of Age/Sex disaggregates	120,631	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	9,047	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	51,268	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	9,048	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	51,268	
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	18,095	
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	102,536	
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	120,631	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	51,699	
HTC_TST_TA	By Test Result: Negative	49,631	
HTC_TST_TA	By Test Result: Positive	2,068	
HTC_TST_TA	Sum of Test Result disaggregates	51,699	
HTC_TST_TA	Age/sex: <1 Male	0	
HTC_TST_TA	Age/sex: 1-4 Male	1,809	
HTC_TST_TA	Age/sex: 5-9 Male	775	
HTC_TST_TA	Age/sex: 10-14 Male	1,292	
HTC_TST_TA	Age/sex: 15-19 Male	2,585	
HTC_TST_TA	Age/sex: 20-24 Male	6,462	
HTC_TST_TA	Age/sex: 25-49 Male	10,340	
HTC_TST_TA	Age/sex: 50+ Male	2,585	
HTC_TST_TA	Age/sex: <1 Female	0	
HTC_TST_TA	Age/sex: 1-4 Female	1,809	
HTC_TST_TA	Age/sex: 5-9 Female	775	

HTC_TST_TA	Age/sex: 10-14 Female	1,294	
HTC_TST_TA	Age/sex: 15-19 Female	2,585	
HTC_TST_TA	Age/sex: 20-24 Female	6,462	
HTC_TST_TA	Age/sex: 25-49 Female	10,340	
HTC_TST_TA	Age/sex: 50+ Female	2,586	
HTC_TST_TA	Sum of Age/Sex disaggregates	51,699	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,877	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	21,972	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	3,878	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	21,972	
HTC_TST_TA	Sum of Aggregated Age/Sex <15	7,755	
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	43,944	
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	51,699	
GEND_GBV_DSD	Number of people receiving post-GBV care	16	
GEND_GBV_DSD	Age: 0-9	0	
GEND_GBV_DSD	Age: 10-14	16	
GEND_GBV_DSD	Age: 15-17	0	
GEND_GBV_DSD	Age: 18-24	0	
GEND_GBV_DSD	Age: 25+	0	
GEND_GBV_DSD	Sum of Age disaggregates	16	
GEND_GBV_DSD	Sex: Male	0	
GEND_GBV_DSD	Sex: Female	16	
GEND_GBV_DSD	Sum of Sex disaggregates	16	
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	16	
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	1,049	
GEND_NORM_DSD	By Age: 0-9	0	





GEND_NORM_DSD	By Age: 10-14	0	
GEND_NORM_DSD	By Age: 15-19	0	
GEND_NORM_DSD	By Age: 20-24	262	
GEND_NORM_DSD	By Age: 25+	787	
GEND_NORM_DSD	Sum of Age disaggregates	1,049	
GEND_NORM_DSD	By Sex: Male	787	
GEND_NORM_DSD	By Sex: Female	262	
GEND_NORM_DSD	Sum of Sex disaggregates	1,049	
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	3,641	
OVC_ACC_DSD	Sex: Male	1,784	
OVC_ACC_DSD	Sex: Female	1,857	
OVC_ACC_DSD	Sum of Sex disaggregates	3,641	
OVC_ACC_DSD	Age: <1	11	
OVC_ACC_DSD	Age: 1-4	506	
OVC_ACC_DSD	Age: 5-9	1,283	
OVC_ACC_DSD	Age: 10-14	1,054	
OVC_ACC_DSD	Age: 15-17	410	
OVC_ACC_DSD	Age: 18+	377	
OVC_ACC_DSD	Sum of Age disaggregates	3,641	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	29,000	
OVC_SERV_DSD	Sex: Male	13,483	
OVC_SERV_DSD	Sex: Female	15,517	
OVC_SERV_DSD	Sum of Sex disaggregates	29,000	
OVC_SERV_DSD	Age: <1	85	
OVC_SERV_DSD	Age: 1-4	812	
OVC_SERV_DSD	Age: 5-9	3,040	
OVC_SERV_DSD	Age: 10-14	10,112	
OVC_SERV_DSD	Age: 15-17	4,750	

OVC_SERV_DSD	Age: 18+	10,201	
OVC_SERV_DSD	Sum of Age disaggregates	29,000	
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	103,163	
CARE_CURR_DSD	Age/sex: <1 Male	507	
CARE_CURR_DSD	Age/sex: 1-4 Male	507	
CARE_CURR_DSD	Age/sex: 5-9 Male	1,013	
CARE_CURR_DSD	Age/sex: 10-14 Male	3,040	
CARE_CURR_DSD	Age/sex: 15-19 Male	4,924	
CARE_CURR_DSD	Age/sex: 20-24 Male	9,847	
CARE_CURR_DSD	Age/sex: 25-49 Male	13,130	
CARE_CURR_DSD	Age/sex: 50+ Male	4,924	
CARE_CURR_DSD	Age/sex: <1 Female	507	
CARE_CURR_DSD	Age/sex: 1-4 Female	507	
CARE_CURR_DSD	Age/sex: 5-9 Female	1,013	
CARE_CURR_DSD	Age/sex: 10-14 Female	3,040	
CARE_CURR_DSD	Age/sex: 15-19 Female	9,031	
CARE_CURR_DSD	Age/sex: 20-24 Female	18,062	
CARE_CURR_DSD	Age/sex: 25-49 Female	24,080	
CARE_CURR_DSD	Age/sex: 50+ Female	9,031	
CARE_CURR_DSD	Sum of Age/Sex disaggregates	103,163	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	5,066	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	32,824	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	5,066	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	60,207	
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	103,163	

CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	18,757	
CARE_NEW_DSD	Age/sex: <1 Male	94	
CARE_NEW_DSD	Age/sex: 1-4 Male	94	
CARE_NEW_DSD	Age/sex: 5-9 Male	187	
CARE_NEW_DSD	Age/sex: 10-14 Male	562	
CARE_NEW_DSD	Age/sex: 15-19 Male	887	
CARE_NEW_DSD	Age/sex: 20-24 Male	1,773	
CARE_NEW_DSD	Age/sex: 25-49 Male	2,364	
CARE_NEW_DSD	Age/sex: 50+ Male	887	
CARE_NEW_DSD	Age/sex: <1 Female	94	
CARE_NEW_DSD	Age/sex: 1-4 Female	94	
CARE_NEW_DSD	Age/sex: 5-9 Female	187	
CARE_NEW_DSD	Age/sex: 10-14 Female	562	
CARE_NEW_DSD	Age/sex: 15-19 Female	1,646	
CARE_NEW_DSD	Age/sex: 20-24 Female	3,292	
CARE_NEW_DSD	Age/sex: 25-49 Female	4,389	
CARE_NEW_DSD	Age/sex: 50+ Female	1,645	
CARE_NEW_DSD	Sum of Age/sex disaggregates	18,757	
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	937	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	5,910	
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	937	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	10,973	
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	18,757	
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	0	
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically	0	

	undernourished.		
FN_THER_DSD	Age: <1	0	
FN_THER_DSD	Age: 1-4	0	
FN_THER_DSD	Age: 5-14	0	
FN_THER_DSD	Age: 15-17	0	
FN_THER_DSD	Age: 18+	0	
FN_THER_DSD	Sum of Age disaggregates	0	
FN_THER_DSD	Aggregated Age: <18	0	
FN_THER_DSD	Aggregated Age: 18+	0	
FN_THER_DSD	Sum of Aggregated Age disaggregates	0	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	0	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	6,764	
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	5,535	
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	3,875	
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	1,660	
PMTCT_EID_DSD	Sum of Infant Age disaggregates	5,535	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	75,126	
TX_CURR_DSD	Age/Sex: <1 Male	225	
TX_CURR_DSD	Age/Sex: 1-4 Male	826	
TX_CURR_DSD	Age/Sex: 5-14 Male	2,516	
TX_CURR_DSD	Age/Sex: 15+ Male	23,796	
TX_CURR_DSD	Age/Sex: <1 Female	226	

TX_CURR_DSD	Age/Sex: 1-4 Female	827	
TX_CURR_DSD	Age/Sex: 5-14 Female	2,517	
TX_CURR_DSD	Age/Sex: 15+ Female	44,193	
TX_CURR_DSD	Sum of age/sex disaggregates	7,137	
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	10	
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	59	
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	3,756	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	27,045	
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	3,757	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	40,568	
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	7,513	
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	67,613	
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	75,126	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	12,903	
TX_NEW_DSD	By Age/Sex: <1 Male	134	
TX_NEW_DSD	By Age/Sex: 1-4 Male	209	
TX_NEW_DSD	By Age/Sex: 5-9 Male	269	
TX_NEW_DSD	By Age/Sex: 10-14 Male	149	
TX_NEW_DSD	By Age/Sex: 15-19 Male	75	
TX_NEW_DSD	By Age/Sex: 20-24 Male	90	
TX_NEW_DSD	By Age/Sex: 25-49 Male	3,092	
TX_NEW_DSD	By Age/Sex: 50+ Male	627	
TX_NEW_DSD	By Age/Sex: <1 Female	120	
TX_NEW_DSD	By Age/Sex: 1-4 Female	134	
TX_NEW_DSD	By Age/Sex: 5-9 Female	299	
TX_NEW_DSD	By Age/Sex: 10-14 Female	134	
TX_NEW_DSD	By Age/Sex: 15-19 Female	239	

TX_NEW_DSD	By Age/Sex: 20-24 Female	821	
TX_NEW_DSD	By Age/Sex: 25-49 Female	5,630	
TX_NEW_DSD	By Age/Sex: 50+ Female	881	
TX_NEW_DSD	Sum of Age/Sex disaggregates	12,903	
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	134	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	761	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	3,884	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	209	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	687	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	7,571	
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	12,903	
TX_NEW_DSD	Pregnancy status	1,574	
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	10,968	
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	12,903	
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	425	
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	710	
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11,022	
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the	597	

	reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	852	
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	11,454	
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,135	
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	9,833	
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,200	
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	11,703	
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12	983	

	months after initiating ART)		
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,145	
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	98	
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	0	
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	0	
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	0	
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	67,983	
TB_SCREEN_DSD	Number of HIV positive adults and children	103,163	





	who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load		
TB_SCREEN_DSD	Age: <1	109	
TB_SCREEN_DSD	Age: 1-4	1,024	
TB_SCREEN_DSD	Age: 5-9	2,192	
TB_SCREEN_DSD	Age: 10-14	2,118	
TB_SCREEN_DSD	Age: 15-19	2,259	
TB_SCREEN_DSD	Age: 20-24	3,633	
TB_SCREEN_DSD	Age: 25-49	44,146	
TB_SCREEN_DSD	Age: 50+	12,502	
TB_SCREEN_DSD	Sum of Age disaggregates	7,702	
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	5,443	
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	62,540	
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	67,983	
TB_SCREEN_DSD	Sex: Male	22,185	
TB_SCREEN_DSD	Sex: Female	45,798	
TB_SCREEN_DSD	Sum of Sex disaggregates	67,983	

### Implementing Mechanism Details

<b>Mechanism ID: 14015</b>	<b>Mechanism Name: FUNZO Kenya</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: IntraHealth International, Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 3,670,000</b>	
<b>Applied Pipeline Amount: 0</b>	



Funding Source	Funding Amount
GHP-State	3,670,000

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 14015			
<b>Mechanism Name:</b> FUNZO Kenya			
<b>Prime Partner Name:</b> IntraHealth International, Inc			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Governance and Systems	OHSS	2,070,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	200,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	800,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	714	725
HRH_PRE	By Graduates: Nurses	223	395
HRH_PRE	By Graduates: Laboratory professionals	104	77
HRH_PRE	By Graduates: Other	387	253
HRH_PRE	Sum of Graduates disaggregated	714	725

### Implementing Mechanism Details

<b>Mechanism ID: 14022</b>	<b>Mechanism Name: APHIAplus Imarisha</b>
----------------------------	---



Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: African Medical and Research Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 4,179,464</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	4,179,464

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID: 14022</b>			
<b>Mechanism Name: APHIAplus Imarisha</b>			
<b>Prime Partner Name: African Medical and Research Foundation</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	374,065	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Care	HKID	1,184,787	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	123,425	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	58,149	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	377,408	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVAB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	309,946	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	357,099	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	467,093	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	789,890	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	137,602	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who	648	

	received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery		
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	682	
PMTCT_ARV_DSD	Life-long ART (including Option B+)	318	
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	259	
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	59	
PMTCT_ARV_DSD	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	330	
PMTCT_ARV_DSD	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	
PMTCT_ARV_DSD	Single-dose nevirapine (with or without tail)	0	
PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	648	
PMTCT_ARV_DSD	Sum of New and Current disaggregates	318	
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	83,412	
PMTCT_STAT_DSD	Number of new ANC and L&D clients	87,802	
PMTCT_STAT_DSD	By: Known positives at entry	1,286	
PMTCT_STAT_DSD	By: Number of new positives identified	2,885	

PMTCT_STAT_DSD	Sum of Positives Status disaggregates	4,171	
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	0	
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	6	
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	0	
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	0	
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	0	
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	6	
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	6	
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	0	
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	0	
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by	0	

	maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)		
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	0	
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	1,083	
VMMC_CIRC_DSD	By Age: <1	0	
VMMC_CIRC_DSD	By Age: 1-9	74	
VMMC_CIRC_DSD	By Age: 10-14	482	
VMMC_CIRC_DSD	By Age: 15-19	425	
VMMC_CIRC_DSD	By Age: 20-24	62	
VMMC_CIRC_DSD	By Age: 25-49	40	
VMMC_CIRC_DSD	By Age: 50+	0	
VMMC_CIRC_DSD	Sum of age disaggregates	1,083	
VMMC_CIRC_DSD	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	5	
VMMC_CIRC_DSD	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	1,078	
VMMC_CIRC_DSD	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0	
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	1,083	
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	0	
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	1,083	



VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	39,516	
PP_PREV_DSD	Total number of people in the target population	153,308	
PP_PREV_DSD	Age/sex: 10-14 Male	9,000	
PP_PREV_DSD	Age/sex: 15-19 Male	0	
PP_PREV_DSD	Age/sex: 20-24 Male	1,000	
PP_PREV_DSD	Age/sex: 25-49 Male	1,575	
PP_PREV_DSD	Age/sex: 50+ Male	0	
PP_PREV_DSD	Age/sex: 10-14 Female	8,227	
PP_PREV_DSD	Age/sex: 15-19 Female	9,714	
PP_PREV_DSD	Age/sex: 20-24 Female	10,000	
PP_PREV_DSD	Age/sex: 25-49 Female	0	
PP_PREV_DSD	Age/sex: 50+ Female	0	
PP_PREV_DSD	Sum of Age/Sex disaggregates	39,516	
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	4,240	
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	4,240	
KP_PREV_DSD	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of	0	

	key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)		
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	225,000	
HTC_TST_TA	By Test Result: Negative	216,000	
HTC_TST_TA	By Test Result: Positive	9,000	
HTC_TST_TA	Sum of Test Result disaggregates	225,000	
HTC_TST_TA	Age/sex: <1 Male	0	
HTC_TST_TA	Age/sex: 1-4 Male	7,875	

HTC_TST_TA	Age/sex: 5-9 Male	3,375	
HTC_TST_TA	Age/sex: 10-14 Male	5,625	
HTC_TST_TA	Age/sex: 15-19 Male	11,250	
HTC_TST_TA	Age/sex: 20-24 Male	28,125	
HTC_TST_TA	Age/sex: 25-49 Male	45,000	
HTC_TST_TA	Age/sex: 50+ Male	11,250	
HTC_TST_TA	Age/sex: <1 Female	0	
HTC_TST_TA	Age/sex: 1-4 Female	7,875	
HTC_TST_TA	Age/sex: 5-9 Female	3,375	
HTC_TST_TA	Age/sex: 10-14 Female	5,625	
HTC_TST_TA	Age/sex: 15-19 Female	11,250	
HTC_TST_TA	Age/sex: 20-24 Female	28,125	
HTC_TST_TA	Age/sex: 25-49 Female	45,000	
HTC_TST_TA	Age/sex: 50+ Female	11,250	
HTC_TST_TA	Sum of Age/Sex disaggregates	225,000	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	16,875	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	95,625	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	16,875	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	95,625	
HTC_TST_TA	Sum of Aggregated Age/Sex <15	33,750	
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	191,250	
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	225,000	
GEND_GBV_DSD	Number of people receiving post-GBV care	268	
GEND_GBV_DSD	Age: 0-9	0	
GEND_GBV_DSD	Age: 10-14	0	
GEND_GBV_DSD	Age: 15-17	0	
GEND_GBV_DSD	Age: 18-24	0	
GEND_GBV_DSD	Age: 25+	268	

GEND_GBV_DSD	Sum of Age disaggregates	268	
GEND_GBV_DSD	Sex: Male	96	
GEND_GBV_DSD	Sex: Female	172	
GEND_GBV_DSD	Sum of Sex disaggregates	268	
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	268	
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	98,644	
GEND_NORM_DSD	By Age: 0-9	0	
GEND_NORM_DSD	By Age: 10-14	0	
GEND_NORM_DSD	By Age: 15-19	0	
GEND_NORM_DSD	By Age: 20-24	24,661	
GEND_NORM_DSD	By Age: 25+	73,983	
GEND_NORM_DSD	Sum of Age disaggregates	98,644	
GEND_NORM_DSD	By Sex: Male	73,983	
GEND_NORM_DSD	By Sex: Female	24,661	
GEND_NORM_DSD	Sum of Sex disaggregates	98,644	
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	1,500	
OVC_ACC_DSD	Sex: Male	799	
OVC_ACC_DSD	Sex: Female	701	
OVC_ACC_DSD	Sum of Sex disaggregates	1,500	
OVC_ACC_DSD	Age: <1	75	
OVC_ACC_DSD	Age: 1-4	150	
OVC_ACC_DSD	Age: 5-9	300	
OVC_ACC_DSD	Age: 10-14	450	
OVC_ACC_DSD	Age: 15-17	450	
OVC_ACC_DSD	Age: 18+	75	
OVC_ACC_DSD	Sum of Age disaggregates	1,500	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and	30,512	

	families affected by HIV/AIDS		
OVC_SERV_DSD	Sex: Male	16,233	
OVC_SERV_DSD	Sex: Female	14,279	
OVC_SERV_DSD	Sum of Sex disaggregates	30,512	
OVC_SERV_DSD	Age: <1	0	
OVC_SERV_DSD	Age: 1-4	4,500	
OVC_SERV_DSD	Age: 5-9	6,000	
OVC_SERV_DSD	Age: 10-14	9,512	
OVC_SERV_DSD	Age: 15-17	9,000	
OVC_SERV_DSD	Age: 18+	1,500	
OVC_SERV_DSD	Sum of Age disaggregates	30,512	
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	12,856	
CARE_CURR_DSD	Age/sex: <1 Male	57	
CARE_CURR_DSD	Age/sex: 1-4 Male	57	
CARE_CURR_DSD	Age/sex: 5-9 Male	114	
CARE_CURR_DSD	Age/sex: 10-14 Male	341	
CARE_CURR_DSD	Age/sex: 15-19 Male	597	
CARE_CURR_DSD	Age/sex: 20-24 Male	1,193	
CARE_CURR_DSD	Age/sex: 25-49 Male	1,591	
CARE_CURR_DSD	Age/sex: 50+ Male	597	
CARE_CURR_DSD	Age/sex: <1 Female	57	
CARE_CURR_DSD	Age/sex: 1-4 Female	57	
CARE_CURR_DSD	Age/sex: 5-9 Female	114	
CARE_CURR_DSD	Age/sex: 10-14 Female	341	
CARE_CURR_DSD	Age/sex: 15-19 Female	1,161	
CARE_CURR_DSD	Age/sex: 20-24 Female	2,322	
CARE_CURR_DSD	Age/sex: 25-49 Female	3,096	
CARE_CURR_DSD	Age/sex: 50+ Female	1,161	

CARE_CURR_DSD	Sun of Age/Sex disaggregates	12,856	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	569	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,978	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	569	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	7,740	
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	12,856	
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	2,338	
CARE_NEW_DSD	Age/sex: <1 Male	11	
CARE_NEW_DSD	Age/sex: 1-4 Male	11	
CARE_NEW_DSD	Age/sex: 5-9 Male	21	
CARE_NEW_DSD	Age/sex: 10-14 Male	64	
CARE_NEW_DSD	Age/sex: 15-19 Male	112	
CARE_NEW_DSD	Age/sex: 20-24 Male	224	
CARE_NEW_DSD	Age/sex: 25-49 Male	299	
CARE_NEW_DSD	Age/sex: 50+ Male	112	
CARE_NEW_DSD	Age/sex: <1 Female	11	
CARE_NEW_DSD	Age/sex: 1-4 Female	11	
CARE_NEW_DSD	Age/sex: 5-9 Female	21	
CARE_NEW_DSD	Age/sex: 10-14 Female	64	
CARE_NEW_DSD	Age/sex: 15-19 Female	207	
CARE_NEW_DSD	Age/sex: 20-24 Female	415	
CARE_NEW_DSD	Age/sex: 25-49 Female	553	
CARE_NEW_DSD	Age/sex: 50+ Female	207	
CARE_NEW_DSD	Sum of Age/sex disaggregates	2,343	

CARE_NEW_DSD	Aggregated Age/sex: <15 Male	106	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	743	
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	106	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	1,383	
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	2,338	
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	0	
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	0	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	2,625	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	2,625	
TB_ART_DSD	Age: 0-4	52	
TB_ART_DSD	Age: 5-14	218	
TB_ART_DSD	Age: 15+	2,355	
TB_ART_DSD	Male	955	
TB_ART_DSD	Female	1,670	
TB_ART_DSD	Sum of Sex disaggregates	2,625	
TB_ART_DSD	Newly tested	525	
TB_ART_DSD	Known HIV-positive	2,100	
TB_ART_DSD	Sum of Test Status disaggregates	2,625	
TB_ART_DSD	Aggregated Age: <15	239	
TB_ART_DSD	Aggregated Age: 15+	2,386	
TB_ART_DSD	Sum of Aggregated Age disaggregates	2,625	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting	520	

	period		
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	648	
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	364	
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	156	
PMTCT_EID_DSD	Sum of Infant Age disaggregates	520	
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	26	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	9,700	
TX_CURR_DSD	Age/Sex: <1 Male	29	
TX_CURR_DSD	Age/Sex: 1-4 Male	106	
TX_CURR_DSD	Age/Sex: 5-14 Male	325	
TX_CURR_DSD	Age/Sex: 15+ Male	3,072	
TX_CURR_DSD	Age/Sex: <1 Female	29	
TX_CURR_DSD	Age/Sex: 1-4 Female	107	
TX_CURR_DSD	Age/Sex: 5-14 Female	325	
TX_CURR_DSD	Age/Sex: 15+ Female	5,707	
TX_CURR_DSD	Sum of age/sex disaggregates	921	
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	6	
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	63	
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	86	
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	82	
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	595	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	2,976	



TX_CURR_DSD	Aggregated Age/Sex: <15 Female	603	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	5,526	
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,198	
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	8,502	
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	9,700	
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	168	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,736	
TX_NEW_DSD	By Age/Sex: <1 Male	24	
TX_NEW_DSD	By Age/Sex: 1-4 Male	19	
TX_NEW_DSD	By Age/Sex: 5-9 Male	26	
TX_NEW_DSD	By Age/Sex: 10-14 Male	21	
TX_NEW_DSD	By Age/Sex: 15-19 Male	24	
TX_NEW_DSD	By Age/Sex: 20-24 Male	57	
TX_NEW_DSD	By Age/Sex: 25-49 Male	361	
TX_NEW_DSD	By Age/Sex: 50+ Male	106	
TX_NEW_DSD	By Age/Sex: <1 Female	28	
TX_NEW_DSD	By Age/Sex: 1-4 Female	19	
TX_NEW_DSD	By Age/Sex: 5-9 Female	30	
TX_NEW_DSD	By Age/Sex: 10-14 Female	24	
TX_NEW_DSD	By Age/Sex: 15-19 Female	49	
TX_NEW_DSD	By Age/Sex: 20-24 Female	149	
TX_NEW_DSD	By Age/Sex: 25-49 Female	672	
TX_NEW_DSD	By Age/Sex: 50+ Female	127	
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,736	
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	43	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	166	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	487	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	50	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	178	

TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	905	
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,736	
TX_NEW_DSD	Pregnancy status	174	
TX_NEW_DSD	Breastfeeding status	157	
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,845	
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,170	
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	21	
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	16	
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	22	
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	18	
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	21	
TX_RET_DSD	Age: 15+ (Denominator: Total number of	49	

	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	24	
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	16	
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	25	
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	21	
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	307	
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	90	
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by	0	

	national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation		
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	390	
LAB_CAP_DSD	By Point-of-care testing sites	390	
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	390	
LAB_CAP_DSD	Sum of Site Support Type disaggregates	390	
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	0	
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	0	
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	465	
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	465	
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	31	
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service	434	

	delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services		
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	465	
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	31	
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	434	
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	465	
FPINT_SITE_DSD	Service delivery type: Community	75	
FPINT_SITE_DSD	Service delivery type: Clinical	390	
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	465	
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	10,285	
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	12,856	
TB_SCREEN_DSD	Age: <1	28	
TB_SCREEN_DSD	Age: 1-4	65	
TB_SCREEN_DSD	Age: 5-9	187	
TB_SCREEN_DSD	Age: 10-14	655	
TB_SCREEN_DSD	Age: 15-19	935	
TB_SCREEN_DSD	Age: 20-24	1,869	
TB_SCREEN_DSD	Age: 25-49	5,609	
TB_SCREEN_DSD	Age: 50+	937	
TB_SCREEN_DSD	Sum of Age disaggregates	1,870	



TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	936	
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	9,349	
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	10,285	
TB_SCREEN_DSD	Sex: Male	3,740	
TB_SCREEN_DSD	Sex: Female	6,545	
TB_SCREEN_DSD	Sum of Sex disaggregates	10,285	

### Implementing Mechanism Details

<b>Mechanism ID: 14034</b>	<b>Mechanism Name: The OVC Scholarship and Leadership Program</b>
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: Equity Group Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,667,390</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,667,390

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)



## Key Issues

(No data provided.)

## Budget Code Information

<b>Mechanism ID:</b> 14034			
<b>Mechanism Name:</b> The OVC Scholarship and Leadership Program			
<b>Prime Partner Name:</b> Equity Group Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,667,390	0

## Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	
PMTCT_STAT_DSD	Number of new ANC and L&D clients	0	
PMTCT_STAT_DSD	By: Known positives at entry	0	

PMTCT_STAT_DSD	By: Number of new positives identified	0	
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	0	
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	0	
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	0	
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0	
PP_PREV_DSD	Total number of people in the target population	0	
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	0	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	
GEND_GBV_DSD	Number of people receiving post-GBV care	0	
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	0	
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to	0	2



	access HIV services		
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	1,520	1,548
OVC_SERV_DSD	Sex: Male	760	
OVC_SERV_DSD	Sex: Female	760	
OVC_SERV_DSD	Sum of Sex disaggregates	1,520	
OVC_SERV_DSD	Age: 15-17	1,520	
OVC_SERV_DSD	Sum of Age disaggregates	1,520	
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	0	
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	0	
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	0	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	0	
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	0	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	0	

TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	0	
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	0	
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	0	
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	0	
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	0	
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	0	
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	0	
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV	0	



	care facility during the reporting period		
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	

### Implementing Mechanism Details

<b>Mechanism ID: 16450</b>	<b>Mechanism Name: Global Give Back Circle</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Kenya Community Development Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 268,421</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	268,421

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)



### Budget Code Information

<b>Mechanism ID:</b> 16450			
<b>Mechanism Name:</b> Global Give Back Circle			
<b>Prime Partner Name:</b> Kenya Community Development Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	268,421	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	
PMTCT_STAT_DSD	Number of new ANC and L&D clients	0	
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	0	
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	0	
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC)	0	

	for HIV prevention program within the reporting period		
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0	
PP_PREV_DSD	Total number of people in the target population	0	
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	0	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	
GEND_GBV_DSD	Number of people receiving post-GBV care	0	
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	0	
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	0	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	255	255
OVC_SERV_DSD	Sex: Male	25	
OVC_SERV_DSD	Sex: Female	230	
OVC_SERV_DSD	Sum of Sex disaggregates	255	
OVC_SERV_DSD	Age: 15-17	255	
OVC_SERV_DSD	Sum of Age disaggregates	255	

CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	0	
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	0	
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	0	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	0	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	0	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	0	
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	0	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	0	
TX_NEW_DSD	Number of adults and children newly enrolled	0	

	on antiretroviral therapy (ART)		
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	0	
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	0	
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	0	
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	0	
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	0	
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	0	
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	0	



TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	0	
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	

### Implementing Mechanism Details

<b>Mechanism ID: 16670</b>	<b>Mechanism Name: HIV Fellowship Program</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Nairobi	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 1,000,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,000,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	1,000,000
----------------------------	-----------

### Key Issues





(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 16670			
<b>Mechanism Name:</b> HIV Fellowship Program			
<b>Prime Partner Name:</b> University of Nairobi			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	1,000,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID:</b> 16679	<b>Mechanism Name:</b> Program Support Services
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: International Business & Technical Consultants Inc.	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 1,250,000	
<b>Applied Pipeline Amount:</b> 0	
Funding Source	Funding Amount
GHP-State	1,250,000

### Sub Partner Name(s)

(No data provided.)



### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 16679			
<b>Mechanism Name:</b> Program Support Services			
<b>Prime Partner Name:</b> International Business & Technical Consultants Inc.			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	700,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	300,000	0

### Implementing Mechanism Indicator Information



(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 16682</b>	<b>Mechanism Name: Kenya National Bureau of Statistics (KNBS) FARA</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Kenya National Bureau of Statistics	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: USAID

<b>Total All Funding Sources: 150,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	150,000

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 16682</b>
----------------------------



<b>Mechanism Name:</b>	<b>Kenya National Bureau of Statistics (KNBS) FARA</b>		
<b>Prime Partner Name:</b>	<b>Kenya National Bureau of Statistics</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	150,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 16684</b>	<b>Mechanism Name: Kenya Disciplined Services ZUIA</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,058,282</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,058,282

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	378,282
Gender: GBV	50,000



Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Condom programming	100,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	<b>16684</b>
<b>Mechanism Name:</b>	<b>Kenya Disciplined Services ZUIA</b>
<b>Prime Partner Name:</b>	<b>Elizabeth Glaser Pediatric AIDS Foundation</b>



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	59,971	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	17,736	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	1,555	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	190,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	63,862	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	525,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	57,974	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	139,269	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	2,915	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets

PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	327		Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	327		Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	245		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	114		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	131		Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	82		Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	327		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	245		Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	6,513		Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	6,513		Redacted
PMTCT_STAT_DS	By: Known positives at entry	154		Redacted

D				
PMTCT_STAT_DS D	By: Number of new positives identified	173		Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	327		Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	75,000		Redacted
PP_PREV_DSD	Total number of people in the target population	290,973		Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	0		Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	4,500		Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	13,500		Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	22,500		Redacted
PP_PREV_DSD	Age/sex: 50+ Male	4,500		Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	0		Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	3,000		Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	6,000		Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	18,000		Redacted
PP_PREV_DSD	Age/sex: 50+ Female	3,000		Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	75,000		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	76,953		Redacted
HTC_TST_DSD	By Test Result: Negative	73,875		Redacted
HTC_TST_DSD	By Test Result: Positive	3,078		Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	76,953		Redacted
HTC_TST_DSD	Age/sex: <1 Male	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	2,693		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	1,154		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	1,924		Redacted



HTC_TST_DSD	Age/sex: 15-19 Male	3,848		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	9,619		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	15,390		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	3,848		Redacted
HTC_TST_DSD	Age/sex: <1 Female	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	2,693		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	1,154		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	1,924		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	3,848		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	9,619		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	15,391		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	3,848		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	76,953		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	5,771		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	32,705		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	5,771		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	32,706		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	11,542		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	65,411		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	76,953		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	2,344		Redacted
CARE_CURR_DS D	Age/sex: <1 Male	4		Redacted
CARE_CURR_DS	Age/sex: 1-4 Male	25		Redacted

D				
CARE_CURR_DS D	Age/sex: 5-9 Male	43		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	34		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	18		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	33		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	501		Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	173		Redacted
CARE_CURR_DS D	Age/sex: <1 Female	4		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	24		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	44		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	34		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	30		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	123		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	1,052		Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	202		Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	2,344		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	106		Redacted
CARE_CURR_DS	Aggregated Age/sex - USE WITH HQ	725		Redacted

D	PERMISSION ONLY: 15+ Male			
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	106		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,407		Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	2,344		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	426		Redacted
CARE_NEW_DSD	Age/sex: <1 Male	1		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	5		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	8		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	6		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	3		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	11		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	98		Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	19		Redacted
CARE_NEW_DSD	Age/sex: <1 Female	1		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	4		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	8		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	6		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	6		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	12		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	177		Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	61		Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	426		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	20		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	131		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	19		Redacted

CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	256		Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	426		Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	370		Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	493		Redacted
FN_THER_DSD	Age: <1	1		Redacted
FN_THER_DSD	Age: 1-4	8		Redacted
FN_THER_DSD	Age: 5-14	25		Redacted
FN_THER_DSD	Age: 15-17	8		Redacted
FN_THER_DSD	Age: 18+	328		Redacted
FN_THER_DSD	Sum of Age disaggregates	370		Redacted
FN_THER_DSD	Aggregated Age: <18	42		Redacted
FN_THER_DSD	Aggregated Age: 18+	328		Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	370		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	105		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	117		Redacted
TB_ART_DSD	Age: 0-4	3		Redacted
TB_ART_DSD	Age: 5-14	7		Redacted
TB_ART_DSD	Age: 15+	95		Redacted
TB_ART_DSD	Male	57		Redacted
TB_ART_DSD	Female	48		Redacted
TB_ART_DSD	Sum of Sex disaggregates	105		Redacted

TB_ART_DSD	Newly tested	63		Redacted
TB_ART_DSD	Known HIV-positive	42		Redacted
TB_ART_DSD	Sum of Test Status disaggregates	105		Redacted
TB_ART_DSD	Aggregated Age: <15	10		Redacted
TB_ART_DSD	Aggregated Age: 15+	95		Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	105		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	262		Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	327		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	196		Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	66		Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	262		Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	13		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	544		Redacted
TX_CURR_DSD	Age/Sex: <1 Male	1		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	6		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	18		Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	173		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	1		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	6		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	18		Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	321		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	50		Redacted
TX_CURR_DSD	Percent children with advanced HIV	22		Redacted

	infection receiving antiretroviral therapy (ART) [CURRENT]			
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	22		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	1		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	1		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	25		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	173		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	25		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	321		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	50		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	494		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	544		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	2		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	497		Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	11		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	6		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	10		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	8		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	4		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	7		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	103		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	36		Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	11		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	6		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	10		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	8		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	6		Redacted

TX_NEW_DSD	By Age/Sex: 20-24 Female	24		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	207		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	40		Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	497		Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	11		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	35		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	150		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	11		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	35		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	277		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	497		Redacted
TX_NEW_DSD	Pregnancy status	103		Redacted
TX_NEW_DSD	Breastfeeding status	11		Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	27		Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	35		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	27		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of	0		Redacted

	service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services			
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	27		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	35		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	0		Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	35		Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	27		Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	27		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	2,226		Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	2,344		Redacted
TB_SCREEN_DSD	Age: <1	7		Redacted
TB_SCREEN_DSD	Age: 1-4	48		Redacted
TB_SCREEN_DSD	Age: 5-9	85		Redacted
TB_SCREEN_DSD	Age: 10-14	65		Redacted
TB_SCREEN_DSD	Age: 15-19	45		Redacted
TB_SCREEN_DSD	Age: 20-24	150		Redacted





TB_SCREEN_DSD	Age: 25-49	1,474		Redacted
TB_SCREEN_DSD	Age: 50+	352		Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	250		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	205		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	2,021		Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	2,226		Redacted
TB_SCREEN_DSD	Sex: Male	790		Redacted
TB_SCREEN_DSD	Sex: Female	1,436		Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	2,226		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 16687</b>	<b>Mechanism Name: Kenya Prison Services</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Health Strat Kenya	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,610,046</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,610,046

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	350,000
Gender: GBV	30,000



Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Condom programming	100,000
Motor Vehicles: Purchased	100,000

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID: 16687</b>			
<b>Mechanism Name: Kenya Prison Services</b>			
<b>Prime Partner Name: Health Strat Kenya</b>			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	199,257	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	57,617	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	199	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	160,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	250,184	0

Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	377,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	102,688	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	462,728	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	373	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	71		Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	71		Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	53		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	25		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	28		Redacted

PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	18		Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	71		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	53		Redacted
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	184		Redacted
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	184		Redacted
PMTCT_ARV_TA	Life-long ART (including Option B+)	138		Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	64		Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	74		Redacted
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	46		Redacted
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0		Redacted

PMTCT_ARV_TA	Sum of Regimen Type disaggregates	184		Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	138		Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,869		Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	1,869		Redacted
PMTCT_STAT_DS D	By: Known positives at entry	33		Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	38		Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	71		Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	3,614		Redacted
PMTCT_STAT_TA	Number of new ANC and L&D clients	3,614		Redacted
PMTCT_STAT_TA	By: Known positives at entry	87		Redacted
PMTCT_STAT_TA	By: Number of new positives identified	97		Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	184		Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	100,000		Redacted
PP_PREV_DSD	Total number of people in the target population	250,000		Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	5,000		Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	30,000		Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	30,000		Redacted
PP_PREV_DSD	Age/sex: 50+ Male	5,000		Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	5,000		Redacted



PP_PREV_DSD	Age/sex: 20-24 Female	10,000		Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	10,000		Redacted
PP_PREV_DSD	Age/sex: 50+ Female	5,000		Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	100,000		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	44,213		Redacted
HTC_TST_DSD	By Test Result: Negative	42,445		Redacted
HTC_TST_DSD	By Test Result: Positive	1,768		Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	44,213		Redacted
HTC_TST_DSD	Age/sex: <1 Male	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	1,547		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	663		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	1,106		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	2,210		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	5,527		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	8,843		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	2,210		Redacted
HTC_TST_DSD	Age/sex: <1 Female	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	1,547		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	663		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	1,106		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	2,211		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	5,527		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	8,843		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	2,210		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	44,213		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,316		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	18,790		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ	3,316		Redacted

	PERMISSION ONLY: <15 Female			
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	18,791		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	6,632		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	37,581		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	44,213		Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	113,692		Redacted
HTC_TST_TA	By Test Result: Negative	109,144		Redacted
HTC_TST_TA	By Test Result: Positive	4,548		Redacted
HTC_TST_TA	Sum of Test Result disaggregates	113,692		Redacted
HTC_TST_TA	Age/sex: <1 Male	0		Redacted
HTC_TST_TA	Age/sex: 1-4 Male	3,979		Redacted
HTC_TST_TA	Age/sex: 5-9 Male	1,705		Redacted
HTC_TST_TA	Age/sex: 10-14 Male	2,843		Redacted
HTC_TST_TA	Age/sex: 15-19 Male	5,685		Redacted
HTC_TST_TA	Age/sex: 20-24 Male	14,212		Redacted
HTC_TST_TA	Age/sex: 25-49 Male	22,738		Redacted
HTC_TST_TA	Age/sex: 50+ Male	5,684		Redacted
HTC_TST_TA	Age/sex: <1 Female	0		Redacted
HTC_TST_TA	Age/sex: 1-4 Female	3,979		Redacted
HTC_TST_TA	Age/sex: 5-9 Female	1,706		Redacted
HTC_TST_TA	Age/sex: 10-14 Female	2,842		Redacted
HTC_TST_TA	Age/sex: 15-19 Female	5,685		Redacted
HTC_TST_TA	Age/sex: 20-24 Female	14,212		Redacted
HTC_TST_TA	Age/sex: 25-49 Female	22,738		Redacted
HTC_TST_TA	Age/sex: 50+ Female	5,684		Redacted
HTC_TST_TA	Sum of Age/Sex disaggregates	113,692		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	8,527		Redacted

HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	48,319		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	8,527		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	48,319		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	17,054		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	96,638		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	113,692		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	4,362		Redacted
CARE_CURR_DS D	Age/sex: <1 Male	7		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	47		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	80		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	63		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	33		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	62		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	932		Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	322		Redacted
CARE_CURR_DS D	Age/sex: <1 Female	7		Redacted
CARE_CURR_DS	Age/sex: 1-4 Female	45		Redacted



D				
CARE_CURR_DS D	Age/sex: 5-9 Female	83		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	62		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	55		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	229		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	1,959		Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	376		Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	4,362		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	197		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,349		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	197		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	2,619		Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	4,362		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	1,586		Redacted
CARE_NEW_DSD	Age/sex: <1 Male	2		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	17		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	29		Redacted

CARE_NEW_DSD	Age/sex: 10-14 Male	23		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	10		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	43		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	367		Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	71		Redacted
CARE_NEW_DSD	Age/sex: <1 Female	2		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	16		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	30		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	23		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	24		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	44		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	658		Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	227		Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	1,586		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	71		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	491		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	71		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	953		Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	1,586		Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	1,377		Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	1,837		Redacted
FN_THER_DSD	Age: <1	4		Redacted
FN_THER_DSD	Age: 1-4	30		Redacted
FN_THER_DSD	Age: 5-14	93		Redacted
FN_THER_DSD	Age: 15-17	28		Redacted
FN_THER_DSD	Age: 18+	1,222		Redacted
FN_THER_DSD	Sum of Age disaggregates	1,377		Redacted

FN_THER_DSD	Aggregated Age: <18	155		Redacted
FN_THER_DSD	Aggregated Age: 18+	1,222		Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	1,377		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	196		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	218		Redacted
TB_ART_DSD	Age: 0-4	5		Redacted
TB_ART_DSD	Age: 5-14	13		Redacted
TB_ART_DSD	Age: 15+	178		Redacted
TB_ART_DSD	Male	106		Redacted
TB_ART_DSD	Female	90		Redacted
TB_ART_DSD	Sum of Sex disaggregates	196		Redacted
TB_ART_DSD	Newly tested	117		Redacted
TB_ART_DSD	Known HIV-positive	79		Redacted
TB_ART_DSD	Sum of Test Status disaggregates	196		Redacted
TB_ART_DSD	Aggregated Age: <15	18		Redacted
TB_ART_DSD	Aggregated Age: 15+	178		Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	196		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	204		Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	255		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	153		Redacted
PMTCT_EID_DSD	By infants who received their first	51		Redacted

	virologic HIV test between 2 and 12 months of age			
PMTCT_EID_DSD	Sum of Infant Age disaggregates	204		Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	10		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	2,372		Redacted
TX_CURR_DSD	Age/Sex: <1 Male	4		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	25		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	78		Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	755		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	4		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	25		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	78		Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	1,403		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	214		Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	1		Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	1		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	4		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	4		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	107		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	755		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	107		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	1,403		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	214		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	2,158		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	2,372		Redacted

TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	8		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	513		Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	11		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	6		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	11		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	8		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	4		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	7		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	107		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	37		Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	11		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	6		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	11		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	8		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	6		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	25		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	214		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	41		Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	513		Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	11		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	36		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	155		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	11		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	36		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	286		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex	513		Redacted

	disaggregates			
TX_NEW_DSD	Pregnancy status	80		Redacted
TX_NEW_DSD	Breastfeeding status	9		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	396		Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	466		Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10		Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	27		Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	360		Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	12		Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those	31		Redacted

	who have died, those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	423		Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	37		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	360		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	43		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	423		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating	159		Redacted

	ART)			
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	187		Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	18		Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	24		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	3		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	15		Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	18		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	4		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of	20		Redacted



	PEPFAR-supported HIV service delivery points			
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	24		Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	18		Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	18		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	4,144		Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	4,362		Redacted
TB_SCREEN_DSD	Age: <1	13		Redacted
TB_SCREEN_DSD	Age: 1-4	89		Redacted
TB_SCREEN_DSD	Age: 5-9	158		Redacted
TB_SCREEN_DSD	Age: 10-14	122		Redacted
TB_SCREEN_DSD	Age: 15-19	84		Redacted
TB_SCREEN_DSD	Age: 20-24	279		Redacted
TB_SCREEN_DSD	Age: 25-49	2,744		Redacted
TB_SCREEN_DSD	Age: 50+	655		Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	466		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	382		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	3,762		Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	4,144		Redacted
TB_SCREEN_DSD	Sex: Male	1,470		Redacted
TB_SCREEN_DSD	Sex: Female	2,674		Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	4,144		Redacted



### Implementing Mechanism Details

<b>Mechanism ID: 16698</b>	<b>Mechanism Name: Coordinating Comprehensive Care for Children ( 4Cs)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Relief Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	16698		
<b>Mechanism Name:</b>	Coordinating Comprehensive Care for Children ( 4Cs)		
<b>Prime Partner Name:</b>	Catholic Relief Services		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Care	HKID	0	0
------	------	---	---

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 16705</b>	<b>Mechanism Name: IDU - HIV Combination Prevention</b>
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: United Nations Office on Drug and Crime (UNODC)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 942,904</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	942,904

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)



### Budget Code Information

<b>Mechanism ID:</b> 16705			
<b>Mechanism Name:</b> IDU - HIV Combination Prevention			
<b>Prime Partner Name:</b> United Nations Office on Drug and Crime (UNODC)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	942,904	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	280	
KP_MAT_DSD	Sex: Male	224	
KP_MAT_DSD	Sex: Female	56	
KP_MAT_DSD	Sum of Sex disaggregates	280	
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	6,053	
KP_PREV_DSD	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	140	
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of	140	



	key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)		
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,700	
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	700	

### Implementing Mechanism Details

<b>Mechanism ID: 16709</b>	<b>Mechanism Name: Accelerating Progress Against TB</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Center for Health Solutions (CHS)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,800,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,800,000



**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 16709			
<b>Mechanism Name:</b> Accelerating Progress Against TB			
<b>Prime Partner Name:</b> Center for Health Solutions (CHS)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	1,800,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 16710	<b>Mechanism Name:</b> Expanding Health Insurance Coverage
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Equity Group Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID: 16710</b>			
<b>Mechanism Name: Expanding Health Insurance Coverage</b>			
<b>Prime Partner Name: Equity Group Foundation</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17190</b>	<b>Mechanism Name: Wezesha Project</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Life Skills Promoters	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 902,458</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	902,458

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 17190			
<b>Mechanism Name:</b> Wezesha Project			
<b>Prime Partner Name:</b> Life Skills Promoters			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	902,458	0

**Implementing Mechanism Indicator Information**



Indicator Number	Label	2015	2016
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	
PMTCT_ARV_DSD	Life-long ART (including Option B+)	0	
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	0	
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	0	
PMTCT_ARV_DSD	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	
PMTCT_ARV_DSD	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	
PMTCT_ARV_DSD	Single-dose nevirapine (with or without tail)	0	
PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	0	
PMTCT_ARV_DSD	Sum of New and Current disaggregates	0	
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	
PMTCT_ARV_TA	Life-long ART (including Option B+)	0	
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	0	
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on	0	

	treatment at the beginning of the current pregnancy		
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0	
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	0	
PMTCT_ARV_TA	Sum of New and Current disaggregates	0	
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	
PMTCT_STAT_DSD	Number of new ANC and L&D clients	0	
PMTCT_STAT_DSD	By: Known positives at entry	0	
PMTCT_STAT_DSD	By: Number of new positives identified	0	
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	0	
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	0	
KP_MAT_DSD	Sex: Male	0	
KP_MAT_DSD	Sex: Female	0	
KP_MAT_DSD	Sum of Sex disaggregates	0	
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	0	
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	0	
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical	0	

	intra-operative AE(s)		
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	0	
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	0	
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	0	
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	0	
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	0	
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)	0	
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	0	
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	
VMMC_CIRC_DSD	By Age: <1	0	
VMMC_CIRC_DSD	By Age: 1-9	0	

VMMC_CIRC_DSD	By Age: 10-14	0	
VMMC_CIRC_DSD	By Age: 15-19	0	
VMMC_CIRC_DSD	By Age: 20-24	0	
VMMC_CIRC_DSD	By Age: 25-49	0	
VMMC_CIRC_DSD	By Age: 50+	0	
VMMC_CIRC_DSD	Sum of age disaggregates	0	
VMMC_CIRC_DSD	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	0	
VMMC_CIRC_DSD	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	0	
VMMC_CIRC_DSD	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0	
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	0	
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	0	
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	0	
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0	
PP_PREV_DSD	Total number of people in the target population	0	
PP_PREV_DSD	Age/sex: 10-14 Male	0	
PP_PREV_DSD	Age/sex: 15-19 Male	0	
PP_PREV_DSD	Age/sex: 20-24 Male	0	
PP_PREV_DSD	Age/sex: 25-49 Male	0	

PP_PREV_DSD	Age/sex: 50+ Male	0	
PP_PREV_DSD	Age/sex: 10-14 Female	0	
PP_PREV_DSD	Age/sex: 15-19 Female	0	
PP_PREV_DSD	Age/sex: 20-24 Female	0	
PP_PREV_DSD	Age/sex: 25-49 Female	0	
PP_PREV_DSD	Age/sex: 50+ Female	0	
PP_PREV_DSD	Sum of Age/Sex disaggregates	0	
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	0	
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	
KP_PREV_DSD	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on	0	

	evidence and/or meet the minimum standards required)		
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	
HTC_TST_DSD	By Test Result: Negative	0	
HTC_TST_DSD	By Test Result: Positive	0	
HTC_TST_DSD	Sum of Test Result disaggregates	0	
HTC_TST_DSD	Age/sex: <1 Male	0	
HTC_TST_DSD	Age/sex: 1-4 Male	0	
HTC_TST_DSD	Age/sex: 5-9 Male	0	
HTC_TST_DSD	Age/sex: 10-14 Male	0	
HTC_TST_DSD	Age/sex: 15-19 Male	0	
HTC_TST_DSD	Age/sex: 20-24 Male	0	
HTC_TST_DSD	Age/sex: 25-49 Male	0	
HTC_TST_DSD	Age/sex: 50+ Male	0	
HTC_TST_DSD	Age/sex: <1 Female	0	
HTC_TST_DSD	Age/sex: 1-4 Female	0	
HTC_TST_DSD	Age/sex: 5-9 Female	0	
HTC_TST_DSD	Age/sex: 10-14 Female	0	
HTC_TST_DSD	Age/sex: 15-19 Female	0	
HTC_TST_DSD	Age/sex: 20-24 Female	0	
HTC_TST_DSD	Age/sex: 25-49 Female	0	
HTC_TST_DSD	Age/sex: 50+ Female	0	
HTC_TST_DSD	Sum of Age/Sex disaggregates	0	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ	0	



	PERMISSION ONLY: <15 Male		
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	0	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0	
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	0	
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	0	
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	0	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	
HTC_TST_TA	By Test Result: Negative	0	
HTC_TST_TA	By Test Result: Positive	0	
HTC_TST_TA	Sum of Test Result disaggregates	0	
HTC_TST_TA	Age/sex: <1 Male	0	
HTC_TST_TA	Age/sex: 1-4 Male	0	
HTC_TST_TA	Age/sex: 5-9 Male	0	
HTC_TST_TA	Age/sex: 10-14 Male	0	
HTC_TST_TA	Age/sex: 15-19 Male	0	
HTC_TST_TA	Age/sex: 20-24 Male	0	
HTC_TST_TA	Age/sex: 25-49 Male	0	
HTC_TST_TA	Age/sex: 50+ Male	0	
HTC_TST_TA	Age/sex: <1 Female	0	
HTC_TST_TA	Age/sex: 1-4 Female	0	
HTC_TST_TA	Age/sex: 5-9 Female	0	
HTC_TST_TA	Age/sex: 10-14 Female	0	
HTC_TST_TA	Age/sex: 15-19 Female	0	
HTC_TST_TA	Age/sex: 20-24 Female	0	
HTC_TST_TA	Age/sex: 25-49 Female	0	
HTC_TST_TA	Age/sex: 50+ Female	0	

HTC_TST_TA	Sum of Age/Sex disaggregates	0	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	0	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0	
HTC_TST_TA	Sum of Aggregated Age/Sex <15	0	
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	0	
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	0	
GEND_GBV_DSD	Number of people receiving post-GBV care	0	
GEND_GBV_DSD	Age: 0-9	0	
GEND_GBV_DSD	Age: 10-14	0	
GEND_GBV_DSD	Age: 15-17	0	
GEND_GBV_DSD	Age: 18-24	0	
GEND_GBV_DSD	Age: 25+	0	
GEND_GBV_DSD	Sum of Age disaggregates	0	
GEND_GBV_DSD	Sex: Male	0	
GEND_GBV_DSD	Sex: Female	0	
GEND_GBV_DSD	Sum of Sex disaggregates	0	
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	0	
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	0	
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	0	
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	0	
GEND_NORM_DSD	By Age: 0-9	0	
GEND_NORM_DSD	By Age: 10-14	0	





GEND_NORM_DSD	By Age: 15-19	0	
GEND_NORM_DSD	By Age: 20-24	0	
GEND_NORM_DSD	By Age: 25+	0	
GEND_NORM_DSD	Sum of Age disaggregates	0	
GEND_NORM_DSD	By type of activity: Individual	0	
GEND_NORM_DSD	By type of activity: Small Group	0	
GEND_NORM_DSD	By type of activity: Community-level	0	
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	549	16,343
OVC_ACC_DSD	Sex: Male	274	
OVC_ACC_DSD	Sex: Female	275	
OVC_ACC_DSD	Sum of Sex disaggregates	549	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	6,100	22,029
OVC_SERV_DSD	Sex: Male	3,000	
OVC_SERV_DSD	Sex: Female	3,100	
OVC_SERV_DSD	Sum of Sex disaggregates	6,100	
OVC_SERV_DSD	Age: <1	0	
OVC_SERV_DSD	Age: 1-4	500	
OVC_SERV_DSD	Age: 5-9	1,000	
OVC_SERV_DSD	Age: 10-14	2,500	
OVC_SERV_DSD	Age: 15-17	2,100	
OVC_SERV_DSD	Age: 18+	0	
OVC_SERV_DSD	Sum of Age disaggregates	6,100	
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	
CARE_CURR_DSD	Age/sex: <1 Male	0	
CARE_CURR_DSD	Age/sex: 1-4 Male	0	

CARE_CURR_DSD	Age/sex: 5-9 Male	0	
CARE_CURR_DSD	Age/sex: 10-14 Male	0	
CARE_CURR_DSD	Age/sex: 15-19 Male	0	
CARE_CURR_DSD	Age/sex: 20-24 Male	0	
CARE_CURR_DSD	Age/sex: 25-49 Male	0	
CARE_CURR_DSD	Age/sex: 50+ Male	0	
CARE_CURR_DSD	Age/sex: <1 Female	0	
CARE_CURR_DSD	Age/sex: 1-4 Female	0	
CARE_CURR_DSD	Age/sex: 5-9 Female	0	
CARE_CURR_DSD	Age/sex: 10-14 Female	0	
CARE_CURR_DSD	Age/sex: 15-19 Female	0	
CARE_CURR_DSD	Age/sex: 20-24 Female	0	
CARE_CURR_DSD	Age/sex: 25-49 Female	0	
CARE_CURR_DSD	Age/sex: 50+ Female	0	
CARE_CURR_DSD	Sun of Age/Sex disaggregates	0	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	0	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0	
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	0	
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	0	
CARE_NEW_DSD	Age/sex: <1 Male	0	
CARE_NEW_DSD	Age/sex: 1-4 Male	0	
CARE_NEW_DSD	Age/sex: 5-9 Male	0	

CARE_NEW_DSD	Age/sex: 10-14 Male	0	
CARE_NEW_DSD	Age/sex: 15-19 Male	0	
CARE_NEW_DSD	Age/sex: 20-24 Male	0	
CARE_NEW_DSD	Age/sex: 25-49 Male	0	
CARE_NEW_DSD	Age/sex: 50+ Male	0	
CARE_NEW_DSD	Age/sex: <1 Female	0	
CARE_NEW_DSD	Age/sex: 1-4 Female	0	
CARE_NEW_DSD	Age/sex: 5-9 Female	0	
CARE_NEW_DSD	Age/sex: 10-14 Female	0	
CARE_NEW_DSD	Age/sex: 15-19 Female	0	
CARE_NEW_DSD	Age/sex: 20-24 Female	0	
CARE_NEW_DSD	Age/sex: 25-49 Female	0	
CARE_NEW_DSD	Age/sex: 50+ Female	0	
CARE_NEW_DSD	Sum of Age/sex disaggregates	0	
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	0	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	0	
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	0	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	0	
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	0	
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	0	
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	0	
FN_THER_DSD	Age: <1	0	
FN_THER_DSD	Age: 1-4	0	
FN_THER_DSD	Age: 5-14	0	
FN_THER_DSD	Age: 15-17	0	
FN_THER_DSD	Age: 18+	0	
FN_THER_DSD	Sum of Age disaggregates	0	
FN_THER_DSD	Aggregated Age: <18	0	

FN_THER_DSD	Aggregated Age: 18+	0	
FN_THER_DSD	Sum of Aggregated Age disaggregates	0	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	0	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	0	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	0	
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	0	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	0	
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	0	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	0	
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	0	
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	0	
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	0	
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical	0	



	laboratory tests		
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	0	
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	0	
HRH_PRE	By new graduates who are licensed and registered: Doctors	0	
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	0	
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	
TB_SCREEN_DSD	Age: <1	0	
TB_SCREEN_DSD	Sum of Age disaggregates	0	

### Implementing Mechanism Details

<b>Mechanism ID: 17191</b>	<b>Mechanism Name: Watoto Wazima Initiative)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Reformed Church of East Africa	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	



G2G: No	Managing Agency:
---------	------------------

<b>Total All Funding Sources: 155,680</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	155,680

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	17191		
<b>Mechanism Name:</b>	Watoto Wazima Initiative)		
<b>Prime Partner Name:</b>	Reformed Church of East Africa		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	155,680	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	0	0

**Implementing Mechanism Indicator Information**

Indicator Number	Label	2015	2016
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	
PMTCT_STAT_DSD	Number of new ANC and L&D clients	0	
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	0	
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	0	
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0	
PP_PREV_DSD	Total number of people in the target population	0	



KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	0	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	
GEND_GBV_DSD	Number of people receiving post-GBV care	0	
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	0	
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	288	1,442
OVC_ACC_DSD	Sex: Male	144	
OVC_ACC_DSD	Sex: Female	144	
OVC_ACC_DSD	Sum of Sex disaggregates	288	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	3,200	3,800
OVC_SERV_DSD	Sex: Male	1,600	
OVC_SERV_DSD	Sex: Female	1,600	
OVC_SERV_DSD	Sum of Sex disaggregates	3,200	
OVC_SERV_DSD	Age: 1-4	200	
OVC_SERV_DSD	Age: 5-9	500	
OVC_SERV_DSD	Age: 10-14	1,000	
OVC_SERV_DSD	Age: 15-17	1,500	
OVC_SERV_DSD	Sum of Age disaggregates	3,200	
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following	0	



	during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load		
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	0	
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	0	
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	0	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	0	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	0	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	0	
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	0	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	0	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	0	
TX_RET_DSD	Number of adults and children who are still	0	

	alive and on treatment at 12 months after initiating ART		
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	0	
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	0	
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	0	
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	0	
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	0	
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	0	
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV	0	



	care facility during the reporting period		
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	

### Implementing Mechanism Details

Mechanism ID: 17707	TBD: Yes
REDACTED	

### Implementing Mechanism Details

Mechanism ID: 17709	Mechanism Name: Capacity Bridge Mechanism
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: IntraHealth International, Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 2,950,000	
Applied Pipeline Amount: 0	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,950,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)



## Key Issues

(No data provided.)

## Budget Code Information

<b>Mechanism ID:</b> 17709			
<b>Mechanism Name:</b> Capacity Bridge Mechanism			
<b>Prime Partner Name:</b> IntraHealth International, Inc			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	500,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	1,250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	HTXS	800,000	0
-----------	------	---------	---

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17711</b>	<b>Mechanism Name: Implementation and expansion of blood safety</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: National Blood Transfusion Service, Kenya	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 1,250,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,250,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	500,000
----------------------------	---------

### Key Issues

(No data provided.)



### Budget Code Information

<b>Mechanism ID:</b> 17711			
<b>Mechanism Name:</b> Implementation and expansion of blood safety			
<b>Prime Partner Name:</b> National Blood Transfusion Service, Kenya			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	1,250,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID:</b> 17712	<b>Mechanism Name:</b> Strengthening Strategic Information in Kenya
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of California at San Francisco	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 3,050,000	
<b>Applied Pipeline Amount:</b> 0	
Funding Source	Funding Amount
GHP-State	3,050,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)



Human Resources for Health	1,800,000
Key Populations: MSM and TG	200,000
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	250,000
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Food and Nutrition: Policy, Tools, and Service Delivery	800,000

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 17712			
<b>Mechanism Name:</b> Strengthening Strategic Information in Kenya			
<b>Prime Partner Name:</b> University of California at San Francisco			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	3,050,000	0

### Implementing Mechanism Indicator Information



(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 17718</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

**Implementing Mechanism Details**

<b>Mechanism ID: 17719</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

**Implementing Mechanism Details**

<b>Mechanism ID: 17944</b>	<b>Mechanism Name: Linkages</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,597,240</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,597,240

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)





## Key Issues

(No data provided.)

## Budget Code Information

<b>Mechanism ID:</b> 17944			
<b>Mechanism Name:</b> Linkages			
<b>Prime Partner Name:</b> FHI 360			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	2,597,240	0

## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

<b>Mechanism ID:</b> 17945		<b>Mechanism Name:</b> mHealth	
Funding Agency: HHS/CDC		Procurement Type: Cooperative Agreement	
Prime Partner Name: mHealth Kenya			
Agreement Start Date: Redacted		Agreement End Date: Redacted	
TBD: No		New Mechanism: Yes	
Global Fund / Multilateral Engagement: N/A			
G2G: No		Managing Agency:	

<b>Total All Funding Sources:</b> 950,000	
<b>Applied Pipeline Amount:</b> 0	
Funding Source	Funding Amount
GHP-State	950,000

## Sub Partner Name(s)



(No data provided.)

### Cross-Cutting Budget Attribution(s)

Key Populations: FSW	80,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Monitoring and evaluation of SW programs

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 17945 <b>Mechanism Name:</b> mHealth <b>Prime Partner Name:</b> mHealth Kenya			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	950,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID:</b> 17947	<b>Mechanism Name:</b> Implementation of Sustainable Laboratory Quality Systems
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Medical and Research Foundation	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 895,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	895,000

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Motor Vehicles: Purchased	179,286
---------------------------	---------

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 17947</b>			
<b>Mechanism Name: Implementation of Sustainable Laboratory Quality Systems</b>			
<b>Prime Partner Name: African Medical and Research Foundation</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	700,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Prevention	HMBL	30,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	165,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17948</b>	<b>Mechanism Name: Laboratory Networking</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Society for Laboratory Medicine	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 200,000</b>	
<b>Applied Pipeline Amount: 0</b>	
Funding Source	Funding Amount
GHP-State	200,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues



(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 17948			
<b>Mechanism Name:</b> Laboratory Networking			
<b>Prime Partner Name:</b> African Society for Laboratory Medicine			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	200,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID:</b> 17950	<b>Mechanism Name:</b> Implementation of Sustainable Laboratory Quality Systems
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Maryland	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 2,609,437	
<b>Applied Pipeline Amount:</b> 0	
Funding Source	Funding Amount
GHP-State	2,609,437

### Sub Partner Name(s)

(No data provided.)



### Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	90,000
---------------------------	--------

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 17950			
<b>Mechanism Name:</b> Implementation of Sustainable Laboratory Quality Systems			
<b>Prime Partner Name:</b> University of Maryland			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	1,984,437	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	475,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID:</b> 17951	<b>Mechanism Name:</b> Implementation of Sustainable Laboratory Quality Systems
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 895,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	895,000

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Motor Vehicles: Purchased	93,700
---------------------------	--------

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 17951			
<b>Mechanism Name:</b> Implementation of Sustainable Laboratory Quality Systems			
<b>Prime Partner Name:</b> FHI 360			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	700,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Prevention	HMBL	30,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	165,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17954</b>	<b>Mechanism Name: Implementation of Sustainable Laboratory Quality Systems</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Global Implementation Solutions	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,585,000</b>	
<b>Applied Pipeline Amount: 0</b>	
Funding Source	Funding Amount
GHP-State	2,585,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	120,000
---------------------------	---------





## Key Issues

(No data provided.)

## Budget Code Information

<b>Mechanism ID:</b> 17954			
<b>Mechanism Name:</b> Implementation of Sustainable Laboratory Quality Systems			
<b>Prime Partner Name:</b> Global Implementation Solutions			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	2,000,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	90,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	495,000	0

## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

<b>Mechanism ID:</b> 17956	<b>Mechanism Name:</b> VMCC QA Support
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 270,014	
<b>Applied Pipeline Amount:</b> 0	



Funding Source	Funding Amount
GHP-State	270,014

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Gender: Gender Equality	54,003
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	17956		
<b>Mechanism Name:</b>	VMMC QA Support		
<b>Prime Partner Name:</b>	JHPIEGO		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	270,014	0

**Implementing Mechanism Indicator Information**

(No data provided.)



### Implementing Mechanism Details

Mechanism ID: 17957	TBD: Yes
REDACTED	

### Implementing Mechanism Details

Mechanism ID: 17958	TBD: Yes
REDACTED	

### Implementing Mechanism Details

Mechanism ID: 17959	Mechanism Name: Sustaining National HMIS Kenya
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: University of Nairobi	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 700,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	700,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)



### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 17959			
<b>Mechanism Name:</b> Sustaining National HMIS Kenya			
<b>Prime Partner Name:</b> University of Nairobi			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	700,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID:</b> 17960	<b>Mechanism Name:</b> Avenir Health
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Council	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 50,000	
<b>Applied Pipeline Amount:</b> 0	
Funding Source	Funding Amount
GHP-State	50,000

### Sub Partner Name(s)



(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 17960			
<b>Mechanism Name:</b> Avenir Health			
<b>Prime Partner Name:</b> Population Council			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	50,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID:</b> 17963	<b>TBD:</b> Yes
<b>REDACTED</b>	

### Implementing Mechanism Details

<b>Mechanism ID:</b> 17964	<b>Mechanism Name:</b> Measure Evaluation IV
<b>Funding Agency:</b> USAID	<b>Procurement Type:</b> Cooperative Agreement
<b>Prime Partner Name:</b> University of North Carolina	
<b>Agreement Start Date:</b> Redacted	<b>Agreement End Date:</b> Redacted



TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 150,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	150,000

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	17964		
<b>Mechanism Name:</b>	Measure Evaluation IV		
<b>Prime Partner Name:</b>	University of North Carolina		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	150,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)





**Agency Information - Costs of Doing Business**  
**U.S. Agency for International Development**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
USG Staff Salaries and Benefits		11,752,643		11,752,643	0
<b>Total</b>	<b>0</b>	<b>11,752,643</b>	<b>0</b>	<b>11,752,643</b>	<b>0</b>

**U.S. Department of Defense**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Computers/IT Services		11,467		11,467	0
ICASS		138,542		138,542	0
Indirect Costs		467,649		467,649	0
Institutional Contractors		1,696,682		1,696,682	0
Management Meetings/Professional Development		156,944		156,944	0
Non-ICASS Administrative Costs		616,941		616,941	0
Staff Program Travel		910,818		910,818	0
USG Staff Salaries and Benefits		0		0	0





<b>Total</b>	<b>0</b>	<b>3,999,043</b>	<b>0</b>	<b>3,999,043</b>	<b>0</b>
--------------	----------	------------------	----------	------------------	----------

**U.S. Department of Health and Human Services/Centers for Disease Control and Prevention**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Capital Security Cost Sharing		100,000		100,000	0
Computers/IT Services		750,000		750,000	0
ICASS		1,275,000		1,275,000	0
Institutional Contractors		550,000		550,000	0
Management Meetings/Professional Development		95,125		95,125	0
Non-ICASS Administrative Costs		2,916,649		2,916,649	0
Staff Program Travel	0	1,627,000		1,627,000	0
USG Staff Salaries and Benefits	3,320,000	2,646,897		5,966,897	0
<b>Total</b>	<b>3,320,000</b>	<b>9,960,671</b>	<b>0</b>	<b>13,280,671</b>	<b>0</b>

**U.S. Department of State**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
-------------------------------	-----	-----------	-----------	---------------------------------------	------------------



ICASS		336,800		336,800	0
Management Meetings/Professional Development		0		0	135,200
Non-ICASS Administrative Costs		0		0	15,000
Staff Program Travel		0		0	35,000
USG Staff Salaries and Benefits		0		0	578,000
<b>Total</b>	<b>0</b>	<b>336,800</b>	<b>0</b>	<b>336,800</b>	<b>763,200</b>

### U.S. Peace Corps

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Computers/IT Services		4,326		4,326	0
Non-ICASS Administrative Costs		13,877		13,877	0
Peace Corps Volunteer Costs		639,123		639,123	0
Staff Program Travel		13,915		13,915	0
USG Staff Salaries and Benefits		295,471		295,471	0
<b>Total</b>	<b>0</b>	<b>966,712</b>	<b>0</b>	<b>966,712</b>	<b>0</b>

